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Abstract 
How far does screening women for domestic (partner) 
violence in different health-care settings meet criteria 
for a screening programme? Systematic reviews of nine 
UK National Screening Committee criteria 
G Feder,1* J Ramsay,2 D Dunne,2 M Rose,2 C Arsene,2 
R Norman,2 S Kuntze,2 A Spencer,2 L Bacchus,3 G Hague,1 
A Warburton,4 and A Taket5 
1University of Bristol, UK 
2Queen Mary University of London, UK 
3London School of Hygiene and Tropical Medicine, UK 
4University of Manchester, UK 
5Deakin University, Melbourne, Australia 
 
*Corresponding author 
     
Objectives: The two objectives were: (1) to  identify, 
appraise and synthesise research that  is relevant to 
selected  UK  National  Screening  Committee   (NSC) 
criteria  for a screening programme  in  relation  to partner 
violence; and  (2)  to  judge whether current evidence 
fulfils  selected NSC  criteria  for  the  implementation of 
screening  for partner violence  in health‐care  settings. 
Data sources: Fourteen electronic databases from 
their  respective  start dates  to 31 December 2006. 
Review methods: The review examined seven 
questions  linked  to  key NSC  criteria: QI: What  is  the 
prevalence of partner violence against women and 
what are  its health consequences? QII: Are screening 
tools valid and reliable? QIII:  Is screening for partner 
violence  acceptable  to women? QIV: Are  interventions 
effective once partner violence  is disclosed  in a health‐ 
care  setting? QV: Can mortality or morbidity be  reduced 
following screening? QVI:  Is a partner violence screening 
programme acceptable  to health professionals and the 
public? QVII:  Is  screening  for partner violence  cost‐ 
effective? Data were selected using different  inclusion/ 
exclusion  criteria  for  the  seven  review questions. 
The quality of the primary studies was assessed using 
published appraisal tools. We grouped the findings of the 
surveys, diagnostic accuracy and  intervention studies, 
and qualitatively analysed differences between outcomes 
in relation to study quality, setting, populations and, 
where applicable,  the nature of  the  intervention. We 
systematically  considered  each  of  the  selected NSC 
criteria against  the  review evidence. 
Results: The lifetime prevalence of partner violence 
against women in the general UK population ranged 
from 13% to 31%, and in clinical populations it was 
13–35%. The 1‐year prevalence ranged from 4.2% 
to 6% in the general population. This showed that 
partner violence against women  is a major public health 
problem and potentially appropriate  for screening and 
intervention.  The  HITS  (Hurts,  Insults,  Threatens  and 
Screams) scale was  the best of several short screening 
tools  for use  in health‐care settings. Most women 
patients  considered  screening  acceptable  (range 35–
99%),  although  they  identified  potential  harms.  The 
evidence  for effectiveness of advocacy  is growing, and 
psychological  interventions may be effective, but not 
necessarily  for women  identified  through  screening. No 
trials of  screening programmes measured morbidity  
and mortality. The acceptability of partner violence 
screening among health‐care professionals  ranged  from 
15%  to  95%,  and  the  NSC  criterion  was  not  met. 
There were no  cost‐effectiveness  studies, but a Markov 
model of a pilot  intervention to  increase  identification of 
survivors of partner violence  in general practice  found 
that such an  intervention was potentially cost‐effective. 
Conclusions: Currently there is insufficient evidence to 
Abstract 
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implement a  screening programme  for partner  violence 
against women either  in health services generally or  in 
specific clinical  settings. Recommendations  for  further 
research  include:  trials of system‐level  interventions and 
of psychological and advocacy  interventions; trials to test 
theoretically explicit  interventions  to help understand 
what works  for whom, when and  in what  contexts; 
qualitative studies exploring what women want  from 
interventions;  cohort  studies measuring  risk  factors, 
resilience  factors and the  lifetime trajectory of partner 
violence; and  longitudinal studies measuring the  long‐ 
term prognosis  for  survivors of partner  violence. 
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Glossary and  list of abbreviations 
 
The primary studies included in the review come from a range of disciplines and countries. Inevitably  
this means that different terms are used sometimes to denote a similar organisation or service. Where this 
occurs we have amended these to reflect general usage in the UK. 
  
Glossary 
 
 
Accident and emergency (A&E) 
department Hospital department providing 
emergency care.  
Advocacy Advocacy generally refers to the 
provision of support and access to resources in 
the community. In the UK, advocates tend to be 
employed outside the health system and are not 
qualified professionals. In the USA, advocates 
may be employed in health and community 
settings and are often qualified social workers.  
Counselling  A form of psychological treatment, 
using a range of models. In the UK, this 
term is more generally used to denote formal 
psychological treatment provided by a qualified 
professional. In the USA, counselling may 
refer to empathetic support in the context of 
education and referrals (what would be termed 
‘advocacy’ in the UK), or formal psychological 
treatment.  
Emergency department (ED)  Non-UK term for 
accident and emergency department (see above).  
Integrative review Integrative reviews 
summarise past research and draw overall 
conclusions from the body of literature on a 
particular topic. They can include editorials and 
letters in addition to journal articles. They tend 
not to conduct secondary statistical analyses on 
identified studies. 
 
Matched, yoked and randomised 
design Design of a trial in which participants 
are matched (or yoked) together on specified 
variables (such as age), then one member of 
each grouping is randomly assigned to the 
intervention group and the other acts as a 
control.  
Nursing studies Studies published in nursing 
journals or studies whose authors have nursing 
credentials.  
Refuge A safe house where women experiencing 
domestic abuse can live free from violence.  
System-centred interventions Interventions 
that are designed to improve the response of the 
organisations and professionals that come into 
contact with abused women. The ultimate goal 
of these interventions is to improve outcomes 
for abused women, although such outcomes 
may not be measured directly. They include staff 
training interventions and the provision of more 
resources.  
Survivors of domestic violence Women who 
have experienced or are currently experiencing 
physical, sexual or emotional abuse from a 
husband or partner or ex-husband or ex-partner.  
Trauma centre  A non-UK term for accident and 
emergency department (see above).  
Woman-centred interventions Interventions 
that are targeted directly at abused women with 
the aim of reducing abuse or improving the 
health of the women. They include advocacy and 
psychological interventions, including all forms 
of therapy and counselling. 
Glossary and  list of abbreviations  
 
 
  
 
List of abbreviations 
 
   
AAS 
   
Abuse Assessment Screen 
  
ESID 
  
Experimental Social 
ANOVA analysis of variance Innovation and 
ARI Abuse Risk Inventory Dissemination 
ASI-A Addiction Severity Index GP general practitioner 
  Alcohol composite score GSI Global Severity Index 
ASI-D Addiction Severity Index HARK Humiliation, Afraid, Rape 
  Drug composite score and Kick Screening Tool 
AUC area under curve HCP health-care professional 
BDI Beck Depression Inventory HEVAN Health Ending Violence and 
BRFSS Behavioural Risk Factor Abuse Now 
  Surveillance Survey HITS Hurts, Insults, Threatens 
BSI Brief Symptom Inventory and Screams scale 
CAPS Clinician Administered HMO health management 
  PTSD Scale organisation 
CAS Composite Abuse Scale HSQ Health Screening 
CASP Critical Appraisal Skills Questionnaire 
  Programme ICER incremental cost- 
CBCL Child Behaviour Checklist effectiveness ratio 
CBT cognitive  behavioural IPA intimate partner abuse 
  therapy IPC Internal-Powerful Others- 
CES-D Center for Epidemiologic Chance 
  Studies Depression Scale IPV intimate partner violence 
CME continuing medical ISA (ISA-P, Index of Spouse Abuse 
  education ISA-NP) (Index of Spouse Abuse 
CPP child–parent  psychotherapy Physical and Non-Physical 
CRC Community  Resources subscales) 
  Checklist ISEL Interpersonal Support 
CSEI Coopersmith Self-esteem Evaluation List 
  Inventory ITT intention to treat 
CTS (CTS2) Conflict Tactics Scale JCAHO Joint Commission on the 
  (Conflict Tactics Scale- Accreditation of Healthcare 
  Revised) Organizations 
DAS Danger Assessment Scale LBW low birth weight 
DC 0-3 TSD Diagnostic Classification 0-3 LR likelihood ratio 
  Traumatic stress disorder MMPI- Minnesota  Multiphasic 
DOR diagnostic odds ratio PTSD Personality  Inventory–Post- 
DSM-IV Diagnostic and Statistical traumatic Stress Disorder 
  Manual of Mental Disorders IV MMTP Methadone Maintenance 
DV domestic violence Treatment Programme 
ED emergency department MOOSE Meta-analysis of 
EFI Enright Forgiveness Observational Studies in 
  Inventory Epidemiology 
EHQ Employment Harassment NICE National Institute for Health 
  Questionnaire and Clinical Excellence 
EMS emergency medical services NPV negative predictive value 
EMT emergency medical NSC National Screening 
  technician Committee 
EOR effectiveness in obtaining ONS Office of National Statistics 
  resources OR odds ratio 
EPDS Edinburgh Postnatal OVAT Ongoing Violence 
  Depression Scale   Assessment Tool 
 
viii 
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PCL-S 
   
PTSD Checklist Stressor 
  
S&S 
  
support and survival 
  Specific version SAFE Stop Abuse for Everyone 
PCT primary care trust SAMHSA Substance Abuse and 
PHC primary health care Mental Heralth Services 
PHN public health nurse Administration 
PPV positive predictive value SCL-90-R Symptoms Checklist-90 
PreDoVe Prevention of Domestic Revised (psychiatric 
  Violence study symptoms) 
PSAI Perinatal Self-Administered SD standard deviation 
  Inventory SE standard error 
PSS Post-traumatic Stress SES socioeconomic  status 
  Disorder Symptom Scale SF-36 Short Form (36) Health 
PTSD post-traumatic  stress Survey 
  disorder SRBQ Sexual Risk Behaviour 
PVI Partner Violence Interview Questionnaire 
PVS Partner Violence Screen STAI State–Trait Anxiety 
QALY quality-adjusted  life-year Inventory 
QUADAS Quality Assessment of STaT Slapped, Threatened or 
  Diagnostic Accuracy Studies Thrown scale 
QUORUM Quality of Reporting STROBE Strengthening the Reporting 
  of Meta-analyses of of Observational Studies in 
  Randomised Controlled Epidemiology 
  Trials (criteria) SVAWS Severity of Violence Against 
RADAR Routine screening; Ask Women Scale 
  direct questions; Document SWA Salford Women’s Aid 
  your findings; Assess patient TANF Temporary Assistance for 
  safety; Review patient Needy Families 
  options and referrals USPSTF United States Preventative 
  (project) Services Task Force 
RAST Rape Aftermath Symptom VAWA Violence Against Women Act 
  Test (of 1994) 
RCT randomised controlled trial WAST Woman Abuse Screening 
ROC receiver operating Tool 
  characteristic WCDVS Women, Co-occurring 
RPRS Relapse Prevention and Disorders and Violence 
  Relationship Safety Study 
  Programme WEB Women’s Experience with 
RR relative risk Battering scale 
RSEI Rosenberg Self-esteem WHO World Health Organization 
  Inventory    
 
All abbreviations that have been used in this report are listed here unless the abbreviation is 
well known (e.g. NHS), or it has been used only once, or it is a non-standard abbreviation used 
only in figures/tables/appendices, in which case the abbreviation is defined in the figure legend 
or in the notes at the end of the table. 
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Executive summary 
  
Background 
Partner violence against women is physical, sexual 
or emotional abuse with coercive control of a 
woman by a man or woman partner or ex-partner. 
It is a common problem, with a detrimental effect 
on health and well-being. Although there is a 
consensus that health services need to respond 
to partner violence, there is uncertainty whether 
screening for partner violence in health-care 
settings is effective and appropriate. 
  
Objectives 
 
This review has two specific aims: 
 
• To identify, appraise and synthesise research 
across a range of study designs that are relevant 
to selected UK National Screening Committee 
(NSC) criteria for a screening programme in 
relation to partner violence. 
• To make a judgment on whether current 
evidence is sufficient for fulfilment of selected 
NSC criteria for the implementation of 
screening for partner violence in health-care 
settings. 
 
The research questions 
There are seven review questions (linked to key 
NSC criteria):  
• Question I: What is the prevalence of partner 
violence against women and what are its health 
consequences? (NSC criterion 1) 
• Question II: Are screening tools valid and 
reliable? (NSC criteria 5 and 6) 
• Question III: Is screening for partner violence 
acceptable to women? (NSC criterion 7) 
• Question IV: Are interventions effective once 
partner violence is disclosed in a health-care 
setting? (NSC criteria 10 and 15) 
• Question V: Can mortality or morbidity be 
reduced following screening? (NSC criterion 
13) 
• Question VI: Is a partner violence screening 
programme acceptable to health professionals 
and the public? (NSC criterion 14) 
• Question VII: Is screening for partner violence 
cost-effective? (NSC criterion 16) 
  
Methods 
Data sources 
Fourteen electronic databases from their respective 
start dates to 31 December 2006. 
 
Study selection 
Different sets of inclusion/exclusion criteria were 
required for the seven review questions. All criteria 
were applied independently by two reviewers, and 
disagreements were adjudicated by a third reviewer. 
 
Data  extraction  and 
assessment of quality 
Data were extracted onto electronic forms and 
ordered into summary tables including the results 
of quality appraisal. These tables formed the 
basis of our narrative synthesis of the primary 
studies. The quality of the primary studies was 
assessed using published appraisal tools in accord 
with the different review questions and the study 
designs: STROBE (Strengthening the Reporting 
of Observational Studies in Epidemiology) 
for observational studies; QUADAS (Quality 
Assessment of Diagnostic Accuracy Studies) 
for diagnostic accuracy studies; CASP (Critical 
Appraisal Skills Programme) for qualitative studies 
and reviews; USPSTF (United States Preventative 
Services Task Force) criteria for intervention 
studies; and the Jadad score for randomised 
controlled trials. 
 
Data synthesis 
We grouped the findings of the surveys, diagnostic 
accuracy and intervention studies and qualitatively 
analysed differences between outcomes in relation 
to study quality, setting (country, type of health- 
care facility), populations (if available, ethnicity, 
socioeconomic status, method of identification/ 
disclosure) and, in the case of intervention studies, 
the nature of the intervention. For review questions 
III and VI we combined the findings of qualitative 
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and quantitative studies. We also used the results 
from qualitative studies of survivors of partner 
violence to comment on the scope of our review. 
We systematically considered each of the selected 
NSC criteria against the review evidence. 
  
Results 
 
• Question I: The prevalence in the UK of 
partner violence against women and the 
magnitude of health sequelae vary with study 
design and population. In samples drawn from 
the general population, lifetime prevalence 
ranged from 13% to 31%, and in samples from 
clinical populations it ranged from 13% to  
35%. One-year prevalence ranged from 4.2% to 
6% in the general population studies. Even the 
lower estimates for prevalence, morbidity and 
mortality show that partner violence against 
women is a major public health problem 
and potentially an appropriate condition for 
screening and intervention. 
• Question II: Several short screening tools are 
relatively valid and reliable for use in health- 
care settings. The HITS (Hurts, Insults, 
Threatens and Screams) scale had the best 
predictive power (sensitivity ranged from 86% 
to 100%, specificity ranged from 86% to 99%), 
concurrent and construct validity (r ranged 
from 0.75 to 0.85, p < 0.001) and reliability 
(Cronbach’s alpha ranged from 0.61 to 0.80), 
with a suitable cut-off score. 
• Question III: Most women patients considered 
screening acceptable (range 35–99%), although 
they identified potential harms, particularly 
with regard to stigmatisation and breach of 
confidentiality. Informants thought that, 
besides identifying women experiencing 
partner violence, the aims of screening should 
also include information giving and signalling 
willingness for clinicians to talk about partner 
violence. 
• Question IV: Effect sizes for post-traumatic 
stress disorder (PTSD) ranged from 0.10 (an 
individual psychological intervention) to 1.23 
(an individual psychological intervention); 
depression ranged from 0.16 (an individual 
psychological intervention) to 1.77 (an 
individual psychological intervention); self- 
esteem ranged from 0.10 (an individual 
psychological intervention) to 2.55 (an 
individual psychological intervention); and 
physical abuse ranged from 0.02 (advocacy) to 
0.48 (advocacy). The evidence for effectiveness 
of advocacy is growing, particularly for 
women who have actively sought help or 
are in a refuge. The two studies of advocacy 
interventions in women identified through 
screening in health-care services were based in 
antenatal  clinics.  Psychological  interventions 
and work with survivors and their children  
may be effective, but not necessarily for women 
identified  through  screening. 
• Question V: There were no trials of screening 
programmes measuring morbidity and 
mortality. The proxy outcome measure 
of referral rates ranged widely from a 
difference of 4% to 67% between control 
and intervention sites. The proxy outcome 
measure of identification showed little change, 
ranging from 25% to 3% between control and 
intervention sites. Studies using proxy outcome 
measures generally had weak designs and 
execution. 
• Question VI: There was heterogeneity in 
the outcomes of qualitative and survey 
studies about the acceptability to health-care 
professionals of partner violence screening. 
The acceptability of partner violence screening 
among health-care professionals ranged widely 
from 15% to 95%, but overall the evidence 
showed that this NSC criterion is not met. 
• Question VII: There were no cost-effectiveness 
studies of partner violence screening 
interventions. A Markov model of a pilot 
intervention to increase identification of 
survivors of partner violence in general 
practice found that such an intervention was 
potentially  cost-effective. 
  
Conclusions 
Implications for health care 
Currently there is insufficient evidence to 
implement a screening programme for partner 
violence against women either in health services 
generally or in specific clinical settings. It may 
be inappropriate to judge a policy of routine 
enquiry about partner violence by the NSC 
criteria, particularly as women perceive other 
valid purposes of screening besides identification. 
Even if the scope of routine enquiry is wider than 
screening, it is debatable whether that policy would 
be justified within health services. 
 
Recommendations for research 
1. Trials of system-level interventions to improve 
the response of health services to survivors 
of partner violence. These may incorporate 
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routine or selective enquiry and, potentially, 
could compare differences in outcomes 
between the two policies. 
2. Trials of psychological and advocacy 
interventions after disclosure, in health-care 
settings, of partner violence. Such trials would 
measure quality of life, mental health and 
further abuse. 
3. Trials to test theoretically explicit interventions 
to help understanding of what works (or 
does not work) for whom, when and in what 
contexts. 
4. Qualitative studies exploring what women want 
from interventions after disclosure of partner 
violence. 
5. Cohort studies measuring risk factors, 
resilience factors and the trajectory of partner 
violence through the life course. 
6. Longitudinal studies measuring the long-term 
prognosis for survivors of partner violence 
after their identification in health-care settings.  
Programmes addressing these six research 
questions need to have the resources and expertise 
to include participants from majority and ethnic 
minority communities in the UK. 
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Chapter 1 
Background 
  
Aims of the review 
This review has two aims: 
 
• to identify, appraise and synthesise research 
across a range of study designs that are relevant 
to selected UK National Screening Committee 
(NSC) criteria for a screening programme in 
relation to domestic (partner) violence 
• to make a judgment on whether current 
evidence is sufficient for fulfilment of selected 
NSC criteria for the implementation of 
screening for domestic (partner) violence in 
health-care settings. 
  
Previous systematic reviews 
of partner violence studies 
Screening 
Our previous systematic review,1,2 based on an 
evaluation of quantitative studies that addressed 
the NSC criteria, concluded that these criteria 
were not fulfilled and that implementation 
of a screening programme was not justified. 
Contemporaneous reviews by North American 
colleagues have come to similar conclusions.3 The 
Canadian Task Force on Preventive Health Care 
used a broad analytic framework but only critically 
appraised intervention studies; its conclusion, that 
no recommendation could be made for or against 
screening, was based largely on those studies.4 The 
US Preventive Task Force included and critically 
appraised assessment as well as intervention studies 
and concluded that there was insufficient evidence 
for a screening programme.5  The main findings 
from these reviews are detailed in Appendix 1. 
The most recent systematic reviews evaluating 
the effectiveness of screening included studies 
published up until December 2002. No previous 
reviews have included qualitative studies to address 
any of the review questions. 
 
The effectiveness of screening may vary between 
different health-care settings because of variation 
in prevalence of partner violence in different 
groups of patients, across the life course, and 
because of differences in acceptability within 
different health-care settings and between groups 
of health-care practitioners. Previous reviews 
of screening have not addressed this potential 
heterogeneity. Therefore it is possible that criteria 
for screening may be fulfilled in some settings 
with specific groups of patients but not in others. 
Our previous review evaluating the effectiveness 
of screening1 included three studies from primary 
care – community health centres, an internal 
medicine practice, and HMO (health management 
organisation) primary care clinics – two studies 
from antenatal settings and four from accident and 
emergency (A&E) departments. 
 
Interventions after screening 
A key element in the justification for a screening 
programme is an effective intervention or 
interventions following a positive screening test. 
In addition to reviews specifically designed to 
inform policy about screening, since 1998 there 
have been six systematic reviews of partner 
violence intervention studies relevant to health- 
care settings: Chalk and King,6  Abel,7  Hender,8 
Cohn and colleagues,9 Klevens and Sadowski,10 
and Ramsay and colleagues.2 The most recent 
review of intervention studies, commissioned 
by the Department of Health’s policy research 
programme,11 included studies cited on the source 
bibliographic databases before October 2004.  
This is a growing research field, and new studies 
may change the overall negative conclusion about 
the appropriateness of screening based on previous 
reviews. 
  
Use of the term 
‘partner violence’ 
A variety of terms are in current use to denote 
domestic violence perpetrated against an 
intimate partner, such as ‘partner violence’, 
‘intimate partner violence’ (IPV), ‘spouse abuse’, 
‘partner abuse’ and ‘battering’. There is still no 
international, or even national, consensus about 
the most appropriate term to use for this form of 
domestic violence. However, many experts in the 
field believe that ‘domestic violence’ is a misleading 
term because ‘domestic’ implies that the violence 
Background 
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always happens within the home. Similarly, many 
see ‘IPV’ as inappropriate, as there is nothing 
‘intimate’ about an abusive relationship. In this 
review we use the term ‘partner violence’ as this 
better reflects the nature of the problem. However, 
although this is our preferred term, when citing 
other sources we have retained their terminology 
where appropriate. We define partner violence 
against women as physical, sexual or emotional 
abuse with coercive control of a woman by a man 
or woman partner who is, or was, in an intimate 
relationship with the woman. In the US research 
literature ‘battered women’ is a common term; in 
this review we have consistently replaced this term 
with ‘survivors of partner violence’. 
  
What about male survivors 
of partner violence? 
Our overall review question is restricted to 
screening for partner violence perpetrated 
against women. Partner violence against men 
in heterosexual or same sex relationships is a 
social problem with potential long-term health 
consequences for male survivors,12 but is not the 
focus of this review. Although some population 
studies suggest that the lifetime prevalence of 
physical assaults against a partner is comparable 
between genders, even those studies report that 
violence against women is more frequent and more 
severe, and that women are three times more likely 
than men to sustain serious injury and five times 
more likely to fear for their lives.13 
  
Definitions of screening 
and routine enquiry 
Screening, as defined by the NSC, is a public health 
service in which members of a defined population, 
who do not necessarily perceive they are at risk 
of, or are already affected by a disease or its 
complications, are asked a question or offered a 
test, to identify those individuals who are more 
likely to be helped than harmed by further tests 
or treatment to reduce the risk of a disease or its 
complications.14  
Routine enquiry, as it pertains to partner violence, 
refers to ‘asking all people within certain 
parameters about the experience of domestic 
violence, regardless of whether or not there are 
signs of abuse, or whether domestic violence is 
suspected.’15  
The use of the term ‘screening’ as defined by the 
NSC refers to the application of a standardised 
question or test according to a procedure that does 
not vary from place to place, and that is how we use 
the term in this report. We acknowledge that many 
understand the term in a more general sense than 
this definition. To avoid confusion it is preferable  
to use the term routine enquiry where procedures 
are not necessarily standardised, but where 
question(s) are asked routinely, for example at  
every visit within time-specific or other parameters. 
Although there is not always a clear distinction 
between routine enquiry and screening, there is a 
flexibility of application in the former that is absent 
in the latter; a policy of routine enquiry does not 
necessarily have to fulfil the criteria for a screening 
programme.16 Our review focuses on the criteria  
for screening, but in our final chapter we discuss the 
limitations of the screening model in relation to 
partner violence. 
  
Extending the scope 
of previous reviews 
We extended the scope of previous reviews in three 
ways. First, earlier reviews did not include a full 
assessment of the test characteristics of screening 
tools. We therefore aimed to evaluate the predictive 
properties of screening tools that could be used 
in clinical practice. Second, previous reviews 
have generated a vigorous correspondence,17 
including an oft-repeated criticism that restriction 
to quantitative studies omits important evidence 
about the acceptability and value of screening 
or routine enquiry about partner violence in 
health-care settings. We therefore have included 
qualitative evidence in this review when it helped 
to answer a specific review question. Third, no 
previous review has addressed the economic  
costs related to the provision of services for 
abused women. We therefore searched for studies 
that evaluated the cost or cost-effectiveness of 
interventions for partner violence relevant to 
health-care settings and have also reported the 
economic modelling of a primary care partner 
violence intervention. 
3© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
Health TechnologyAssessment 2009; Vol. 13:No. 16DOI: 10.3310/hta13160  
 
T 
   
 
  
Chapter 2 
Objectives  and  the  review questions 
  
here are seven review questions. We have 
linked each of these to key NSC criteria for a 
screening programme. The figure in Appendix 2 
places the criteria we are reviewing in an analytic 
framework for research on partner violence and 
health, and is adapted from a framework used by 
the Canadian Preventive Task Force.18 
  
Question I: What is the 
prevalence of partner 
violence against women and 
its health consequences? 
NSC   criterion   1:   The   condition   should   be   an 
important health problem 
There is no longer any debate about the public- 
health impact of partner violence, although 
prevalence rates and the magnitude of health 
sequelae vary depending on population and 
study design. But even the lower estimates for 
prevalence, morbidity and mortality make partner 
violence a potentially appropriate condition for 
screening and intervention. To answer this question 
we systematically searched for reviews from 1990 
onwards on the health impact of partner violence, 
and summarised these along with prevalence data 
from individual studies from the UK published 
from 1995 onwards. 
  
Question II: Are screening 
tools valid and reliable? 
NSC criterion 5: There should be a simple, safe, 
precise and validated screening test 
We reviewed the predictive properties and validity 
of current partner violence screening questions 
where they are evaluated against a standard 
criterion, such as the Conflict Tactics Scale.19,20  We 
also summarised more general information about 
the screening tools, such as the number of items 
asked and the length of time required to administer 
the tool. 
Specific questions: 
 
• Can screening efficiently and accurately 
identify women at risk of or experiencing 
partner violence? 
• Does accurate identification differ as a function 
of the number of items asked or the setting in 
which the tool is administered? 
 
NSC criterion 6: The distribution of  test  values  in the 
target population should be known and a suitable cut-
off level defined and agreed 
The distribution of test values in women 
experiencing partner violence was extracted and 
analysed. 
  
Question III: Is screening 
for partner violence 
acceptable to women? 
NSC criterion 7: The test should be acceptable to the 
population 
We reviewed acceptability of screening for partner 
violence by searching for quantitative surveys and 
qualitative studies eliciting the views of women. 
Findings from the different study designs were 
triangulated. 
 
Specific review questions: 
 
• Is screening generally acceptable to women? 
• Do women’s views about screening differ as a 
function of previous exposure to screening? 
• Do women’s views about screening differ as a 
function of abuse status? 
• Are there any other factors associated with 
acceptability/non-acceptability? 
– age and ethnicity 
– health-care setting 
– mode of screening. 
• What harms do women report associated with 
screening for partner violence (qualitative 
studies only)? 
4 
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Question IV: Are 
interventions effective once 
partner violence is disclosed 
in a health-care setting? 
NSC criterion 10: There should be an effective 
treatment or intervention for patients identified 
through early detection, with evidence of early 
treatment leading to better outcomes than late 
treatment 
We reviewed quantitative studies of interventions 
that are relevant to women identified through 
screening procedures. This included studies 
of interventions initiated as a direct result of 
screening by health professionals, or interventions 
conducted outside of screening that nevertheless 
show what could be achieved if a woman’s abuse 
status was ascertained. We endeavoured to identify 
any evidence for a differential effect of early 
treatment on outcomes. We extended our previous 
systematic review,11 which included studies cited on 
the source bibliographic databases before October 
2004. 
 
Specific review questions: 
 
• Is there an improvement in abused women’s 
experience of abuse, perceived social support, 
quality of life and psychological outcome 
measures as a result of interventions accessed 
or potentially accessible as a result of screening 
(quantitative studies only)? 
• Is there an improvement for abused women’s 
children in terms of quality of life, behaviour 
and educational attainment following their 
mothers’ participation in programmes accessed 
or potentially accessed as a result of screening 
(quantitative studies only)? 
• What are the positive outcomes that abused 
women want for themselves and their children 
from programmes that include screening 
or other health-care-based interventions 
(qualitative studies only)? 
 
NSC criterion 15: The benefit from the screening 
programme should outweigh the physical and 
psychological harm  (caused by  the  test, diagnostic 
procedures and treatment) 
We considered direct and indirect harms of  
whole screening programmes, where reported, by 
reviewing evidence from the intervention studies 
and qualitative studies. 
Question V: Can mortality 
or morbidity be reduced 
following screening? 
NSC  criterion  13:  There  must  be  evidence  from high  
quality  Randomised  Controlled  Trials   that the 
screening programme is effective in reducing 
mortality or morbidity. Where screening is aimed 
solely at providing information to allow the person 
being screened to make an ‘informed choice’ (e.g. 
Down’s syndrome, cystic fibrosis carrier screening), 
there must be evidence from high quality trials that 
the test accurately measures risk. The information 
that is provided about the test and its outcome must 
be of value and readily understood by the individual 
being  screened 
 
We searched for evidence from randomised 
controlled trials (RCTs) and reviewed these if 
available. We also included other controlled studies 
of interventions that implemented screening 
programmes or included partner violence 
screening as an aim in educational interventions 
for health-care professionals. 
 
Specific review questions: 
 
• What are the changes in identification, 
information giving and referrals (made and 
attended) from screening and other system- 
based interventions in health-care and 
community/voluntary sector settings? 
• Is there evidence from RCTs and other 
controlled studies that there is a cessation or 
reduction in abuse following abused women’s 
participation in programmes including 
screening (quantitative studies only)? 
• Are there any measured harms from screening 
interventions (quantitative studies only)? 
Question VI: Is a partner 
violence screening 
programme   acceptable 
to health professionals 
and the public? 
NSC   criterion   14:   There   should   be   evidence that 
the complete screening programme (test, diagnostic 
procedures, treatment/intervention) is clinically, 
socially and ethically acceptable to health 
professionals and the public 
We reviewed quantitative and qualitative studies of 
acceptability to health professionals. 
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The issue of whether the test is acceptable to the 
public is addressed in question III, albeit only from 
the perspective of women. We did not address the 
issue of whether the programme is acceptable to 
male members of the general public. 
 
Specific review questions: 
 
• Is screening for partner violence generally 
acceptable to health professionals? 
• Do health professionals’ views about screening 
differ as a function of previous experience of 
screening? 
• Do health professionals’ views about screening 
differ as a function of their role (e.g. physician, 
nurse, psychiatrist) or the setting in which they 
work (e.g. family practice, A&E, antenatal, 
dental practice)? 
• Are there any other factors associated with 
acceptability/non-acceptability? 
– age and ethnicity 
– training on partner violence. 
  
Question VII: Is screening 
for partner violence 
cost-effective? 
NSC criterion 16: The opportunity cost of the 
screening programme (including testing, diagnosis, 
treatment, administration, training and quality 
assurance) should be economically balanced in 
relation to expenditure on medical care as a whole 
(i.e. value for money) 
We reviewed studies evaluating the cost- 
effectiveness of screening. We complemented this 
with a cost-effectiveness model based on a pilot 
study of a primary care-based intervention that 
aimed to improve the identification of women 
patients  experiencing  partner  violence. 
  
NSC criteria not addressed 
by this review 
NSC criterion 2: The epidemiology and natural history 
of the condition, including development from latent 
to declared disease, should be adequately understood 
and there should be a detectable risk factor, disease 
marker, latent period or early symptomatic stage 
We did not address this criterion because of its 
problematic application to the issue of partner 
violence: partner violence is not a condition in the 
disease model sense, and screening is not limited 
to detection of early stages of abuse. 
NSC criterion 3: All the cost-effective primary 
prevention interventions should have been 
implemented as far as practicable 
In terms of partner violence, primary prevention 
interventions are largely in educational and media 
settings and we did not review these. This criterion 
is not relevant to a decision to implement a 
screening programme in health-care settings.  
Review of evidence for criteria 8, 9 and 12 were 
part of our original proposal. Below we explain why 
we did not include them in the final review. 
 
NSC criterion 8: There  should  be  an  agreed  policy on 
the further diagnostic investigation of individuals 
with a positive test result and on the choices available 
to those individuals 
Further ‘diagnostic investigation’ is not relevant to 
the care of women who are identified in partner 
violence screening programmes. 
 
NSC criterion 9: There should be agreed evidence- 
based policies covering which individuals should be 
offered treatment and the choices available to those 
individuals 
Although some primary studies in our review 
discussed choices available to women disclosing 
abuse, there are no ‘evidenced-based policies’ for 
these treatment choices and, in the context of our 
resources for the reviews, we judged this criterion 
of secondary importance compared with those we 
did review. 
 
The following criteria need to based on audit and 
policy research. They only need to be considered 
once the evidence-based criteria are met: 
 
NSC criterion 12: Clinical management of  
the condition and patient outcomes should be 
optimised by all health-care providers prior to 
participation in a screening programme. 
 
NSC criterion 17: There should be a plan 
for managing and monitoring the screening 
programme and an agreed set of quality assurance 
standards.  
NSC criterion 18: Adequate staffing and facilities 
for testing, diagnosis, treatment and programme 
management should be available prior to the 
commencement of the screening programme.  
NSC criterion 19: All other options for managing 
the condition should have been considered (e.g. 
improving treatment, providing other services), 
to ensure that no more cost effective intervention 
6 
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could be introduced or current interventions 
increased within the resources available.  
NSC criterion 20: Evidence-based information, 
explaining the consequences of testing, 
investigation and treatment, should be made 
available to potential participants to assist them in 
making an informed choice. 
NSC criterion 21: Public pressure for widening 
the eligibility criteria for reducing the screening 
interval, and for increasing the sensitivity of the 
testing process, should be anticipated. Decisions 
about these parameters should be scientifically 
justifiable to the public. 
7© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
Health TechnologyAssessment 2009; Vol. 13:No. 16DOI: 10.3310/hta13160  
 
   
 
  
Chapter 3 
Review methods 
  
Inclusion and 
exclusion  criteria 
The generic criteria that applied to all seven 
questions are listed in Tables 1 and 2.  
Further question-specific criteria are listed below. 
All criteria were applied independently by two 
reviewers and disagreements were adjudicated by a 
third reviewer. 
 
Question I: What is the prevalence of partner violence 
and its health consequences? 
• Primary studies of prevalence restricted to UK 
populations from 1995 onwards. 
• Review of health consequences restricted to 
systematic reviews from 1990 onwards. 
 
Question II: Are screening tools valid and reliable? 
• Included study designs had to be validation 
studies, i.e. they evaluated a screening tool 
against a standard criterion/comparator. 
• The comparator had to have high sensitivity 
and specificity. 
• The comparator could have any number of 
items, but the index screening tool had to 
comprise 12 items or fewer. The rationale 
behind this postprotocol decision was the 
requirement for screening tools to be used in  
a clinical, not research setting. Long screening 
tools would be unsuitable due to the time 
needed to complete them, and we chose 12 
items as an arbitrary cut-off. This reduced 
the number of screening tools reviewed but 
improved the clinical applicability of our 
findings. 
• Studies were excluded if non-standardised 
clinical interviews were used as the comparator. 
 
Question   III:   Is   screening   for   partner   violence 
acceptable to women? 
• Studies only reporting women’s perceived 
barriers to disclosure but not their views about 
the acceptability of screening were excluded. 
 
Question IV: Are interventions effective once partner 
violence is disclosed in a health-care setting? 
• Intervention studies on co-morbid populations 
were included if all the participants had 
experienced partner violence or if the outcome 
data for those who had experienced partner 
violence were reported separately. 
• Studies of interventions with children 
were included if the mothers were also 
involved; either the mothers received their 
own interventions or they played a role in 
interventions targeted at their children. 
 
Question V: Can mortality or morbidity be reduced 
following screening? 
• Studies that measured mortality, morbidity 
or quality of life outcomes for women were 
included. 
• Studies of screening intervention studies 
that measured proxy measures that were 
potentially associated with decreased morbidity 
and mortality were included, particularly 
documentation of abuse or referral to expert 
partner violence services. 
• Studies where documentation was limited to 
recording the disclosure of abuse, without 
recording more detailed information (about, 
e.g., context, safety and, perhaps, the 
perpetrator), were excluded. 
• Studies reporting changes in identification 
rates with no other outcomes were excluded. 
• Studies that only reported one proxy outcome 
were excluded, unless this was referral to 
expert partner violence services. 
 
Question VI: Is a partner violence screening 
programme acceptable to health professionals  and the 
public? 
• In addition to survey studies, intervention 
studies reporting attitude change were 
included and the before and after data 
reported separately. 
• We did not include studies addressing the issue 
of whether screening is acceptable to male 
members of the public. 
• Papers that only reported on the perceived 
barriers to screening were excluded. 
• Studies were excluded if they only measured 
screening behaviour without reporting attitudes 
towards screening for partner violence. 
 Review m
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TABLE 1 Inclusion criteria for primary studies ordered by review questions 
 
Review questionsb 
 
Inclusion criteria QI QII QIII QIV QV QVI QVII
Participants              
Women aged over 15 years       ×  
Women that report a lifetime experience of partner violence   ×     ×  
Settings              
Health‐care settings – no restrictions on geographical/national setting        
Primary studies conducted  in services outside health‐care systems to which referral can be made  from a health‐care setting       ×  
Study designs              
Randomised  controlled  studies, non‐randomised parallel group  studies,  interrupted  time  series  studies, before‐and‐after  studiesa   ×      × 
Cohort studies   ×    ×   × 
Case–control studies   ×     ×  × 
Cross‐sectional studies   ×   ×  ×   × 
Clusters of case studies  ×  ×   ×  ×   × 
Prevalence  studies   ×   ×  ×  ×  × 
Qualitative  designs  ×  ×   ×  ×   × 
Questionnaire surveys  ×  ×   ×  ×   × 
Studies where  verbal  interaction  (researcher–participant)  aids  results’  formulation  ×  ×   ×  ×   × 
Studies where abused women’s views discussed separately  ×  ×   ×  ×  ×  × 
Studies evaluating a screening tool against a standard criterion  ×    ×  ×  ×  × 
Economic evaluations of  screening  interventions  ×  ×   ×  ×  ×  
Aims of studies included              
Interventions aimed at reducing abuse or  improving the health of the women   ×  ×    ×  × 
Interventions aimed at training staff  ×  ×  ×  ×  ×  ×  × 
Interventions aimed at providing more organisation/system  resources  ×  ×  ×  ×  ×  ×  × 
Studies determining effectiveness of  screening  interventions  ×  ×  ×   ×  ×  × 
Studies determining prevalence of partner violence   ×  ×  ×  ×  ×  × 
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Inclusion criteria 
Review questionsb 
QI QII QIII 
 
QIV 
 
QV 
 
QVI 
 
QVII
Studies determining validity and reliability of screening  ×  ×  ×  ×  ×  × 
Studies determining  cost‐effectiveness of  screening  ×  ×  ×  ×  ×  ×   
Studies determining acceptability of  screening  to women  ×  ×    ×      × 
Studies determining harms associated with  screening  ×  ×  ×  ×    ×  × 
Studies determining acceptability of screening to health professionals and public  ×  ×  ×  ×  ×    × 
Included outcomes              
Incidence of abuse  (physical, sexual, psychological, emotional,  financial)   ×  ×    ×  
Physicalc  and psychosociald  health   ×  ×    ×  
Proxy measurese  ×  ×  ×    ×  
Measures of validity and reliability of screening tools  ×   ×  ×  ×  ×  × 
Degree of acceptability of  screening amongst women  ×  ×   ×  ×  ×  × 
Degree of acceptability of screening  to health professionals  ×  ×  ×  ×  ×   × 
Cost of providing screening  ×  ×  ×  ×  ×  ×  
Changes  in  identification,  information giving and referrals  from screening  ×  ×  ×  ×   ×  × 
Included reporting formats              
Studies published  in peer‐reviewed  journals and  in books by academic publishers        
Funder‐published research reports        
Studies  reported  in European  languagesf        
Reviews, from 1990, on the health impact of partner violence   ×  ×  ×  ×  ×  × 
Studies,  from 1995,  reporting prevalence data  for partner violence  from  the UK   ×  ×  ×  ×  ×  × 
= inclusion criterion;×=not an inclusion criterion.
a    Either women in the ‘before’ group act as  the comparison group (historical controls) or women receiving intervention act as their own controls.
b   QI: What  is the prevalence of partner violence and its health consequences? QII: Are screening tools valid and reliable? QIII: Is screening for partner violence acceptable to women?
QIV: Are  interventions effective once partner violence is disclosed in a health‐care setting? QV: Can mortality or morbidity be reduced following screening? QVI: Is a partner violence
screening programme acceptable  to health professionals and the public? QVII: Is screening for partner violence cost‐effective? For QI, QII and QVII we only included quantitative
data; for QIII, QIV, QV and QVI we included both qualitative and quantitative data.
c   Physical health includes deaths, physical  injuries, including harm, chronic health disorders, sexual health, general measures of physical health.
d   Psychosocial health includes depression, anxiety, post‐traumatic stress, self‐efficacy, self‐esteem, quality of life, perceived social support.
e   Proxy measures include socioeconomic measures (income, housing, employment), the use of safety behaviours, the use of refuges/shelters, the use of counselling, calls to police,
police reports filed, protection orders sought, referral or information‐giving by professionals.
f   We restricted our choice of language to European languages fromWestern Europe, North America and Australasia – i.e. locations considered to be culturally equivalent to the UK.
 Review m
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Table 2  Exclusion criteria for primary studies ordered by review questions 
 
Review questionsa 
 
Exclusion criteria QI QII QIII QIV QV QVI QVII 
Participants              
Female survivors of partner violence aged under 15 years   ×     ×  × 
Female survivors of other  (non‐partner) abuse  (e.g. stranger  rape, adult survivors of child abuse, elder abuse)   ×     ×  × 
Male survivors of partner abuse of any age        
Children of abused women, abused children, and the perpetrators of abuse   ×     ×  
Participants with no previous history of partner violence   ×  ×    ×  × 
Settings              
Studies conducted  in non‐health‐care settings  that are not considered  relevant  to health‐care policy        
Study designs               
Single case studies        
Study aims excluded               
Interventions  targeted at perpetrators of partner violence        
Studies reporting  joint treatments, such as couple and family therapy (even  if the therapy was administered separately to 
women) 
      
Interventions aimed at helping the survivors of child or elder abuse        
Intervention studies  initiated to help the survivors of abuse committed by other family members (such as  in‐laws)        
Interventions targeted directly at helping children of women being abused by  intimate partners        
Interventions aimed at abused men        
Studies determining the acceptability of screening that have not distinguished the perspectives of male and female 
members of  the public 
×  ×   ×  ×   × 
Community and societal  interventions conducted with  the aim of  increasing public awareness of the problem of partner 
abuse 
  ×   ×  ×  
Criminal justice interventions        
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Exclusion criteria 
Review questionsa 
QI QII QIII 
 
QIV 
 
QV 
 
QVI 
 
QVII 
Excluded outcomes              
Studies that do not report outcomes relating to abuse        
Studies that do not report outcomes relating to at  least one of: physical and psychosocial health, socioeconomic  indicators  × ×   × 
and other proxy measures
Primary studies that only measure change  in knowledge or attitudes of professionals about partner abuse     ×   ×  
Studies that only measure  identification of abused women or documentation or safety assessments   ×   ×  ×   
Excluded reporting formats              
Self‐published research reports        
PhD  theses, masters’ and undergraduate dissertations        
Papers published  in non‐European  languages        
Conference abstracts        
Reviews, before 1990, on  the health  impact of partner violence   ×  ×  ×  ×  ×  × 
Prevalence data for partner violence from the UK reported before 1995   ×  ×  ×  ×  ×  × 
= exclusion criterion;×=not an exclusion criterion.
a   See footnote a in Table1.
Review methods  
 
 
   
Question VII: Is screening for partner violence cost- 
effective? 
• Studies had to include an analysis of costs of a 
health-care-based partner violence intervention 
or screening programme. 
  
Identification of 
primary  studies 
We systematically searched for relevant studies 
using strategies that combined content terms 
and study designs (search strings available from 
authors). Searches were made of the international 
literature for published peer-reviewed studies. The 
following sources were used to identify studies. 
 
Electronic databases 
1. Cochrane Collaboration Central Register 
(CENTRAL/CCTR) 
2. Biomedical sciences databases: 
i. MEDLINE 
ii. EMBASE 
iii. CINAHL (Cumulative Index to Nursing 
and Allied Health Literature) 
iv. Database of Abstracts of Reviews for 
Effectiveness (DARE) 
v. National Research Register (NRR) 
vi. Health Management Information 
Consortium (HMIC) 
vii. MIDIRS (Midwives Informatin and 
Resource Service) 
viii. British Nursing Index (BNID) 
ix. NHS Economic Evaluation. 
3. Social sciences databases: 
i. Social Science Citation Index (SSCI) 
ii. International Bibliography of the Social 
Sciences (IBSS) 
iii. PsycINFO 
iv. Applied Social Sciences Index and 
Abstracts (ASSIA). 
Searches of these databases included all studies 
referenced from their respective start dates to 31 
December 2006. In addition to original research 
papers, we also searched for any relevant review 
articles. 
 
In the case of Question I, we only searched for 
review articles in six of the electronic databases: 
MEDLINE, EMBASE, CINAHL, DARE, British 
Nursing Index and Social Science Citation Index. 
We also used backward and forward citation 
tracking to identify other studies and we scrutinised 
papers in the reference lists of included studies. 
 
12 
Other sources 
1. Personal communication with the first or 
corresponding authors of all included articles. 
2. Consultation with members of partner 
violence organisations/research networks in 
the UK, Western Europe, North America and 
Australasia. 
 
We did not hand search any journals. 
  
Selection of studies 
 
Two reviewers independently selected studies 
for inclusion in the review. Where possible, 
disagreement between the two reviewers was 
resolved by discussion. If agreement could not 
be reached then a third reviewer adjudicated. 
Agreement rates across all databases ranged from 
70% to 98%, the average inter-rater agreement 
being 88%. If additional information was needed to 
resolve a disagreement, then this was sought either 
from the first or corresponding author of the study 
in question. 
  
Data extraction and 
methodological  appraisal 
by reviewers 
Data from included studies were extracted by one 
reviewer and entered onto electronic collection 
forms. All of the extractions were independently 
checked by a second reviewer. Again, where 
possible, any disagreements between the two 
reviewers were resolved by discussion. If this was 
not possible, then a third reviewer adjudicated 
and all such decisions were documented. Where 
necessary, the first authors of studies or the 
correspondence authors were contacted to assist 
in resolving the disagreement. One reviewer 
appraised study quality and strength of design in 
relation to the review questions. 
  
Analysis of primary 
data extracted 
The data extraction forms were used to  
compile summary tables of the data and quality 
classification. These formed the basis for our 
narrative synthesis of the primary studies. We 
grouped the findings of the primary studies and 
analysed differences between studies in relation 
to setting (country, type of health-care facility), 
populations (ethnicity, socioeconomic status, 
Health TechnologyAssessment 2009; Vol. 13:No. 16DOI: 10.3310/hta13160 
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
 
 
   
 
  
method of identification/disclosure) and, in the 
case of intervention studies, the nature of the 
intervention. We performed narrative sensitivity 
analysis for each question, testing whether the 
overall findings persisted when the poor-quality 
studies were excluded. When effect sizes were not 
reported, we calculated Cohen’s d if the mean 
changes and standard deviations were reported in 
the papers or were available from the authors. For 
the quantitative studies, after consideration of the 
heterogeneity of interventions and outcomes and 
the overall purpose of this review – assessing the 
extent to which criteria for a screening programme 
were fulfilled – we chose not to pool the data from 
different  studies. 
  
Application of the appraisal 
criteria to our reviews 
We appraised our reviews of intervention studies 
(Questions 4 and 8) using the Quality of Reporting 
of Meta-analyses of Randomised Controlled Trials 
(QUORUM) criteria.21   We appraised our review 
of prevalence studies using the Meta-analysis of 
Observational Studies in Epidemiology (MOOSE) 
criteria.22 
  
Synthesis of the 
qualitative data 
There is no standard method for combining 
qualitative studies. We therefore used a type 
of qualitative meta-analysis.23 We drew on 
Schutz’s framework of constructs24 and on the 
metaethnographic method articulated by Britten 
and colleagues,25,26  although we prefer the term 
‘meta-analysis’ as the studies analysed were not 
ethnographies. The analysis started with two 
parallel strands: (1) identification and examination 
of first- and second-order constructs in the primary 
studies, and (2) methodological appraisal. These 
strands were brought together in the formulation  
of third-order constructs expressing the conclusions 
of the meta-analysis.  
First-order constructs were based on results in the 
primary studies relevant to the review question. 
Second-order constructs were the interpretations 
or conclusions of the primary investigators that 
related to the review question. These constructs 
were identified and grouped from data on the 
extraction forms, referring back to the original 
papers when necessary. For identification of 
second-order constructs, where the investigators 
only presented recommendations, we interpreted 
these as the authors’ conclusions. We intended 
to examine three different types of relationship 
between the constructs extracted from the studies: 
 
1. constructs that were similar across a number 
of studies (reciprocal constructs) and, through 
a process of repeated reading and discussion, 
would yield third-order constructs that would 
express our synthesis of findings that were 
directly supported across different studies 
2. constructs that seemed in contradiction 
between studies; we planned to explain these 
contradictions by examining factors in the 
studies and, where there was a plausible 
explanation, to articulate these as third-order 
constructs 
3. unfounded second-order constructs; i.e. 
conclusions by primary study authors that 
did not seem to be supported by first-order 
constructs.  
This method allows generalisations to be made that 
are not possible from individual qualitative studies. 
 
Further details of the analysis by review question 
are given below. 
 
Question I: What is the prevalence of partner violence 
against women and its health consequences? 
We summarised the prevalence data reported 
in primary studies and the evidence for health 
consequences in systematic reviews. We plotted 
incidence and prevalence with 95% confidence 
intervals and tested the effect on variation of type 
of population (clinical versus community) and 
types of violence with logistic regression models. 
For health consequences, when we cited primary 
studies this was for illustrative purposes only. 
 
Question II: Are screening tools valid and reliable? 
In our narrative analysis of the results of these 
studies we evaluated the effectiveness and accuracy 
of the screening tools in terms of: test sensitivity 
and specificity, test positive and negative predictive 
values, positive and negative likelihood ratios, and 
the diagnostic odds ratio. Where feasible, we had 
also planned to pool results from primary studies 
of the same screening tool that were graded good 
or fair and that had comparable effect measures 
(e.g. sensitivity/specificity, predictive values, risk 
estimates).27   However, no meta-analyses of the 
screening tool evaluations were possible because 
of the heterogeneity of the index tools used in the 
primary studies. Some of the primary studies did 
not fully report diagnostic accuracy, but did report 
the numbers of true positives, false positives, true 
negatives and false negatives for both the index 13 
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and comparator tools. In those cases we calculated male members of the public). We also analysed 
the diagnostic accuracy of the index tool. If the if attitudes varied as a function of individual 
raw data were not available, we requested it from health professional-related variables (such as age, 
the authors. Reliability was judged by Cronbach’s ethnicity, previous training on partner violence, 
alpha, coefficient alpha or Cohen’s kappa. personal experience of caring for abused patients), 
  demographic features (such as the country where 
Question  III:  Is  screening  for  partner  violence the study was conducted, the occupation of the 
acceptable to women? health professional) and features relating to the 
In addition to summarising the data in terms screening process (such as the questions asked, 
of the acceptability of screening to women, we who should ask the questions, where the screening 
also examined if attitudes varied as a function of should occur, barriers to screening). By examining 
women-related variables (such as age, ethnicity, these factors we explored whether and how these 
abuse status, educational status), demographic factors interact to increase or decrease health 
features (such as the country where the study was professionals’ positive attitudes towards screening 
conducted, the setting in which the women were women for partner violence. 
recruited) and features relating to the screening 
process (such as the questions asked and who asked Question VII: Is screening for partner violence cost- 
them). In a synthesis of the interview- and focus effective? 
group-based qualitative and questionnaire-based In anticipation of a paucity of cost-effectiveness 
quantitative studies, we explored whether and how (or any economic) studies of screening for partner 
these factors are associated with women’s positive violence in health-care settings, we modelled the 
attitudes towards partner violence screening. We impact of an intervention in general practice to 
did not perform a meta-regression of the surveys increase identification and referral of women 
because of the heterogeneity of the clinical settings, experiencing partner violence. We used real cost 
of the demographic data collected from the data from a pilot study (PreDoVe, Prevention of 
informants, and the measures of acceptability. Domestic Violence) we completed in three east 
  London practices.28 This model allowed us to 
Question IV: Are interventions effective once partner link intermediate outcomes such as referrals and 
violence is disclosed in a health-care setting? levels of abuse, to medium- and longer-term 
We calculated effect sizes where means and outcomes and costs such as abuse measures, quality 
standard deviations were reported or were of life, employment, housing and civil justice. 
obtainable from the authors of studies. Meta- We combined our data with secondary sources to 
analyses of the studies were planned, but the data estimate the impact on outcomes and costs that 
could not be pooled because of the heterogeneity could not be measured within the pilot study. 
of settings, demographics of the women The model estimated the cost-effectiveness of 
participants, study designs (including the duration the intervention and gave special attention to the 
of follow-up) and the outcomes measured. It was following aspects: 
not possible to construct funnel plots to investigate 
potential publication bias. • Micro-level data collection – PreDoVE collected 
  detailed resource use by women data, and 
Question V: Can mortality or morbidity be reduced we have combined these with unit cost data 
following screening? available from the NHS and relevant studies.29 
Where data were reported, we calculated • Confidence intervals around the estimates 
confidence intervals for differences in identification – we estimated the distribution of costs and 
and referrals between intervention and control outcomes of partner violence. This allowed 
groups. Pooling of data to calculate an overall effect us to investigate the probability that the 
size was not feasible because of the weak study intervention is cost-effective and to establish 
designs: there was only one RCT. a confidence interval around the cost- 
  effectiveness  estimate. 
Question VI: Is a partner violence screening • Sensitivity analyses – we varied all costs and 
programme acceptable to health professionals and outcomes by 25% in univariate analyses. 
the public? • The time lag between cause and effect – the 
  study captured the extent to which women 
These data were summarised in terms of the access services over time, including periods of 
acceptability of screening to health professionals time when the women choose to delay seeking 
(women’s views are given above and we did not 
14 seek to include studies examining the views of 
additional help. 
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Appraisal of 
methodological  quality 
The quality of the primary studies was assessed 
using appraisal tools in accord with the different 
review questions and the nature of the data 
collected. 
 
Question I: What is the prevalence of partner violence 
against women and its health consequences? 
The papers reporting the prevalence studies 
were appraised using the current version of the 
Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) checklist.30  In 
assessing the studies for inclusion, the following 
methodological issues were considered: selection, 
confounding and measurement bias. In this review, 
for each item in the checklist a score of zero or  
one was assigned. The maximum total score was 
22. Although this tool focuses on reporting rather 
than the quality of the primary studies per se, it 
does discriminate between studies of better or 
worse quality. We appraised the methodological 
quality of reviews with the Critical Appraisal Skills 
Programme (CASP) systematic review appraisal 
tool31. The scores for individual items informed 
a judgment about whether the review was high, 
medium or low quality. This judgment was made 
independently by two reviewers who did not 
disagree. 
 
Question II: Are screening tools valid and reliable? 
The papers reporting the validation of screening 
tools were appraised using the 14-item Quality 
Assessment of Diagnostic Accuracy Studies 
(QUADAS).32 The tool allows studies to be rated 
for bias (eight items), variability (one item) and 
reporting (five items); these include patient 
spectrum, selection criteria, reference standard, 
disease progress, partial verification, differential 
verification, incorporation, test execution, blind 
analysis, interpretation, indeterminate results 
and study withdrawals (see Appendix 3.1). The 
QUADAS does not have a scoring system and the 
outputs are narrative results relating to the various 
sources of bias rather than a single score. This is an 
advantage in assessing diagnostic accuracy studies, 
as total scores tend to ignore the importance of 
individual items and do not take account of the 
direction of bias under different contexts. We used 
the QUADAS to assess both within-study bias (the 
level of methodological quality of each primary 
study) and between-study bias (the proportion of 
studies that have not accounted for a particular 
bias) to give an overall picture of the quality of the 
validation studies in this field. 
Question   III:   Is   screening   for   partner   violence 
acceptable to women? 
Quantitative studies that examined women’s 
attitudes towards screening for partner violence 
were appraised using the STROBE30 checklist 
(see Question I above). In addition to scoring 
the individual primary studies, we ranked all the 
studies and carried out a sensitivity analysis by 
comparing results for those studies in the top 
quartile with the results for all the studies. 
 
We appraised the methodological quality of 
qualitative studies for this question with the 
CASP qualitative appraisal tool.31 The tool has 10 
questions that address three broad issues: rigour 
(has a thorough and appropriate approach been 
applied to key research methods in the study?); 
credibility (are the findings well presented and 
meaningful?); and relevance (how useful are the 
findings?). In this review, for each item in the 
checklist a score of zero or one was assigned and 
a maximum score of 41 was possible. As for the 
quantitative studies, the resulting scores of the 
primary studies were ranked and those in the 
upper quartile were used for a sensitivity analysis. 
We have shown in a previous study that ranking of 
CASP scores for qualitative studies is a relatively 
robust method for ranking them by quality.33 
 
Question IV: Are interventions effective once partner 
violence is disclosed in a health-care setting? 
The United States Preventative Services Task 
Force (USPSTF)34 quality appraisal framework was 
used to assess the primary intervention studies 
included in the review. This tool rates the internal 
validity of a study (in terms of good, fair or poor) 
and its external validity, as well as the quality 
of execution of the study and its study design. 
The overall strength of evidence for each type of 
intervention could then be determined on the basis 
of the following criteria: the suitability of study 
design (greatest, moderate and least); the quality  
of execution of the study (based on the internal 
validity of the primary studies); the number of 
studies that fulfilled minimum suitability and 
quality criteria; and the size and consistency 
of reported effects. The combination of these 
factors determined the final score for evidence of 
effectiveness for each category of interventions 
(strong, sufficient or insufficient). For studies that 
used an RCT design, we also applied the Jadad 
score35 to obtain a further assessment of quality. 
Trials with lower Jadad scores are associated with 
overestimates of treatment effect. For further 
details of the USPSTF and Jadad quality appraisal 
methods, see Appendices 3.2 and 3.3. 
15 
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Question V: Can mortality or morbidity be reduced 
following screening? 
These studies were also appraised using the 
USPSTF quality appraisal framework34 and the 
Jadad score.35 
 
Question VI: Is a partner violence screening 
programme acceptable to health professionals  and 
the public? 
In accordance with our assessment of the 
methodological quality of studies included 
under Question III, we once again used the 
STROBE checklist30  to appraise the quality of the 
quantitative studies and the CASP tool31 to appraise 
the qualitative studies we included. Sensitivity 
analyses of those studies that ranked in the upper 
quartiles for methodological quality were also 
performed. 
 
Question VII: Is screening for partner violence cost- 
effective? 
We did not find any studies that fulfilled our 
inclusion criteria. 
Application of 
review evidence to 
National Screening 
Committee criteria 
Once the review was completed, its findings were 
summarised in relation to NSC criteria. The 
research group systematically considered each of 
these criteria against the review evidence using 
informal consensus to judge the extent to which the 
criteria were fulfilled. As noted in our proposal, the 
timescale of the review did not allow engagement 
with an external reference group. We did present 
our initial findings to a meeting of the National 
Domestic Violence and Health Research Forum. 
These findings and the design of the reviews were 
discussed by the Forum. There were no specific 
suggestions for further searching or analysis; 
comments on the questionable applicability of  
the NSC criteria to domestic violence screening 
informs our discussion of this issue in Chapter 11. 
We approached Health Ending Violence and Abuse 
Now (HEVAN), the domestic violence practitioners’ 
forum (Loraine Bacchus was secretary of the 
group), but no meeting was possible within the 
timescale of the review. 
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Chapter 4 
What  is  the prevalence of partner violence 
against women and its impact on health? 
(Question  I) 
  
Prevalence of partner 
violence against 
women in the UK 
 
One of the prerequisites for an effective screening 
programme in clinical settings, and the first NSC 
criterion, is that the condition is an important 
health problem. Two dimensions of importance 
are prevalence and health impact. In this section 
we review prevalence studies in England, Wales, 
Scotland and Northern Ireland. 
 
Methodological  challenges 
Measuring the prevalence of partner violence is 
problematic; studies employ different definitions, 
use different questions, and examine different 
populations and time frames. Additionally, there 
are various methods of administering questions, for 
example self-completed or researcher-completed, 
which may affect responses.36  
The most common definition of partner violence 
used in UK prevalence studies only includes 
physical violence. More recent studies have 
broadened the definition to include emotional, 
sexual, psychological and financial abuse, as 
well as stalking. Others, although making 
reference to emotional and sexual violence in 
the definition of partner violence, only report 
the prevalence of physical violence. Even with 
this restricted focus, there are disparities: some 
researchers include threats of physical violence, 
others include only severe physical violence. 
The number and content of questions used to 
measure prevalence vary between studies. An 
additional obstacle to comparing studies is the 
modification of instruments without detailing 
how, or if, the instrument in its adapted format 
has been validated. Prevalence rates are reported 
over differing time frames. Reporting lifetime 
prevalence rates may suffer from the problem of 
recall bias. However, reporting 1-year prevalence 
(abuse in the past year) may under-represent the 
problem as women may not yet have had sufficient 
time to acknowledge or identify their experiences 
as partner violence. These disparities go some way 
to accounting for the varying prevalence rates.  
Prevalence studies are likely to under-represent  
the extent of the problem, as violence may not be 
disclosed to the researcher. Furthermore, it is likely 
that some women experiencing partner violence 
are beyond the reach of epidemiological studies as 
their abusive partners may not allow them to speak 
to a researcher alone, or may not even allow them 
to leave the house. 
 
Results 
Sixteen studies (reported in 18 papers) met our 
inclusion criteria. Lifetime prevalence ranged from 
13% to 31% in the five community-based samples 
(general population) and from 13% to 41% in the 
11 studies of women recruited in health service 
settings (clinical populations). One-year prevalence 
ranged from 4.2% to 6% in the general population 
studies and from 4% to 19.5% in the clinical 
population studies. For details of study design, 
study results and quality appraisal, see Appendix 
4.1. 
  
General population 
 
A study by Dominy and Radford37 reported a 31% 
lifetime prevalence of physical, emotional, sexual 
and psychological abuse in women living in Surrey. 
A random sample of 484 women in shopping malls 
and markets was administered a questionnaire. The 
sample was intended to be representative of the 
population of married women or those with long- 
term partners. However, the venues and timing 
of the sampling meant that women in full-time 
employment or education were likely to be under- 
represented. Women isolated by their partner or 
having their movements closely monitored by a 
partner were also likely to be under-represented. 
For these reasons, both the prevalence cited for 
partner isolation and the overall prevalence of 
partner violence may be an underestimate. 17 
Review Question I  
  
 
  
 
Walby and Allen36 measured the prevalence of 
physical and sexual violence in England and 
Wales. The study recruited a sample of 22,463 
people, weighted to ensure that it was nationally 
representative. A lifetime prevalence of 25.9% 
and 1-year prevalence of 6%* were found for 
female respondents reporting physical, emotional 
and financial abuse, threats or force. Lifetime 
prevalence of sexual assault was estimated at 16.6% 
and 2.1%. These figures may be an underestimate 
as only people living in private households were 
included in the sampling frame, so women staying 
in refuges or with relatives were not included. The 
study found that younger women and those who 
were separated were at greater risk of violence.  
An updated version of the above study38 used a 
computerised self-completion method to estimate 
the prevalence of physical, emotional and financial 
abuse, threats or force amongst a nationally 
representative sample of 24,498 men and women. 
Prevalence figures were adjusted to make them 
comparable with figures from the above study. 
The adjusted lifetime prevalence was 25.4% and 
the 1-year prevalence was 4.7%. The lifetime 
prevalence of sexual assault was 22.7% and the 1-
year prevalence was 2.7%. 
 
A study by Carrado39 used sampling quotas to 
ensure the sample of 971 women asked about 
partner violence was representative of the general 
population with regards to age, socioeconomic 
group, relationship status and geographical 
region. The questions relating to violence were 
administered as a self-completion questionnaire, 
part of a regular commercial bimonthly survey. The 
questions were derived from the Conflict Tactics 
Scale.19 The study found a 13% lifetime prevalence 
of physical assault and 1-year prevalence of 5%. It 
also reported a higher prevalence in women who 
are young and single.  
Mirrlees-Black and Byron40 used a representative 
sample of 6098 women to estimate the prevalence 
of partner violence (defined as physical assault)  
in 16–59-year-olds in England and Wales. 
They found a lifetime prevalence of 22.7% and 1-
year prevalence of 4.2%. They also found that 
prevalence decreased with age. 
       
*The figures reported here are those recalculated by 
Finney38 (and presented in Table A.5 of that report) so as to 
18 enable comparisons with the 2001 findings.36 
  
  
Clinical populations 
General practice 
A study by Richardson et al.41 measured the 
prevalence of partner violence in 1207 women 
attending a general practice, finding a 41% lifetime 
prevalence and a 17% 1-year prevalence of physical 
abuse by a partner. Prevalence was higher among 
women who were divorced or separated, and 
amongst women aged 16–24 years, and lower in 
women born outside the UK. 
 
Antenatal/postnatal  care 
We found five papers (four studies) that estimated 
the prevalence of partner violence in women 
attending antenatal or postnatal clinics in the UK.  
Bacchus and colleagues42 measured the lifetime 
prevalence and 1-year prevalence of physical, 
sexual and emotional abuse in a cohort of 892 
women attending maternity services in south 
London; they asked about partner violence at 
booking, at 34 weeks of gestation and postpartum. 
The study reported a lifetime prevalence of 13% 
and prevalence (during the pregnancy) of 6.4%.  
A second study conducted by Bacchus and 
colleagues43,44  measured a 23.5% lifetime 
prevalence of partner violence (physical, sexual 
and psychological) from a sample of 200 women 
receiving antenatal or postnatal care at a south 
London hospital.  
In a study based on a cohort of 7591 women from 
18 weeks’ gestation to 33 months postpartum, 
Bowen and colleagues45 found that the prevalence 
(during pregnancy and a 33-month postpartum 
period) of partner violence steadily increased 
through the second half of pregnancy and after 
delivery. At 18 weeks’ gestation, 5.1% of the women 
experienced some form of abuse (physical, sexual 
or emotional) and this increased to 11% at 33 
months after the birth. However, this study had 
substantial limitations, including a high attrition 
rate (45%), which may result in an underestimated 
prevalence, because those experiencing partner 
violence were more likely to be lost to follow- 
up. Moreover, the questionnaires were posted 
to women, which may have discouraged some 
respondents from reporting abuse if they were 
still living with the abuser. A further complication 
of this study is that the women who completed 
the study differed from those lost to follow-up: 
they were more likely to have attended higher 
education, have fewer children, be married, be at 
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least 25 years old when their first child was born, 
and be homeowners.  
A questionnaire survey by Johnson and colleagues46 
of 500 consecutive women in an antenatal booking 
clinic in a hospital in the north of England found 
a 17% lifetime prevalence of physical, sexual and 
emotional abuse in pregnant women. Abuse was 
most prevalent in women aged between 26 and 30 
years.  
Thus lifetime prevalence of partner abuse in 
women receiving antenatal or postnatal care in the 
UK ranges from 13% to 24%. One-year prevalence 
was estimated at 6.4% or 11% depending on the 
type of study and the stage of pregnancy at which 
women are asked about abuse. 
 
Accident and emergency 
departments 
We found three primary studies that measured the 
prevalence of partner violence in women attending 
accident and emergency departments in the UK. 
 
In a study by Boyle and Todd,47 using randomly 
allocated time blocks, complete data were collected 
from 256 patients attending the emergency 
department of a Cambridge hospital. The study 
reported a 22.1% lifetime prevalence of physical, 
sexual and emotional abuse.  
Sethi and colleagues48,49 purposefully sampled 22 
nursing shifts, representative of day, night and 
weekend shifts. A questionnaire was administered 
to 198 women attending an inner city accident and 
emergency department. The study found a 34.8% 
lifetime prevalence of physical abuse. Prevalence 
was highest in women aged 30–39 and not in paid 
employment. A 6.1% 1-year prevalence of physical 
abuse in the past year was also reported. Neither 
this nor the Cambridge study reported which 
specific instrument was used to measure the rate of 
violence, so the difference in prevalence between 
the two studies might also be due to the use of 
different instruments in addition to population 
differences.  
Wright and Kariya50 sought to ask consecutive 
assault victims attending a Scottish accident and 
emergency department over a 2-month period 
about partner violence. The paper reported that 
41% of the 46 women asked had experienced 
partner violence in the past 2 months and that 
63% of the women who were survivors of partner 
violence had experienced previous incidents. The 
paper did not define types of assault and probably 
only measured physical assault.  
Among women attending accident and emergency 
departments in the UK, the prevalence of partner 
violence has been estimated between 22% and 35% 
depending on the definition adopted. 
 
Gynaecology clinics 
We found one study that examined the 
prevalence of partner violence in women 
attending gynaecology clinics in the UK. The 
study, by John and colleagues,51 reported a 21% 
lifetime prevalence of physical violence and a 
1-year prevalence of 4%, with most abuse being 
perpetrated by ex-husbands or ex-boyfriends (32% 
and 29% respectively). Prevalence was highest in 
women aged 31–40 years. 
 
Pregnancy counselling 
A study by Keeling52 of women attending 
pregnancy counselling when seeking a termination 
reported a 35.1% lifetime prevalence for physical 
and emotional abuse, with 19.5% of the women 
having experienced abuse in the past year. 
 
Family planning 
A study by Keeling and Birch53 of women attending 
family planning clinics reported a 34.9% lifetime 
prevalence of physical, sexual, emotional and 
financial abuse, with a 1-year prevalence of 14%. 
Higher prevalence rates were observed in women 
aged 35–39 years and 45–49 years.  
Figures 1 and 2 display the 1-year and lifetime 
prevalences (with 95% confidence intervals) of 
partner violence reported in the primary studies, in 
order of standard error. Table 3 lists the studies and 
the definitions of intimate partner violence (IPV) 
used.  
Table 4 shows the results of a logistic regression 
model testing whether the definition of IPV used 
in the studies or type of population (community 
versus clinical) is associated with variation in 
prevalence. We found that community populations 
have significantly lower prevalence, but there was 
no consistent relationship between the number of 
different types of IPV measured and the reported 
prevalence. 
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Figure 1  Plot of 1‐year prevalence of partner violence with 95%  confidence  intervals. *See Table 3  for definitions of  IPV used  in  these 
studies. Note:  Bowen  200545   –  18 weeks’  gestation  to  33 months’  postnatal  prevalence; Wright  199750   –  2‐month  prevalence. 
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Figure 2  Plot of  lifetime prevalence of partner violence with 95%  confidence  intervals. *See Table 3  for definitions of  IPV used  in  these 
studies. 
 
Discussion 
Estimates of prevalence based on community 
samples can underestimate the extent of partner 
violence,56 and estimates of prevalence in clinical 
samples will overestimate population prevalence, 
as survivors of partner violence are more likely  
to need health care than the general public (see 
below). Both types of studies are useful, however. 
Community samples will give a better estimate  
of population prevalence, and clinical samples 
are essential for understanding the impact of 
partner violence on health services. Several studies 
20 excluded non-English speakers, which may affect 
the generalisability of results, particularly in UK 
urban areas.  
Those general population studies that scored most 
highly on the STROBE36,39  assessment tool (see 
Appendix 4.1) had estimates of prevalence that 
differed from the lower quality studies; however, 
there was similar variation in prevalence rates 
between high-quality studies, so this variation  
cannot be accounted for by study quality (see 
Appendix 4.2). It was difficult to compare the 
clinical population studies due to the heterogeneity 
of settings, age of the women and the definition 
of partner violence, but again study quality 
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Table 3 Definitions of intimate partner violence (IPV) used in studies in Figures 1 and 2 
 
Study Definition of IPV Study Definition of IPV 
Bacchus et al., 
200442 
*Bacchus et al., 
200444 
Physical, sexual, emotional  Johnson et al., 200346  Physical,  sexual, emotional 
Physical, sexual, psychological  Keeling, 200452  Physical,  emotional 
Bowen et al., 200545         Physical, sexual, emotional  *Keeling and Birch, 200453  Physical,  sexual, emotional, 
financial 
Boyle and Todd, 
200347 
Physical, sexual, emotional  Mirrlees‐Black and Byron, 199940  Physical 
Carrado, 199639  Physical  Richardson et al., 200241  Physical 
Coid et al., 200354  Sexual  Sethi et al., 200448  Physical 
Dominy and 
Radford, 199637 
Physical, emotional, sexual and 
psychological 
Walby and Allen, 200436  Physical, emotional, financial 
and threats 
*Finney, 200638  Physical, emotional, financial and 
threats 
*Walby and Allen, 200436  Sexual 
*Finney, 200638  Sexual  Wright and Kariya, 199750  Physical 
John et al., 200451  Physical 
  
Table 4   Logistic  regression of population  (community vs clinical) and definition of  intimate partner violence  (IPV; physical, emotional/ 
psychological,  threats, sexual an d/or  financial)  in  relation  to prevalence  
  
Comparison 
 
Incidence rate 
ratio 
95% Lower 
confidence 
limit 
95% Upper 
confidence 
limit 
  
p-Value 
Lifetime prevalence 
Setting: community vs clinical 
 
 
0.77
 
0.73
 
0.82
 
 
< 0.001
Count of 2 vs 1  1.22  1.18  1.25  < 0.001 
Types of 3 vs 1  0.74  0.66  0.82  < 0.001 
Violence 4 vs 1  1.27  1.04  1.56  0.02 
One-year prevalence 
Setting: community vs clinical 
 
 
0.24 
 
0.22 
 
0.27 
 
 
< 0.001 
Count of 2 vs 1  1.83  1.70  1.96  < 0.001 
Types of 3 vs 1  0.93  0.83  1.05  0.24 
Violence 4 vs 1  1.19  0.86  1.65  0.30 
 
does not seem to predict prevalence. Within the 
clinical population studies, the prevalence seems 
to be highest in women attending accident and 
emergency departments. The lowest prevalence 
appears to be in antenatal populations; however, 
this may be due to women in these samples being 
younger than in other clinical populations. 
  
Health impact 
Results 
We found 13 reviews reporting the health consequences of 
partner violence. Publication dates 
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ranged from 1995 to 2006. Three 
reported mental health outcomes,57–59  
five reported reproductive health 
effects 60–64  and five reported effects 
on children.65–69 For details of review 
study design and quality appraisal 
see Appendix 4.3. 
 
Mental health 
A meta-analysis by Stith and 
colleagues70 synthesised results from 
primary studies published between 
1980 and 2000 that measured the 
association of partner violence with 
depression and with alcohol abuse. 
Six studies, with a total 
of 899 participants, reported the association with 
depression. The pooled effect size was moderately 21 
Review Question I  
  
 
  
 
large (r = 0.28, p < 0.001). The authors state that 
it is reasonable to assume that depression is a 
consequence of partner violence, although they 
did not substantiate this as a separate analysis of 
longitudinal studies. Eleven studies, with a total 
of 7084 participants, reported the association 
between alcohol abuse and partner violence, which 
was relatively small (r = 0.13, p < 0.001), with some 
evidence for a bidirectional effect.  
Golding57   conducted a meta-analysis and reviewed 
results from published English language studies 
on physical abuse and threats of physical force as 
risk factors for mental health problems in women. 
Studies were excluded if no specific prevalence 
rates were given or if the study was limited to 
women experiencing abuse during pregnancy. 
Authors looked at the strength of association, 
consistency, temporality and biological gradient. 
Significant associations were found between 
partner violence and all outcome measures: 
depression, suicidality, post-traumatic stress 
disorder (PTSD), alcohol abuse or dependence, 
and drug abuse or dependence. When prevalence 
rates of mental health problems among survivors 
of partner violence were compared with those 
reported in general populations, the association 
with abuse was strong. A second indicator of 
strength of association was the odds ratio calculated 
from the subset of studies of survivors of partner 
violence in which comparison groups were used. 
The weighted mean odds ratio ranged from 3.6 to 
3.8 in studies of depression, suicidality and PTSD, 
and was 5.6 in studies of alcohol and drug abuse or 
dependence. Although absolute prevalence rates 
varied across studies, the magnitude of association 
between partner violence and mental health 
problems was more consistent. The size of this 
association was statistically homogeneous in studies 
of PTSD, alcohol abuse and drug abuse. In studies 
of depression and suicidality, the variability among 
odds ratios was accounted for by sampling frames. 
The studies indicate that depression tends to lessen 
following the cessation of violence, and depression 
and PTSD seem to respond to the presence 
or absence of violence. Severity or duration of 
violence was associated with the prevalence or 
severity of both depression and PTSD, suggesting 
that dose–response relationships appear to exist 
for these disorders. Overall this review provides 
compelling evidence that adverse mental health 
outcomes can be a consequence of physical abuse 
or the threat of physical violence. 
 
Jones and colleagues58 reviewed 43 studies of 
survivors of partner violence published between 
22 1991 and 2001, to estimate the association of 
   
 
  
partner violence and PTSD. A consistent finding 
across varied samples (from clinical settings, 
refuges, hospitals and community agencies) was 
that a substantial proportion of survivors (31–84%) 
exhibit PTSD symptoms. The review also found 
that the partner violence refuge population is at a 
higher risk for PTSD than survivors who are not in 
refuge. The extent, severity and type of abuse were 
found to be associated with the intensity of PTSD. 
 
Reproductive health 
In a review of 14 published case–control and cohort 
studies, Murphy and colleagues64 determined 
whether there is evidence for an association 
between physical, sexual or emotional abuse during 
pregnancy and low birthweight. Studies had to  
have English language abstracts, focus on women 
abused during pregnancy or pregnant women 
with a past abusive relationship, and fulfil quality 
criteria. Only 8 out of 14 studies fulfilled all the 
inclusion criteria and were entered into a meta- 
analysis; this gave a pooled odds ratio of 1.4 (95% 
confidence interval 1.1–1.8) for a low birthweight 
baby in women who reported physical, sexual or 
emotional abuse during pregnancy, compared 
with non-abused women. Removing the two case– 
control studies from the analysis reduced the odds 
ratio to 1.3 (95% confidence interval 1.0–1.8). 
This meta-analysis provides tentative evidence of 
an association between partner violence during 
pregnancy and low birthweight babies.  
Boy and Salihu62 reviewed 30 peer-reviewed  
studies on the impact of partner violence (physical, 
sexual and emotional) on pregnancy and birth 
outcomes. To be included in their review, studies 
must have been peer reviewed and research 
based, included a study population of at least five 
women, pertained to partner violence, included 
pregnant participants and included data on the 
outcomes searched. One study, which focused on 
partner violence and trauma during pregnancy, 
found that 88% of the pregnant women who had 
been physically injured had been attacked by 
their husband or boyfriend. In this population 
eight fetal deaths occurred, with one fetal death 
being the result of an assault, yielding a violence- 
related fetal mortality rate of 16.0 per 1000. Of 
the six studies focusing on maternal mortality, one 
case–control death review found that a woman 
abused during pregnancy was three times more 
likely to be killed by a partner as a woman who 
is not abused (odds ratio 3.08, 95% confidence 
interval 1.9–5.1). The remaining five studies on 
maternal mortality were based on death reviews 
and reported that more than half the deaths were 
the result of murder; the involvement of a husband 
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or boyfriend was documented in multiple instances. 
Three death reviews focused on intentional trauma 
deaths; all noted that the majority of homicides 
were the result of partner violence. Twenty- 
three studies looked at partner violence and 
pregnancy outcomes. Three cohort studies found 
no significant differences between abused women 
and non-abused women, 7 studies reported mixed 
results, and the remaining 13 found significant 
differences between the outcomes of abused 
women and non-abused pregnant women. The 
three cohort studies that found no association 
between physical violence and negative outcomes 
did, however, note differences between abused 
and non-abused pregnant women: abused women 
were more likely to have uterine contractions and 
increased peripartum complications (p < 0.05)71 
and were also significantly more likely to report 
substance use during the pregnancy (p < 0.001).72 
Out of the seven studies reporting mixed results, 
two addressed fetal death and found that mothers 
abused during pregnancy were 3.7 times more 
likely to have a fetal death (95% confidence interval 
1.36–9.94); they also suffered higher rates of 
miscarriage (p < 0.05). None of the seven studies 
indicated a relationship with low birthweight or 
preterm delivery; however, two studies found the 
smallest babies were born to abused women. Six 
of the seven studies reported a variety of negative 
behaviours and complications in abused women. 
Abused women were found to have more kidney 
infections (odds ratio 2.7, 95% confidence interval 
1.3–5.5) and were 1.5 times more likely to deliver 
by Caesarean section. Three studies reported 
significantly higher rates of substance abuse during 
pregnancy in abused compared with non-abused 
women. Ten of the 13 studies with significant 
differences found a significantly higher proportion 
of low birthweight babies in women abused during 
pregnancy. In the studies reporting a relationship 
between low birthweight and partner violence, 
the percentage of abused women delivering a 
low birthweight infant ranged from 9% to 22%. 
Preterm delivery was also reported as a negative 
outcome due to violence. Four studies reported an 
increased risk of preterm delivery among abused 
women compared with non-abused women. One 
study found a statistically significant difference  
only in a private hospital. The relative risk for 
delivering a preterm infant if the pregnant woman 
was abused ranged from 1.6 (95% confidence 
interval 1.14–2.28) to 2.7 (95% confidence interval 
1.7–4.4). Victims of violence were more likely to 
have negative health behaviours during pregnancy: 
10 studies reported greater use of alcohol and 
other substances when compared with non-abused 
women; and two studies also noted that abused 
women were at increased risk of low weight gain 
during pregnancy.  
A review of nursing studies (including qualitative 
designs) published after 1995 on the relationship 
between partner violence and women’s 
reproductive health was conducted by Campbell 
and colleagues.61 Two studies examined the effects 
of forced sex on women’s health. One study found 
that sexually assaulted women had significantly 
more gynaecological problems than those who 
were not sexually assaulted (p = 0.026). That study 
also found that women reporting more forced sex 
experiences reported significantly greater levels of 
depression (p = 0.018) and a less positive physical 
self-image than those not sexually assaulted. The 
second study found that women who were sexually 
and physically abused had more symptoms than 
those who were only sexually abused. One study 
investigated the association between abuse and 
risk of sexually transmitted infections, and found 
the rate among the abused, assaulted and raped 
groups (29%, 31% and 31.3% respectively) was 
significantly higher than in non-abused women 
(14.9%, p = 0.0001). One study examined records 
from 389 sexual assault victims, 71% of whom knew 
the perpetrator; it found that more than three- 
quarters (78.3%) of those resuming sexual activities 
reported sexual difficulties and 17.1% reported 
gynaecological pain, but almost all of them had 
normal general physical (98%) and gynaecological 
(95%) examinations.  
A literature review by Jasinski60 reviewed findings 
on the relationship between partner violence and 
pregnancy, including the health consequences  
for the mother and child. Two studies were found 
that suggested partner violence was associated 
with late booking into antenatal care. Five studies 
found an association between partner violence 
and low birthweight, whereas two did not. The 
author raised the possibility that the finding of no 
relationship may be due to confounding variables, 
such as low socioeconomic status and gestation. 
Sample size differences and the lack of a standard 
cut-off for what constitutes low birthweight may 
also account for the conflicting findings. Evidence 
regarding the relationship between partner 
violence and premature labour was also found 
to be contradictory, with four studies finding an 
association and three finding none. 
 
Nasir and Hyder63 reviewed findings from three 
English language studies on the impact of 
partner violence on adverse pregnancy outcomes 
in developing countries. A study in Nicaragua 
demonstrated that women with low birthweight 23 
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babies were more likely to have experienced abuse 
during pregnancy (odds ratio 2.07 for threats, 
3.27 for slaps, 5.04 for blows), and a multivariate 
analysis showed partner violence to be a strong risk 
factor. A study in India reported that women who 
had suffered beatings were significantly more likely 
to have experienced miscarriage or infant death 
(p < 0.05). Another study failed to demonstrate 
any significant difference in pregnancy outcomes 
between abused and non-abused women in China; 
however, it is not stated which outcomes were 
measured. 
 
Impact on children’s health 
In total, we identified five reviews reporting the 
impact that witnessing partner violence had on the 
health of child witnesses. Publication dates range 
from 1995 to 2006.  
Buehler and colleagues65 conducted a meta-analysis 
of 68 studies (including dissertations), published in 
English, to explore whether interparental conflict 
is associated with internalising and externalising 
problems in children aged 5–18 years. The 
average effect size of the association between 
interparental conflict and youth problem behaviour 
was 0.32 (weak to moderate effect). Variability in 
these effects was explained by the characteristics 
of participants and methodological variables. 
The review provides some evidence that conflict 
between parents is one of several important familial 
correlates of internalising and externalising youth 
problem behaviours; however, the authors state this 
conclusion must be tempered given that 66% of the 
effects in this meta-analysis were non-significant. 
 
A review by Bair-Merritt and colleagues,66 
measuring the relationship between exposure to 
partner violence and postnatal physical health 
using contemporaneous control groups, contained 
22 studies. Eight studies addressed general health 
and use of health services. Although children 
exposed to partner violence are at risk of under- 
immunisation, the evidence is inconclusive 
regarding overall health status and use of health 
services. Evidence was insufficient to draw a 
conclusion about whether abused women are less 
likely to breastfeed than non-abused women, as 
only one study was found which addressed this 
issue. Evidence was also insufficient to draw a 
conclusion about whether infants born to abused 
mothers were more likely to have poor weight  
gain than infants born to non-abused mothers, 
as only two studies addressed this issue. Based on 
seven studies, there was an association between 
witnessing partner violence and adolescent and 
24 adult risk-taking behaviours (including smoking, 
   
 
  
alcohol abuse, drug abuse, sexually transmitted 
infections, teenage pregnancy and unintended 
adult pregnancy).  
Kitzmann and colleagues67 conducted a meta- 
analysis of 118 studies reported in English and 
published before 2000 (including dissertations) 
examining psychological, emotional, behavioural, 
social and academic outcomes of children exposed 
to physical aggression between parents or carers. 
Similar estimates of effect were obtained for a 
range of outcomes. Exposure to partner violence 
is associated with children internalizing and 
externalising problems to a similar degree. The 
effect sizes for social and academic outcomes 
were of similar magnitude as those found for 
internalising and externalising. The authors also 
synthesised effect sizes for measures of children’s 
specific cognitive, behavioural and emotional 
responses to simulated or hypothetical episodes 
of conflict between adults. As a group, effect  
sizes based on these specific measures did not 
differ from those based on measures of general 
adjustment. Relative to other children, children 
exposed to partner violence showed greater 
negative affect and more negative cognitions in 
response to stimulated or hypothetical conflict 
between adults, and were more likely to report 
that they would intervene or show aggression in 
response to conflict. There was less consistent 
evidence that witnesses were more likely to 
withdraw or show less positive coping, perhaps 
because these responses are more difficult to assess. 
 
An ‘integrative’ review was conducted by Attala and 
colleagues.68 The reviewers included 11 studies 
reported in peer-reviewed journals (with over 800 
children and their parents); the studies investigated 
the effects on children, aged up to 18 years, of 
witnessing partner violence. Three of the studies 
were qualitative. Four studies examined partner 
violence and the impact on children’s emotional 
conditions or physical aggression. The first study 
found marital distress was positively associated with 
increased concern and social support-seeking by 
children. Children whose parents reported marital 
aggression and dissatisfaction were also found to 
demonstrate more preoccupation with physical 
aggression, concern and support-seeking responses 
than children with non-distressed parents. The 
second study found that preschoolers who had 
experienced familial violence had below-average 
self-concept scores. Preschool children were 
reported to have more difficulties in adjustment 
than children at school. The third study found 
that children who had recently witnessed violence 
between parents tended to have the lowest levels of 
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social competence ratings, whereas their mothers 
reported the greatest health and emotional 
difficulties. The fourth study found that there  
was no significant difference in the amount of 
behavioural problems demonstrated by children 
who had witnessed partner violence, children who 
had been abused by their parents, and children 
who had experienced child abuse and witnessed 
partner violence.  
Three studies examined partner violence and the 
impact on children’s externalising and internalising 
behaviours. The first study found that, compared 
with controls, survivors reported feeling more 
highly stressed as parents. The amount of stress 
was the most powerful predictor of children’s 
behaviour problems. Children from violent families 
had more internalising behaviour problems 
and were more aggressive than children from 
the comparison group. The second study found 
that witnessing physical and verbal interparental 
violence was related to the type and extent of 
behaviour problems displayed by young children. 
Residents of refuges showed significant levels of 
externalising and internalising behaviours with 
lower levels of functioning than the non-refuge 
group. The third study found that, compared 
with controls, children who witness abuse and 
are abused themselves showed the most distress, 
followed by those witnessing abuse. Preschool 
children were reported to have more difficulties  
in adjustment than children at school. Two studies 
examined the impact of partner violence on 
children’s conduct problems. The first found that 
parental marital abuse was associated with conduct 
problems in children who witnessed it. The second 
study found that two-thirds of the child residents  
of a partner violence refuge had experienced  
abuse or neglect. Of 21 schoolchildren, 46% had 
academic problems; of 28 preschoolers, 39% 
showed developmental delays; and of 48 children 
of all ages, 75% demonstrated behaviour problems. 
Two studies examined partner violence and the 
impact on parental aggression. The first found 
that parental aggression was highly associated with 
having witnessed partner violence as a child. This 
association did not vary by gender or by single 
or dual parent status of the family. The second 
study found a significant association between 
marital conflict and children’s behaviour problems. 
Boys exposed to marital conflict were at risk of 
being abusive in their adult relationships. One 
study examined the impact of partner violence 
on children’s depressive symptoms and found 
that children who were physically abused by their 
parents and who witnessed violence were more 
likely to report depressive symptoms. Mothers of all 
groups reported more problem behaviours than the 
children acknowledged. Fathers in the same study 
groups were no more likely to report behavioural 
problems than fathers from the control group.  
Kolbo and colleagues69 reviewed 29 studies 
of the initial effects on children of witnessing 
partner violence, extending a previous review 
by another group.73 Their findings indicated 
that children who witness partner violence are 
at risk for maladaptation in one or more of the 
following domains of functioning: (1) behavioural, 
(2) emotional, (3) social, (4) cognitive and (5) 
physical. The case studies examining behavioural 
functioning all shared a high degree of congruence 
in their findings of witnesses’ undesirable 
behaviour; however, 4 of the 16 correlational 
studies found no significantly higher instances of 
conduct problems, hyperactivity and aggression 
among witnesses of abuse than among comparison 
children. When only the findings from the recently 
conducted studies are compared, only one study 
does not find significant differences. This suggests 
that the evidence of the effects of witnessing 
partner violence on children’s behavioural 
functioning is less equivocal than in previous 
reviews. However, the reviewers do not state 
whether recently conducted studies are of a higher 
quality than those included in previous reviews. 
 
Emotional functioning was assessed in 21 
correlational studies and five case studies. Although 
the results of the case studies were relatively 
similar, 3 of the 13 correlational studies found 
no significant differences between witness and 
comparison groups. As a whole, these equivocal 
findings are consistent with previous reviews. 
However, when looking at only the most recently 
conducted studies, significant differences in 
emotional functioning and behavioural functioning 
are consistently found between witness and 
comparison groups. Thus the recent research is 
unequivocal in its finding that witnessing partner 
violence affects children’s emotional functioning, 
although the reviewers do not comment on 
whether the recent studies have a higher quality of 
design or execution.  
Eleven studies examined social functioning as an 
outcome. Six studies documented a significant 
relationship between social functioning and 
witnessing partner violence; however, four of 
the five recently conducted studies did not find 
child witnesses to have significantly lower social 
competence scores than comparison groups. 
Although some children from violent homes 
appear to be at increased risk of developing 25 
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problems in social functioning, the relationship 
between witnessing partner violence and the social 
functioning of these children remains unclear, with 
the majority of recent studies finding no significant 
relationship. Eight studies assessed cognitive 
functioning; three of these had been conducted 
since the previous review. Except for the findings  
of Christopoulos and colleagues,74 the recently 
conducted studies all found that children who 
witness abuse are at risk for problems in cognitive 
functioning. However, the limited number of recent 
studies makes it difficult to draw firm conclusions  
of a cause–effect relationship, and no mention is 
made of the quality of these studies.  
Ten of the studies examined physical health. 
One of the only two studies using standardised 
measures suggested a causal relationship after 
finding clinical levels of somatic complaints among 
witnesses of abuse. The second study did not find 
any neurological deficit among such children, 
and evidence of a causal link between exposure to 
violence and health problems remains equivocal. 
The reviewers concluded that although there is 
still some uncertainty about the magnitude and 
consistency of detrimental effects on children’s 
social, cognitive and physical development, the 
evidence for effects on children’s emotional and 
behavioural development is far less equivocal. 
  
Strengths and limitations 
 
The strengths of this review of prevalence and 
health impact studies include the independent 
quality appraisal of primary studies by two 
reviewers (using the STROBE quality appraisal tool 
for prevalence studies and the CASP systematic 
review tool for health impact reviews) and the 
sensitivity analysis based on study quality. These 
reviews fulfil the QUORUM and most of the 
MOOSE reporting criteria lines (see Appendix 
11.1 for MOOSE criteria and Appendix 11.2 for 
a flowchart of this review). Limitations of this 
review include the small number (six) of databases 
searched for studies, and the exclusion of reviews 
of health impact conducted prior to 1990 and 
prevalence studies conducted prior to 1995. 
Limitations of the primary prevalence studies 
include investigators’ modification of instruments 
to measure partner violence without reporting 
how, or if, the adapted version of the instrument 
was validated. Comparisons between the studies 
were problematic because of different definitions 
of partner violence, different questions to establish 
the presence of partner violence and different 
26 questionnaire administration methods. Limitations 
   
 
  
of the reviews of health impact studies include a 
lack of detailed reporting of search strategies, no 
quality appraisal of primary studies and no pooling 
of data. A major limitation in the field of domestic 
violence research is the absence of systematic 
reviews of physical consequences synthesising 
primary studies. 
  
Discussion 
 
The reviews provide strong evidence that partner 
violence can have a substantial detrimental effect 
on mental health. Evidence for the impact on 
pregnancy is more equivocal, but it is likely that 
low birthweight is a consequence of abuse during 
pregnancy. Recent studies on the impact on 
children show a greater prevalence of behavioural 
and mental health problems among children who 
witness partner violence, as well as diminished 
educational attainment. When the better- 
quality systematic reviews are considered, the 
findings on mental health, pregnancy and child 
health consequences are similar to the overall 
findings, although comparison between reviews 
is problematic because they report different 
outcomes. 
  
Synthesis of prevalence 
and health impact studies 
Differences in definition, methodology, sampling 
and assessment make it difficult to estimate 
precisely the prevalence of partner violence in 
the UK. Nonetheless, the studies reported here 
delineate the lower boundaries of partner violence 
prevalence, although possibly not the upper limit 
as under-reporting is likely. It is unarguable that 
partner violence against women is a common 
problem. To fulfil the NSC screening criterion for 
an important health problem, it also has to have a 
substantial impact on health. The reviews of health 
impact that we have considered, notwithstanding 
heterogeneity of morbidity estimates associated 
with partner violence, demonstrate that partner 
violence significantly increases the risk of mental 
illness and substance abuse and is likely to increase 
the risk of pregnancy complications.  
We have not systematically reviewed individual 
studies of other health problems associated with 
partner violence, but they probably support the 
conclusion that partner violence has a substantial 
and persistent detrimental effect on the health of 
women. The most consistent and largest physical 
health difference between abused and non-abused 
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women is in the prevalence of gynaecological 
problems.75 Population-based studies from the USA 
show that the likelihood of abused women having 
gynaecological symptoms is three times greater 
than average.76 Other conditions include chronic 
pain and neurological symptoms,75 gastrointestinal 
disorders77   and  self-reported  cardiovascular 
conditions.78   The evidence for the substantial effect 
of partner violence on population health includes 
the results from the systematic reviews of outcomes 
on children that we have reported here. 
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Chapter 5 
Are screening tools valid and reliable? 
(Question  II) 
  
ighteen tools were assessed in 15 validation 
studies. The total number of participants was 
10,289; studies reporting diagnostic accuracy 
comprised 8433 participants. The tools ranged 
from single questions to 30-item research 
inventories (see Appendix 5.1 for details of 
individual tools). Twelve tools were tested as 
index tools and eight as comparators; the Woman 
Abuse Screening Tool (WAST) and the Women’s 
Experience with Battering Scale (WEB) served 
in both capacities in different studies. Of the 15 
studies, only 10 reported sufficient data to calculate 
diagnostic accuracy. The majority of studies were 
conducted in the USA (11), with two in Canada, 
and the remaining two in France and Brazil. 
Settings varied from general practice (six), accident 
and emergency departments (four), antenatal 
clinics (three), women’s health-care centres (two), 
women’s homes (two), domestic violence refuges 
(two) and an urgent care centre within a hospital 
(one). Publication dates ranged from 1992 to 2006. 
For details of primary studies see Appendix 5.3, 
and for detailed results by study see Appendix 5.4. 
Below we have presented the main findings in a 
narrative form. 
  
The screening tools 
Women’s Experience with 
Battering Scale (WEB) 
Coker and colleagues79   tested the WEB against 
the Index of Spouse Abuse-Physical (ISA-P) in  
two university-associated family (general) practice 
clinics. The original ISA-P has 25 items assessing 
physical abuse; the investigators used a modified 
version consisting of 15 items. Prevalence was 
reported as 11% with the ISA-P. Reliability was 
good: Cohen’s kappa was 60% between the two 
measures, and a Pearson correlation of 0.67 
between the two continuous measures supports the 
kappa statistic. Sensitivity was 86% and specificity 
91%. The scores for each tool were compared with 
partner violence-associated injuries, adverse mental 
health outcomes, and perceived levels of health  
and health-care utilisation. Because the contents 
of each tool overlap and the authors wanted to 
identify which tool was more strongly associated 
with the health outcomes of interest, they 
performed a stratified analysis. Controlling for the 
ISA-P, WEB was found to be significantly associated 
with poor mental health, anxiety, depression, drug 
abuse, PTSD and low social support, whereas the 
ISA-P was only significantly associated with more 
physician visits when controlling for the WEB. In 
women currently experiencing physical partner 
violence only, the continuous ISA-P score (adjusting 
for continuous WEB score) was significantly 
associated with having a partner violence-related 
injury requiring medical care (relative risk 1.06); 
the WEB was not (relative risk 0.99). Amongst 
women reporting an event that could lead to PTSD 
(n = 356), the WEB score was associated with higher 
PTSD symptom scores (relative risk 2.02) and the 
ISA-P score was not (relative risk 0.93). The authors 
conclude that the WEB may identify more women 
experiencing both physical and psychological 
battering and thus increase its clinical value. The 
study has shown the positive scores on the WEB to 
be strongly associated with partner violence-related 
health outcomes. 
 
Ongoing Violence 
Assessment Tool (OVAT) 
In an accident and emergency department, Ernst 
and colleagues80 tested the OVAT against the  
Index of Spouse Abuse (ISA). The ISA detected a 
prevalence of 21% in women and 20% when both 
men and women were included. Reliability was 
reasonable, with a Cronbach’s alpha of 0.6 and a 
kappa of 0.58 (95% confidence interval 0.53–0.63). 
Similar to the WEB, the OVAT showed reasonable 
diagnostic accuracy: a sensitivity of 86% and 
specificity of 83%. 
 
‘Hurts, Insults, Threatens and 
Screams at her’ (HITS) scale 
The HITS scale has been compared with a number 
of tools in different cultural settings. Chen and 
colleagues81 trained medical students to administer 
the HITS alongside the ISA-P and WAST in an 
urban family (general) practice site. Approximately 
70% of the practice population was of Hispanic 
origin; thus English and Spanish versions of the 29 
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tools were used. Prevalence rates varied between  
the two comparators: ISA-P gave a prevalence of 
5.4%, the WAST 9.9%; overall, 10.9% screened 
positive on the ISA-P or WAST. Diagnostic accuracy 
analyses were computed for both English and 
Spanish populations. To assess the nature and 
extent of misclassifications, receiver operating 
characteristic (ROC) analyses were used, which also 
help derive cut-off scores that highlight the greatest 
sum of sensitivity and specificity. Minor differences 
emerged when looking at the two comparisons.  
Comparison of the English versions revealed good 
reliability (Cronbach’s alpha) for the HITS (0.76), 
ISA-P (0.80) and the WAST (0.78). English HITS 
total scores were also significantly correlated with 
ISA-P total scores (r = 0.76, p < 0.001) and WAST 
total scores (r = 0.75, p < 0.001).The area under 
the curve (AUC) for English HITS was 0.99, using 
ISA-P as the criterion. English HITS was effective 
as a screening tool for partner violence (p < 0.001). 
For those using the English language, HITS was 
compared with an English version of the ISA-P. A 
cut-off score of 10.5 created the greatest sum of 
sensitivity (86%) and specificity (99%).  
For the Spanish versions, reliability was 
slightly lower (HITS = 0.61, ISA-P = 0.77 and 
WAST = 0.80); however, correlations between 
the Spanish tools were slightly higher than those 
found between the English tools (HITS and ISA-P 
r = 0.81, p < 0.001; HITS and WAST r = 0.78, 
p < 0.001). This pattern of high correlations was 
also repeated for the total sample. For those 
answering in Spanish, the HITS was compared with 
a translated Spanish version of WAST. The AUC for 
the Spanish HITS was 0.95, and HITS was found to 
be effective as a screening tool (p < 0.001). A cut-off 
of 5.5 maximised sensitivity (100%) and specificity 
(86%).  
HITS has several advantages over WAST. It 
is an acronym (making it easier to remember 
the individual questions), its cut-off scores 
for identifying partner violence are easier to 
remember, and it has a simple scoring protocol 
compared with the WAST multiple scoring 
protocols. One limitation of HITS is that it is 
only validated for detection of current abuse. 
The different cut-off points for the HITS 
between English-speaking and Spanish-speaking 
populations may reflect different views about 
what constitutes abuse. Hispanic women may view 
certain types of abuse as less abusive than other 
cultural groups. 
Sherin and colleagues82 used a modified version of 
the Conflict Tactics Scale (CTS) as a comparator 
against the HITS. In the first phase of the study, 
women were recruited from a family (general) 
practice setting in order to assess reliability and 
concurrent validity of the HITS. In the second 
phase the reliability and concurrent validity of 
the HITS were tested in self-identified survivors 
of partner violence from either a refuge or an 
accident and emergency department. The two 
groups were then compared to assess the construct 
validity of the HITS. In the first phase, HITS 
showed good reliability (Cronbach’s alpha = 80). 
The distribution of CTS and HITS scores suggests 
a low prevalence of partner violence in this 
population, although no prevalence figures were 
reported. Correlation between the two measures 
revealed a positive linear relationship (r = 0.85); 
the subscores for items measuring physical violence 
and verbal violence also showed a good positive 
association (0.82 and 0.81, respectively). No 
significant difference in scores was found due to 
presentation effects. In the second phase of the 
study, the scores from the practice population were 
compared with those of self-identified survivors 
and improvised diagnostic accuracy data were 
computed. With a cut-off score of 10.5 on the 
HITS, 96% of victims and 91% of non-victims 
were correctly identified (analogous to sensitivity 
and specificity analysis). This study provides good 
support for the use of HITS as a screening tool, 
although the accuracy analysis is contestable as a 
modified version of CTS (four reasoning items were 
removed) was employed. 
 
Abuse Assessment Screen (AAS) 
The Abuse Assessment Screen (AAS) has been 
tested against a number of tools, although only 
one study reported diagnostic accuracy data. 
Reichenheim and Moraes83 validated the AAS 
against the Revised Conflict Tactics Scale (CTS2) 
in postnatal maternity wards in Brazil. Three case 
levels of partner violence were specified in this 
study: minor, major and overall. Minor cases were 
those where the participant answered ‘yes’ to at 
least one of five items asking about less severe 
physical acts such as being grabbed, pushed or 
slapped; major cases were defined as when at least 
one of seven more severe acts were reported, such 
as being choked, beaten up or kicked; overall 
cases were those that featured at least one positive 
response from both subsets. Prevalence of partner 
violence found with the CTS2 varied depending 
on the definition of cases used. Prevalence of 
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minor cases was 18%, for major cases it was 8%, 
and overall it was 19%. Diagnostic accuracy data 
for minor cases revealed a poor sensitivity at 32%, 
whereas specificity was very good (99%). Analysis 
of major cases showed an improved sensitivity of 
61%, and specificity of 98%. Analysis of overall 
violence reduced sensitivity to 32%, with specificity 
at 99%. The AAS detects more major cases of 
abuse than either minor or overall violence. This 
observation is further supported by analysis of the 
false negatives; up to 50% of those who screened 
positive for ‘pushed or shoved’ or ‘grabbed’, and 
60% of those who ‘had something thrown at them 
that could hurt’, were missed by the AAS. 
 
Partner Violence Screen (PVS) 
The Partner Violence Screen (PVS) has been 
tested against the ISA and CTS by Feldhaus 
and colleagues84 in an accident and emergency 
department setting. The ISA revealed a current 
prevalence of abuse of 24% (95% confidence 
interval 19–30%) and the CTS showed a prevalence 
of 27% (95% confidence interval 22–34%). The 
study found reasonable diagnostic accuracy for the 
PVS. When compared with the ISA, the sensitivity 
of the PVS was 65% and specificity 80%. The 
physical violence item and two safety items of the 
PVS also showed moderate linear sensitivity (53% 
and 48%, respectively) and reasonable specificity 
(89% and 88%, respectively) when individually 
compared with the ISA. Similarly, comparison with 
the CTS gave reasonable results. Overall, sensitivity 
was 71% and specificity 84%; the physical violence 
item had greater sensitivity and specificity (68% 
and 95%) compared with the ISA, whereas the 
safety item showed slightly lower diagnostic values 
than the ISA (sensitivity was 40%, specificity was 
87%). The single physical abuse question of the 
PVS was more sensitive and specific than the 
questions regarding safety. The negative predictive 
value was also good, with sensitivity of 88% and 
specificity of 89%. The PVS is a three-question tool 
that takes only 20 seconds to administer. About one 
in every four women who entered the emergency 
department had a history of physical or non- 
physical partner abuse, and the PVS was able to 
detect between 65% and 71% of these women. 
 
MacMillan and colleagues85 reported a validation of 
the PVS and WAST (see paragraph below) against 
the Composite Abuse Scale (CAS). Recruitment 
took place in two accident and emergency 
departments, two family practices and two women’s 
health clinics. The study’s original aim was to 
investigate the effects of presentation method of 
the two index tools; specifically computerised, face- 
to-face interview, or pencil and paper presentation. 
Prevalence of partner violence for the CAS was 
10%. The PVS showed only moderate diagnostic 
accuracy, with a sensitivity of 49% and a specificity 
of 94%, although overall accuracy was stated as 
89%, calculated as the number of true positives 
plus the number of true negatives divided by the 
total sample size. 
 
Woman Abuse Screening 
Tool (WAST) 
MacMillan and colleagues85 validated the WAST 
against the CAS. Like the PVS, they found 
only moderate diagnostic accuracy data, with a 
sensitivity of 47% and a specificity of 96%, although 
the overall accuracy was 91%. 
 
Slapped, Threatened or 
Thrown (STaT) scale 
Paranjape and colleagues86  validated the STaT 
against the ISA in an urgent care centre in an inner 
city hospital that provides primary care. For most 
recent relationships, the ISA revealed a lifetime 
prevalence of 33% and a current prevalence of 
15%. Diagnostic accuracy data were computed for 
each STaT score. For scores 1, sensitivity was 95% 
(95% confidence interval 90–100%), specificity 
was 37% (95% confidence interval 29–44%); for 
scores 2, sensitivity was 85% (95% confidence 
interval 77–92%) and specificity was 54% (95% 
confidence interval 46–62%); and finally a score of 
3 had a sensitivity of 62% (95% confidence interval 
51–73%) and a specificity of 66% (95% confidence 
interval 59–73%). Although showing good 
sensitivity, the tool has only moderate specificity. 
 
Behavioural Risk Factor 
Surveillance Survey (BRFSS) 
Bonomi  and  colleagues87   compared  the 
Behavioural Risk Factor Surveillance Survey 
(BRFSS) against the WEB using a telephone 
survey of randomly selected women enrolled for at 
least three years in a Group Health Cooperative. 
Prevalence was found to be 7% using the WEB. 
The authors computed diagnostic accuracy data 
for various elements of the BRFSS. For any kind  
of abuse, good sensitivity and specificity were 
found (72% and 90%, respectively). Sensitivity for 
sexual abuse was 21% and specificity 99%, whereas 
sensitivity for physical abuse was 42% and the 
specificity 95%. For detecting fear due to threats, 
sensitivity was 48% and specificity 97%. Detection 
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of controlling behaviour was slightly better, with  
a sensitivity of 65% and specificity of 94%. The 
difference between these two tools is based on 
their conceptual framework; the BRFSS is based 
upon behavioural acts of abuse, whereas the WEB 
employs a more consequence-orientated approach. 
 
Single question 
The use of a single question was investigated by 
Peralta and Fleming,88 who asked women within 
a family (general) practice setting ‘Do you feel 
safe at home?’ and compared this with a modified 
version of the CTS (six items instead of 19, five of 
which related to psychological and one to physical 
violence). Period prevalence (90 days) of abuse was 
high at 44%, as measured by the modified CTS. 
The researchers examined diagnostic accuracy for 
the single question in three ways: (1) any violence, 
(2) physical violence with or without psychological 
violence, and (3) psychological violence with 
or without physical violence. For any violence, 
sensitivity was very poor at 9%, whereas specificity 
was high at 96%. For physical violence with or 
without psychological abuse, sensitivity was slightly 
improved at 15% and specificity was 95%. For 
psychological violence with or without physical 
violence, sensitivity was 9% and specificity was 96%. 
These results suggest that a single question about 
safety is a poor screening tool for partner violence. 
  
Studies that did not assess 
the diagnostic accuracy 
data of index tools 
Abuse Assessment Screen (AAS) 
McFarlane and colleagues89 tested the AAS against 
the CTS, ISA and the Danger Assessment Scale 
(DAS) in antenatal clinics. The population was 
ethnically heterogeneous: African Americans 
39%, Hispanics 34% and whites 27%. Prevalence 
measured with the AAS was 26% within the last 
year, 17% during pregnancy and 55% when these 
two were combined. When the physical abuse 
(ISA-P) and non-physical abuse (ISA-NP) scores 
were compared against AAS scores, those positively 
screened with the AAS were more likely to have a 
significantly higher score on the ISA. This study 
showed physical abuse during pregnancy to be 
more than twice as high as reported in previous 
literature. A possible explanation for the increased 
rates may be due to the primary care provider, 
rather than a researcher, asking the questions. 
Another explanation may be that a woman was 
32 assessed three times in pregnancy; abuse may not 
have occurred until the third trimester or women 
who at first did not want to disclose abuse did so 
when asked again. Although the prevalence of 
abuse in pregnancy was similar for the AAS and 
both parts of the ISA, the absence of reliability or 
diagnostic accuracy data makes it hard to draw any 
conclusions on the validity and reliability of the 
AAS from this study. 
 
Perinatal Self-Administered 
Inventory (PSAI) 
Sagrestano and colleagues90 administered the 
Perinatal Self-Administered Inventory (PSAI) and 
the CTS to women in antenatal clinics. Based on 
the CTS, the prevalence of verbal aggression was 
84%, and 17% of women had experienced physical 
violence in the past year. During the current 
pregnancy, the prevalence of verbal aggression was 
68% and that of physical violence was 13%. From 
the PSAI, the question ‘Are you experiencing severe 
conflicts with anyone at home?’ did not correlate 
with measures of verbal aggression, and there 
were no significant differences in scores of verbal 
or physical violence between those who endorsed 
the single question and those who did not. The 
other partner violence-related question of the 
PSAI, ‘Are you suffering from mental or physical 
violence abuse right now?’, was not correlated with 
either verbal or physical abuse as determined by 
the CTS, nor were there any significant differences 
in verbal aggression scores between those who 
did and did not respond in the affirmative to 
the suffering abuse question. For the violence 
subscale, paradoxically, those who responded in the 
affirmative to the single question (only 3% of the 
sample) scored significantly lower than those who 
did not. From these findings, the abuse questions of 
the PSAI are unlikely to be reliable screening tools 
for either verbal or physical violence within an 
antenatal setting; however, there are no diagnostic 
accuracy data to support this conclusion. 
 
Woman Abuse Screening 
Tool (WAST) 
Brown and colleagues91   conducted a validation 
study in a Canadian family (general) practice 
setting comparing the WAST with the Abuse Risk 
Inventory (ARI). Prevalence detected with the 
WAST was 9%. The WAST showed good internal 
consistency (coefficient alpha = 0.75) and was 
significantly correlated with the ARI (r = 0.69, 
p = 0.01). In 2001, Brown repeated the study in a 
French-speaking population in a domestic violence 
refuge and private homes setting, and reported 
good internal consistency. As neither study 
Review Question II  
 
Decreasing 
predictive power Sensitivity Specificity Overall (Sen + spec) 
HITS (Spa)  100  AAS  99.2  HITS (imp)  187 
HITS (imp)  96  HITS (Eng)  99  HITS (Spa)  186 ↓ STaT  94.9  Single questiona  95.8  HITS (Eng)  185 HITS (Eng)  86  WAST  95.6  WEB  177 93.7  OVAT  168.8 WEB  85.9  PVSb OVAT  85.7  WEB  91.1  BRFSS  162.1 BRFSS  72.4  HITS (imp)  91  PVS  150.3 PVS  68  BRFSS  89.7  PVSb  142.9 
PVSb  49.2  HITS (Spa)  86  WAST  142.6 
WAST  47  PVS  82.3  STaT  131.6 
AAS  31.7  OVAT  83.1  AAS  130.9 
Single questiona  8.8  STaT  36.6  Single questiona  104.6 
Computation of diagnostic accuracy data  (Sherin et al., 199882). 
Spa, Spanish language (Chen et al., 200581); Eng, English language (Chen et al., 200581); imp, improvised. 
a  Single question: ‘Do you feel safe at home?’ 
b   MacMillan et al., 2006.85 
   
 
  
reported diagnostic accuracy no conclusion about 
construct validity can be drawn. 
 
Single question 
Connelly and colleagues92 used the CTS as a 
comparator to test a single question incorporated 
into a hospital admission protocol: ‘Are you in a 
relationship in which you have been threatened, 
scared or hurt by someone? If yes, whom? [sic]’ 
The specific clinical setting in which the protocol 
was administered is not clear. The CTS gave a 
prevalence of 18%. No diagnostic accuracy data 
were reported. 
  
Diagnostic accuracy 
 
The data for diagnostic accuracy are summarised 
in Table 5. The sensitivity of partner violence 
screening tools ranges from poor to good (9–
100%). Tools that scored sensitivity greater than 
85% include the HITS (both Spanish and 
English versions), STaT, WEB and OVAT. Specificity 
was good across all but one of the tools, ranging 
from 83% to 99%. The one outlier was the STaT 
scale, with a specificity of 37%. Index tools with 
a specificity greater than 85% included the AAS, 
HITS, single question ‘Are you safe at home?’, 
WAST, PVS, WEB and the BRFSS. 
The relatively small number of studies for each 
index tool and the heterogeneity of settings, 
demography of participants and comparator tools 
precluded pooling of the diagnostic accuracy data. 
  
Concurrent validity 
 
Five studies reported concurrent validity (Table 6); 
generally this was high, the exception being the 
PSAI. 
  
Reliability 
 
Six primary studies reported two types of reliability 
data (Table 7): (1) internal consistency, a measure 
based on the correlations between different items 
on the same test (coefficient alpha and Cronbach’s 
alpha); and (2) inter-rater reliability, the degree of 
agreement among scorers (Cohen’s kappa). Most 
studies reported good reliability of the tools that 
were tested. 
  
Sensitivity analyses 
 
If we exclude studies with three or more areas of 
bias as determined by the QUADAS appraisal tool, 
four studies remain, as shown in Table 8. 
   
Table 5  Ranked scores of sensitivity, specificity and summed sensitivity plus specificity  for each  index  tool  in order of decreasing 
predictive power 
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Table 6 Ranked scores of concurrent validity in decreasing order 
 
Decreasing 
concurrent Correlation 
validity Comparison (index vs comparator) (r value) p-Value 
HITS (imp) vs CTS (any)  0.85  Not stated 
HITS (imp) vs CTS (physical)  0.80 
HITS (imp) vs CTS (verbal)  0.81 
HITS (Spa) vs ISA‐P  0.81  < 0.001 
HITS (Spa) vs WAST  0.81  < 0.001 
HITS (Eng) vs ISA‐P  0.76  < 0.001 
 
HITS (Eng) vs WAST  0.75  < 0.001 
WAST vs ARI  0.69  0.01 
WEB vs ISA‐P  0.67  Not stated 
PSAI ‘Are you experiencing severe conflicts with anyone in your 
home?’ vs CTS 
0.16  0.035 
PSAI ‘Are you experiencing severe conflicts with anyone in your 
home?’ vs CTS (verbal)  0.10  > 0.05 
 
PSAI ‘Are you suffering mental or physical abuse now?’ vs CTS  0.03  > 0.05 
 
PSAI ‘Are you suffering mental or physical abuse now?’ vs CTS  – 0.05  > 0.05 
(verbal) 
Computation of diagnostic accuracy data  (Sherin et al., 199882). 
Spa, Spanish language (Chen et al., 200581); Eng, English language (Chen et al., 200581); imp, improvised. 
   
Table 7 Ranked score of reliability in decreasing order 
 
Decreasing reliability Index tool Type Value 
WASTa  Coefficient alpha  0.95 ↓ HITS (imp)  Cronbach’s alpha  0.80 HITS (Eng)  Cronbach’s alpha  0.76 WASTb  Coefficient alpha  0.75 HITS (Spa and Eng combined)  Cronbach’s alpha  0.71 HITS (Spa)  Cronbach’s alpha  0.61 WEB  Cohen’s kappa  0.60 
OVAT  Cohen’s kappa  0.58 
Spa, Spanish  language  (Chen et al., 200581); Eng, English  language  (Chen et al., 200581);  imp,  improvised computation of 
diagnostic accuracy data  (Sherin et al., 199882). 
a   Brown et al., 2001.93 
b  Brown et al., 2000.91 
 
The five higher-quality studies all report diagnostic 
accuracy data, although three84–86 do not report any 
psychometric properties of the index tools they 
validated, a shortcoming that is not captured by the 
QUADAS. The high-quality studies tested the PVS, 
34 WAST, HITS and the single question ‘Do you feel 
safe at home?’ as index tools and found that the 
WAST and HITS performed best overall.  
The number of items in a tool was not associated 
with diagnostic accuracy. There were not enough 
studies testing tools in different health settings to 
Review Question II  
 
 
 
   
Table 8  Higher‐quality studies 
 
 
Study 
Tools assessed (index vs 
comparator) Predictive power Concurrent validity 
 
Reliability 
Feldhaus et al., 
199784 
PVS vs ISA and CTS  142.9  Not stated  Not stated 
Brown et al., 200091  WAST vs ARI  142.6  r = 0.69, p = 0.01  0.75 
Chen et al., 200581  HITS vs WAST:       
  HITS (Spa)  186  ISA‐P r = 0.81, 
p < 0.001 
WAST r = 0.81, 
p < 0.001 
0.61 
  HITS (Eng)  185  ISA‐P r = 0.76, 
p < 0.001 
WAST r = 0.75, 
p < 0.001 
0.76 
  HITS (Spa and Eng 
combined) 
    0.71 
MacMillan et al., 
200685 
PVS and WAST vs CAS  PVS 142.9 
WAST 142.6 
Not stated  Not stated 
Paranjape et al., 
200686 
Single question ‘Do you 
feel safe at home?’ vs 
modified  CTS 
104.6  Not stated  Not stated 
    
judge whether they were more accurate with some 
groups of patients than others. 
  
Which tools are valid 
and reliable? 
When considering the rank of the diagnostic 
accuracy data (sensitivity, specificity and sensitivity 
plus specificity; see Table 5), the HITS scale 
consistently emerges as top ranked, followed 
by the WEB and the OVAT. HITS, an acronym 
derived from the four short questions, is quick to 
administer. Women answer each question using a 
five-point scale from 1 (never) to 5 (frequently); 
answers are then summed to give a potential 
total score ranging from 4 to 20. A cut-off score 
of 10 gives the highest combined sensitivity and 
specificity. It has good diagnostic accuracy in both 
English- and Spanish-speaking populations. A 
limitation of the HITS scale is that it fails to ask 
about sexual abuse or ongoing violence, thus it 
may need to be administered alongside another 
screening tool to detect these forms of abuse.  
The WEB assesses abuse by characterising women’s 
perceptions of their vulnerability to physical 
and psychological danger or loss of control in 
relationships. The tool comprises 10 items and 
uses a six-point Likert-type scale giving a potential 
range of scores from 10 to 60. A score greater than 
20 indicates battering. A disadvantage of the WEB 
is that women may not link abusive behaviours or 
tactics directly to the emotional impact the abuse 
is having on them. Although the WEB identifies 
abuse, it does not necessarily identify the acts of 
abuse, thus further enquiry from the clinician 
would be needed for adequate documentation 
in medical records. As shown in Tables 6 and 
7, respectively, the WEB has good concurrent 
validity against the ISA-P and reasonable reliability 
although the study has more than two areas of bias. 
 
The OVAT aims to detect current abuse asking 
about physical and non-physical violence within 
the past month. The four questions are quick to 
administer and score: three questions are true/ 
false answers, the other is answered on a five-point 
Likert response: 1 (never) to 5 (very frequently). 
The OVAT takes 1 minute or less to administer and 
can be scored immediately. Table 5 shows the OVAT 
has good predictive power. Although no concurrent 
validity was reported in the primary study, the 
OVAT has reasonable reliability (see Table 7)  
On current evidence, tools that scored a low 
combined sensitivity and specificity, such as the 
single question ‘Are you safe at home?’ or the AAS, 
are not good candidates for screening programmes 
in clinical settings. 35 
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Methodological 
considerations 
Several areas of weakness have emerged from this 
review of screening tools. First, only Sherin and 
colleagues82 and Chen and colleagues81  report 
presentation effects, yet studies that account for 
data on presentation effects are more robust. 
Priming of responses due to type of wording or 
impact of questions may influence subsequent 
answers on later questions. Second, modified 
comparators (featured in four studies) may inflate 
or decrease the diagnostic accuracy, particularly 
if those tools have not been psychometrically  
tested. Furthermore, these studies are not truly 
comparable with other studies using the full version 
of the tool, thus comparisons within the field are 
more problematic.  Third,  discrete  categories  of 
violence should be analysed if possible. Peralta and 
Fleming88   analysed the diagnostic accuracy data in 
three ways: any violence, physical violence with or 
without psychological violence, and psychological 
violence with or without physical violence. The 
last two categories overlap, making it difficult to 
ascertain what the tool has identified and what the 
tool can accurately identify.  
Study quality ranged from good to poor (see 
Appendix 5.5). When the number of positive 
responses was totalled for each study (a higher 
number denotes that fewer types of bias occurred  
in the study), 11 out of 15 primary studies scored 
10 or more, i.e. had four or fewer different types of 
bias in the study; two scored nine, i.e. had five types 
of bias. There was ambiguous reporting in three 
of the studies: it is unclear whether Coker and 
colleagues79 used two separate tools or combined 
them into one, which may have increased multi- 
colinearity between the tools; Reichenheim and 
Moraes83 had unclear selection criteria, and Ernst 
and colleagues80 did not adequately report their 
selection criteria and their execution of the index 
test was uncertain.  
None of the studies analysed the score of the index 
tool blinded to the score of the comparator. This 
may be a less important source of bias than others 
because there is little room for interpretation of 
the questionnaire data. Suitable comparators to  
use against an index tool include the CTS2, ISA 
or the CAS. But investigators also used the WAST, 
ARI, WEB, CTS, modified CTS and a modified 
CTS2 as comparators, although they are not 
adequately validated. Multi-colinearity may have 
featured in those studies that combined index and 
comparator tools into one instrument. This may be 
36 further influenced by using the index tool score to 
   
 
  
inform the final diagnosis. Unreported withdrawals 
from the studies may indicate a selection bias, 
particularly if such a feature is systematic across all 
the studies. 
  
Strengths and limitations 
 
The strengths of this review on screening tools 
include quality appraisal of primary studies using 
criteria from the QUADAS and the sensitivity 
analysis based on quality, the calculation of 
diagnostic accuracy (if this was not reported in 
the primary study and data were available) and a 
methodological critique of studies. Furthermore, 
this review question was quality appraised using the 
modified QUORUM checklist, which indicates that 
all the QUORUM criteria were met (see Appendix 
11.3 for QUORUM checklist and flowchart). 
 
Limitations of the review include the arbitrary 
choice of 12 items or less as a criterion for an index 
screening tool. A tally of 12 items was chosen by the 
authors because this was deemed to be a practical 
number of items to administer for screening 
purposes. Further limitations relate to the quality of 
the primary studies and heterogeneity of screening 
tools used by each study, making it impossible to 
pool the studies into a meta-analysis. 
  
Discussion 
 
There are valid and reliable screening tools for 
partner violence against women that can be 
used in health-care settings, fulfilling the NSC 
criterion, although the number of studies reporting 
validation and reliability for any one tool is small. 
The HITS scale shows most diagnostic accuracy, 
concurrent validity and reliability. Even if the study 
by Sherin and colleagues82 is disregarded due to 
its improvised diagnostic accuracy, the HITS still 
ranks above the other tools and has been validated 
in at least one good-quality study.81  A total of 141 
papers were initially selected, which covered a wide 
range of validation studies. We excluded many 
studies because of our upper limit of 12 items in 
a screening tool. It is possible that some of the 
excluded studies may have identified tools that 
had good diagnostic accuracy, but more than 12 
questions would be impractical for use in clinical 
settings. The majority of studies came from North 
America, so their generalisability to UK clinical 
settings is uncertain. The choice of a tool for the 
NHS would need to take into account the use of 
different terms, such as ‘battering’, which is not 
used in the UK but is central to the WEB. The lack 
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of UK studies in this review could reflect a lower 
priority given to validation of partner violence 
screening tools, as screening is not current policy 
within the NHS.  
Finally, we need to heed the caution of Fogarty and 
colleagues94 about judging screening questions for 
partner violence as we would screening tools for 
medical conditions. A woman experiencing partner 
violence who discloses to a clinician has gone 
through ‘…a complex process. Factors involved in 
this process include the woman’s recognition of 
a problem, her willingness to trust her clinician 
with this information, and her perception of the 
clinician’s openness to hearing her story with 
compassion and without judgment.’ 
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Chapter 6 
Is screening for partner violence acceptable to 
women? (Question III) 
  
Qualitative  studies 
Thirteen journal articles and one UK Home Office 
report (total of 13 studies) published between  
2001 and 2006 fulfilled our inclusion criteria 
for this question. For details of the studies and 
quality appraisal scores see Appendix 6.1. Ten  
of the studies were conducted in the USA, two in 
the UK and one in Sweden. The total number of 
participants was 1393, ranging between 795 and 
879.96  The quality score of the primary studies, 
appraised with the CASP criteria, was between 2097 
and 34,98,99 with most of the studies scoring more 
than 27 out of a possible 41. 
 
First-order constructs 
We identified 10 first-order constructs reflecting 
women’s attitudes towards screening in health-care 
settings. 
 
1. Women find screening beneficial, even if they are 
not yet ready to disclose abuse 
Informants said that raising awareness in addition 
to eliciting disclosure of abuse should be an aim 
of screening. Women who did not want to disclose 
abuse still found screening beneficial as it helped 
to remove the stigma attached to partner violence, 
raised awareness of partner violence, gave them 
a sense of validation and conveyed to them that 
when they were ready they could talk to their 
health professional about abuse. Although women 
may not disclose abuse immediately, screening may 
facilitate disclosure later on when they feel more 
comfortable with the health-care professional or 
when their circumstances change and they feel the 
need to get help. 
 
2. Women  gain  a  sense  of  support  and  relief  from 
discussing their situation with someone 
Some women thought that if they could have the 
opportunity to talk with someone about abuse, 
they would feel there is someone to support and 
encourage them. One woman said ‘What I really 
think helped me last pregnancy was people talking 
to me, not at me. Not having that better than 
[thou] attitude. I felt people really, genuinely 
cared’.100 
 
3. Screening may be more acceptable to women where 
there is already an established relationship with the 
health-care professional 
Some women found it more acceptable to be 
screened when they already knew and trusted the 
health-care professional. 
 
4. Screening may be more acceptable to women if the 
health-care professional’s manner is compassionate 
and non-judgmental 
Women emphasised the importance of 
professionals listening to them without judging 
or condemning them; not listening was viewed as 
inhibiting disclosure. Women felt more comfortable 
being screened and being asked sensitive questions 
by health-care professionals who they felt 
understood the complexity of partner violence. 
 
5. Women are concerned that health-care professionals 
do not have the time to listen to them and discuss 
their situation 
Some women expressed concern that appointments 
were not long enough to make effective use of 
confidential time or that there was no time to  
listen. 
 
6. Screening women for partner violence may lead 
to women disclosing abuse, and may facilitate the 
woman leaving the relationship or seeking help 
Many of the women felt that screening gave them 
the opportunity to disclose abuse, either then or at 
a later stage, and that without this opportunity it 
would be harder for them to seek help. 
 
7. Women expressed  concerns  about  potential 
negative repercussions of screening: breach of 
confidentiality, the involvement of children’s services, 
legal repercussions and being judged 
Common concerns included the potential legal 
consequences of revealing abuse and fears 
that abusive partners might find out that the 
relationship had been discussed. Some women 
reported feeling ashamed and concerned that the 
Review Question III 
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health-care professional would judge them harshly 
for staying in an abusive relationship. 
 
8. Screening may be more acceptable to women when 
given a reason for screening 
Some women stated that part of their fear and 
suspicion about screening and disclosing partner 
violence arose from not being sure of the health 
provider’s intentions when asking and the possible 
negative consequences of disclosure. Some women 
felt that they were being screened because health- 
care professionals did not think they were caring 
for their children properly and saw screening as 
part of an investigation of child neglect or abuse. 
 
9. The acceptability of screening may vary depending 
on whether screening is conducted face-to-face or by 
written questionnaire 
Opinions on whether screening should be 
conducted via a written questionnaire or face- to-
face were mixed. Some women preferred to 
talk about their experience and others preferred 
writing it down and not having to disclose out loud. 
 
10. Acceptability  of  screening  may  depend   on the 
gender and the profession of the health-care 
professional 
Some women showed a preference for being 
screened by women; however, most women stated 
that a health-care professional’s interpersonal 
qualities were more important than their gender  
or profession. Others voiced a preference for being 
screened by older rather than younger health-care 
professionals and by doctors rather than nurses. 
 
Second-order constructs 
These constructs represent the conclusions of the 
authors of the primary studies.  
1. Women believe the primary aim of screening 
should be education rather than eliciting 
disclosure. 
2. Screening is generally acceptable to women. 
3. Certain factors increase women’s acceptability 
of screening, such as the health-care 
professional’s manner, being asked in a safe 
and confidential environment, giving a reason 
for asking, not pressuring women to disclose, 
and the quality of the relationship the woman 
has with the professional. 
4. Women have concerns about screening, such as 
lack of time, potential breach of confidentiality 
and fear of involvement of child protection 
services. 
Contradictions within and 
between the studies 
There were no major contradictions between 
constructs either within or between studies. With 
regard to first-order constructs 9 and 10, there 
was variability within and between studies on 
women’s preferences for being screened face- 
to-face or by written questionnaire, and their 
preferences about the gender and the profession 
of the person performing the screening. There 
were no contradictions between the second-order 
constructs.  
These interview- and focus group-based studies 
found that women’s views on partner violence 
screening in health-care settings are complex. 
The emerging constructs were largely consistent 
across studies and did not vary by study quality. 
Generally, the informants find screening acceptable 
with certain caveats, such as the manner of asking 
and the nature of the initial response. One study 
found that women who suffered emotional abuse 
did not feel that they had been appropriately 
screened as the questions asked only covered 
physical violence.100 This raises the possibility 
that women’s acceptance of screening may vary 
depending on the type of abuse they experienced. 
However, the majority of studies did not provide 
a breakdown of the type of abuse experienced by 
the women, and we were not able to explore this 
further. Given the number of qualitative studies, we 
were surprised there were not more contradictory 
findings. Without access to the data it is impossible 
to say whether contradictions were not present or 
were not reported by the authors, many of whom 
seemed to assume that screening for partner 
violence was an essential part of a health-care 
response. 
  
Quantitative studies 
 
Nineteen journal papers (18 cross-sectional studies 
and one case–control study) fulfilled our inclusion 
criteria. For details of the studies see Appendix 
6.2. One study was a telephone survey,101 the 
others were based on face-to-face interviews or 
self-completed questionnaires. Twelve studies 
were conducted in the USA, two in the UK, one in 
Ireland, one in Canada, one in Australia, one in 
Italy and one in Germany. Response rates ranged 
between 49%102  and 100%,103  and the number of 
participants was between 95104 and 3455,105 with a 
total of 11,849 across all the studies. Twelve studies 
were conducted in a range of hospital settings, 
including one in a maternity unit and one in an 
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ambulatory care clinic. Three studies recruited 
women patients from general practices, two from 
health maintenance organisations (HMOs), one 
recruited women attending a family planning clinic 
and one recruited women from a combination of 
general practice, partner violence programmes and 
refuges. There was variation in attitudes towards 
screening between countries and between settings 
within the same country (agreement with partner 
violence screening varied between 35% and 99%). 
The quality score assessed by STROBE30 was 
between 9106 and 20,107 with most of the studies 
scoring more than 14 out of a possible 22. For 
quality scores and results see Appendix 6.3.  
Bair-Merritt and colleagues108 conducted a survey 
in an US paediatric emergency department, 
comparing responses of mothers and other 
female caregivers before (pre) and after (post) 
implementation of a screening programme that 
included displaying partner violence posters and 
cards in the waiting area. The two groups did 
not significantly differ with respect to age, race, 
education or personal partner violence history.  
The post group was less likely to find paediatric 
emergency  department  partner  violence  screening 
acceptable (pre, 76%; post, 63%; odds ratio 0.5; 
95% confidence interval 0.3–0.9) and was less likely 
to say that they would disclose abuse (pre, 85%; 
post, 75%; odds ratio 0.6; 95% confidence interval 
0.3–1.1).  Notwithstanding  this  reduction,  the 
majority of respondents found screening acceptable 
and said they would disclose if asked. There was 
no difference between previously abused and non- 
abused women with regard to the acceptability of 
displaying resources or routine screening.  
Brzank and colleagues106 surveyed 18–60-year- 
old women attending an accident and emergency 
department in a German hospital. Overall, 32% of 
the 806 participants would have wanted to be asked 
about partner violence by their physicians. This 
number increased to 41% in the case of patients 
who had experienced sexual violence, and to 44% 
in the case of patients who experienced physical or 
emotional violence. Almost 65% of the participants 
generally thought that questions about partner 
violence experience should be part of routine 
history taking.  
Caralis and Musialowski109 administered a 
questionnaire to 406 women in ambulatory clinics 
at a US Veterans Affairs Medical Center. They 
reported that 77% of non-abused and 70% of 
abused women agreed that doctors should routinely 
screen for abuse in their practices. 
Friedman and colleagues110 administered a 
questionnaire to 164 women attending a primary 
care physician in the USA. Routine enquiry about 
physical and sexual abuse was favoured by 78% 
and 68% respectively. Older patients were more  
in favour of routine physical abuse enquiry, but 
responses about sexual abuse enquiry did not vary 
by age. Among patients who had not graduated 
from high school education, there was a higher 
proportion in favour of routine enquiry about 
physical abuse and sexual abuse.  
The study by Gielen and colleagues111 included 202 
abused women and 240 randomly selected non- 
abused women recruited from a US metropolitan 
health maintenance organisation. Forty-eight 
percent of the sample agreed that health-care 
providers should routinely screen all women. 
Women thought that screening would make  
it easier for abused women to get help (86%), 
although concerns were raised about increased risk 
of abuse with screening (43%).  
Glass and colleagues105  conducted a study based in 
11 mid-sized community-level hospital emergency 
departments in the USA, and recruited 3455 
women patients. Those who were physically or 
sexually abused in the past year were less likely 
to agree with routine screening than women 
who reported a lifetime history of abuse or who 
reported no partner violence (80% versus 89%, 
p < 01), although the majority of both groups 
agreed with screening.  
The participants in a study by Hurley and 
colleagues103 were 304 non-critically ill women, 
aged 16–95 years, who presented to emergency 
departments at two Canadian health centres. 
Eighty-six percent supported universal screening of 
women patients for partner violence, with no age 
differences. 
 
McCaw and colleagues101 selected two random 
samples of women patients (total 397) – members 
of a non-profit, closed-panel, group-model 
US health maintenance organisation (Kaiser 
Permanente) – before and after an intervention that 
included a screening programme. The majority of 
women (80%) felt that clinicians should screen all 
their women patients for partner abuse. Responses 
to questions about the appropriateness of clinicians 
screening all women patients were similar pre- and 
post-intervention and did not differ by abuse status 
or by age. 
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McDonnell and colleagues112  recruited 481 patients 
attending their first antenatal appointment at 
an Irish hospital. Of the women who answered  
the questions regarding acceptability of partner 
violence screening, 468 (99%) found the questions 
acceptable and considered that all women should 
be asked these questions. There were no differences 
in acceptability by abuse status or by age.  
A study by McNutt and colleagues113 recruited 
women from a health maintenance organisation 
(HMO), partner violence programmes and refuges. 
The survey incorporated questions on what women 
want nurses and physicians to ask, and what they 
want them to do and not do in order to help 
abused women. Forty percent of women in the 
HMO and community-based programmes and 64% 
in refuges agreed with screening.  
Newman and colleagues114 conducted a survey of 
451 women who were unaccompanied by a male 
partner in a paediatric emergency department in  
a US hospital. When asked if it was appropriate to 
screen them for partner violence when they sought 
care for their children, 75% of women stated it 
was. Forty-four percent preferred direct verbal 
questioning, 36% a written questionnaire, and 20% 
suggested other methods of screening.  
Renker and Tonkin102 used anonymous computer 
interviews in two maternity units in the USA.  
Topics covered in the interview included screening 
and interventions, past disclosure to health-care 
providers, preferences or attitudes towards violence 
screening, pregnancy violence and violence severity 
screening. Feelings of anger, embarrassment 
or being offended were not experienced by  
the majority (97%) of women screened by their 
prenatal care providers for partner abuse.  
Richardson and colleagues41 surveyed 1207 women 
in 13 randomly selected general practices in 
London. Eighty percent of women reported that 
they would not mind being asked by their general 
practitioner about abuse or violence in their 
relationship if they had come about something else.  
Romito and colleagues107 conducted a survey  
in six family practice sites in Italy. Women were 
approached and asked if they would like to 
participate in a study to improve how health 
services respond to women’s health problems. 
Eighty-five percent of respondents believed the 
family doctor should ask all women about violence, 
7% thought doctors should not ask, and 8% 
were uncertain. A higher percentage of women 
experiencing current abuse agreed that doctors 
should ask about abuse compared with women 
not currently experiencing abuse, although this 
association was not significant. Younger women 
were significantly less likely to agree that all doctors 
should ask about abuse.  
Sethi and colleagues48 administered a modified 
World Health Organization (WHO) Multi-country 
Domestic Violence Study questionnaire in an 
inner-city accident and emergency department 
in a British hospital. The questions asked about 
the nature of violence and abuse experienced  
and women’s views on being asked about abuse in 
an accident and emergency department setting. 
Overall, 76% felt comfortable when asked about 
partner violence. Eighteen percent felt slightly 
uncomfortable, 5% felt uncomfortable and 
1% felt very uncomfortable. Feelings of being 
uncomfortable were higher in those who had 
experienced abuse compared with those who had 
not (10% versus 3%, p = 0.02). In response to a 
question about the desirable frequency of being 
asked about partner violence, 35% felt it should be 
on all occasions, 26% felt they should usually be 
asked, 38% said seldom and 2% felt never. Many 
women commented on the need for privacy and 
safety and expressed concern about direct questions 
being asked of women presenting with injuries.  
Zeitler and colleagues115 recruited women aged 
between 15 and 24 years who presented for family 
planning services to a US clinic. Almost 90% of 
those surveyed felt that universal screening by 
health-care providers is a ‘very good’ or ‘somewhat 
good’ idea. When respondents were categorised 
according to how much they minded being asked 
about violence, there were no differences according 
to ethnicity, school enrolment, parity, family 
violence or lifetime dating violence experience. 
However, compared with women aged 19–21 years, 
women aged 15–18 years were 2.9 times more likely 
to voice some concern regarding violence screening 
by a provider (36%, p < 0.01).  
Webster and colleagues116 administered a self- 
report questionnaire to 1313 women from five 
Australian hospitals during the visit following  
the consultation at which they had been screened 
for partner violence. Ninety-eight percent of 
respondents believed it was a good idea to ask 
women about partner violence when visiting a 
hospital. There was no difference in the responses 
of women from rural, remote or inner city sites, 
nor were there differences between sites in terms 
of how women felt when asked partner violence 
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questions. Ninety-six percent felt ‘OK’ about being 
asked, 1% felt relieved to be able to talk to someone 
about their problem, and 2% felt uncomfortable. 
Three-quarters of women who felt uncomfortable 
still agreed that it was a good idea to ask about 
partner violence.  
Weinsheimer and colleagues104 recruited 95 
consecutive women in a level 1 trauma centre to 
a questionnaire survey. Although 18% of women 
thought screening infringed their privacy, the 
overwhelming majority (> 90%) felt that it was 
appropriate to ask about partner violence and 
that women should be asked about it in a trauma 
setting. Nearly all (93%) of the 44 women who 
reported a history of partner violence thought a 
trauma centre health-care provider could assist 
them with a safety plan, but about one in four 
abused women thought reporting would increase 
their chances of further harm.  
Witting and colleagues117 surveyed 146 patients 
attending an accident and emergency department, 
giving three hypothetical scenarios of varying 
partner violence risk. Patients’ support for 
‘screening’ increased as the scenarios increased in 
severity: 86% expected it for the high-risk versus 
17% for the low-risk scenario. The majority of 
patients felt that a physician, rather than a nurse, 
should have the primary responsibility for partner 
violence screening, but that the gender of the 
screener did not matter. A higher proportion of 
patients with lower educational status supported 
screening in the emergency department. 
  
Synthesis 
 
We have combined data from the interview- and 
focus group-based qualitative studies with the 
data from the questionnaire-based quantitative 
studies. The main focus of this review question was 
the acceptability to women patients of screening 
for partner violence. This included physical and 
sexual violence, emotional abuse and controlling 
behaviours by current partners or ex-partners. 
Although the proportion of survey respondents 
who found screening by health-care professionals 
acceptable varied between 35% and 99%, our main 
finding is that the majority of survey respondents 
and informants in the qualitative studies did find  
it acceptable even if it made them uncomfortable. 
There was variation in attitudes towards screening 
between countries and between health-care settings 
and by abuse and educational status. In the UK- 
based studies, 20% of respondents did not support 
screening in a general practice context, and 
40% thought women should seldom or never be 
asked about partner violence in an accident and 
emergency department.  
In the sensitivity analysis of the survey estimates of 
acceptability of screening, the variation in results 
could not be explained by the variation in STROBE 
quality scores. Higher-quality studies showed the 
same variation as in the total pool of studies.  
Below we explore the role of the following factors 
in the acceptability of screening by health-care 
professionals:  
• the woman’s age, level of education, financial 
autonomy, and ethnicity 
• whether the woman has ever been abused and 
is currently abused by their partner or ex- 
partner 
• type of health-care setting 
• type of screening questions 
• type of health-care professional. 
 
Age 
Younger women, especially those aged 15–19 years, 
were less likely to agree with screening for partner 
violence.102,107,115  Friedman and colleagues found 
that older patients were more in favor of routine 
physical abuse enquiry.110 Age, however, did not 
influence the acceptability of routine enquiry for 
sexual abuse, although most surveys did not collect 
data on that issue. 
 
Education 
Witting and colleagues found that a higher 
proportion of respondents with lower education 
status supported partner violence screening.117 
Friedman and colleagues also found that, 
regardless of setting, patients who had not 
completed high-school education were more in 
favour of routine enquiry about physical abuse and 
sexual abuse.110 
 
Ethnicity 
Although many of the surveys had ethnically 
diverse samples, most did not report acceptability 
by ethnic group. Zink and colleagues found that 
Latina mothers felt greater discomfort with partner 
violence questions than white American women.118 
The issue was not discussed in the qualitative 
studies. 
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Abuse status 
Seven quantitative studies reported results by abuse 
status, and there was no consistent difference in 
acceptability by abuse status, although several 
found that a lower proportion of women with 
a history of partner violence were in favour of 
screening compared with women without that 
history. Caralis and Musialowski reported that 77% 
of non-abused women and 70% of abused women 
agreed with screening.109 Glass et al. reported that 
80% of women who were acutely abused or who 
were physically or sexually abused in the past year 
agreed with routine screening compared with 89% 
of women who reported a lifetime history of abuse 
or who reported no partner violence.105 Zeitler  
and colleagues reported a similar result: women 
who had experienced physical violence in the last 
year were significantly less likely to report that they 
felt it was a good idea for health-care providers to 
ask all women about violence; but even so, 80% 
of this group were in favour of all women being 
asked.115 However, Friedman and colleagues found 
that 80% of those who reported sexual abuse 
favoured routine physician enquiry about sexual 
abuse compared with 64% of those who reported 
never being sexually abused.110 In the same study, 
patients who reported abuse were just as likely to 
favour routine enquiry as patients who reported 
never being abused. Gielen and colleagues found 
that 48% percent of their sample agreed that 
health-care providers should routinely screen all 
women, with abused women more likely than non- 
abused women to support this policy (54% versus 
42%),111 which concurred with the findings of Sethi 
and colleagues that 43% of accident and emergency 
department patients with a history of abuse  
thought that women should always be asked about 
experience of partner violence, compared with 30% 
among those who had not been abused.48 
 
Screening  settings 
There were no consistent differences in 
acceptability of screening by health-care setting. 
Most of the studies were conducted in various 
hospital settings, with some in general practices, 
in refuges or where women attended their support 
groups; one was in a family planning clinic and 
some included different settings. In several of 
the qualitative studies, informants did say that 
they would prefer screening to be carried out  
by a clinician with whom they already had a 
relationship, which implies that primary care is 
a more acceptable context than an accident and 
emergency department. This finding also implies 
that it may be less appropriate to ask about 
abuse at the first antenatal appointment than at 
subsequent appointments. 
 
Method of administering 
screening questions 
Most quantitative studies did not test acceptability 
of screening in relation to screening modality. 
Those that did and the qualitative studies found a 
range of preferences; there was no single preferred 
modality. 
 
Type of health-care professional 
Acceptability of screening may vary according 
to the gender and the profession of the health- 
care provider asking the questions. Some women 
preferred being screened by female health-care 
professionals; however, the qualitative studies  
found that most women felt that a professional’s 
interpersonal skills were more important than their 
gender or profession. Others voiced a preference 
for being screened by older health-care providers 
and doctors. Richardson and colleagues41 found 
that 20% of women reported that they would mind 
being asked by their general practitioner about 
abuse or violence in their relationship if they had 
come about something else, with 23% objecting to a 
nurse asking; 42% reported that they would find it 
easier to discuss these issues with a woman doctor, 
and 3% expressed a preference for a male doctor.  
Romito and colleagues found that women’s 
responses concerning who they would like to 
discuss violence issues with ranged from (more 
than one answer was possible) the family doctor 
(54%), a psychologist (28%), women who had 
similar experiences (22%), a social worker (9%) 
and the police (7%).107  Webster and colleagues116 
also reported a range of responses from women 
when asked about which health-care professionals 
should screen for partner violence: 1068 (65%)  
of the women nominated midwives, 1055 (64%) 
nominated general practitioners, 809 (49%) 
selected social workers, and 771 (47%) selected 
hospital doctors. Only 42 (2%) thought no one 
should ask. A number of women wrote comments 
such as ‘anyone who cares should ask’.  
From the qualitative studies it seems that in 
general women gain a sense of support and 
relief from discussing their situation with a 
health-care professional. Some women found 
it more acceptable to be screened by a health- 
care professional where there was an already- 
established relationship and trust had been built 
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up. Women also placed great emphasis on the 
capacity of health-care professionals to listen to 
them discuss their problems without judging or 
condemning them; not listening was viewed as 
inhibiting disclosure. Women felt more comfortable 
being screened and asked sensitive questions by 
health-care professionals who they felt understood 
the complexity of partner violence and who 
established  a  personal  connection.95,97,98,100,119,120 
Some women also stated that part of their fear 
and suspicion associated with disclosing partner 
violence and being screened arose from not being 
sure of the health provider’s intentions in asking 
and what would happen if they told the provider. 
Some women felt that they were being screened 
because the health-care providers did not think 
they were caring for their children properly, and 
saw screening as a search for child neglect or 
abuse.119 By giving a reason for screening, health- 
care providers may alleviate these fears and build 
up trust. Some women expressed concern that 
appointments were not long enough to make 
effective use of confidential time, or felt that 
health-care professionals did not have the time to 
listen.119 Many of the women felt that screening 
gave them the opportunity to disclose abuse, 
either then or at a later stage, and that without 
this opportunity it would be harder for them 
to seek help. Women expressed concerns with 
possible negative repercussions of screening, such 
as breach of confidentiality, the involvement of 
children’s services, legal repercussions and being 
judged.120  Common concerns highlighted included 
the legal repercussions of revealing abuse and  
fears that abusive partners might find out that the 
relationship had been discussed. Some women 
reported feeling ashamed and concerned that 
others would judge them poorly. 
  
Strengths and limitations 
 
The strengths of this review include the 
synthesising of qualitative and quantitative studies 
to answer this question, the quality appraisal 
of studies (using the STROBE checklist for 
quantitative studies and the CASP tool for the 
qualitative studies) and the performance of a 
sensitivity analysis. Respondent-related variables, 
such as demographic features and abuse status, 
and features relating to the screening process, such 
as setting, type of questions and the health-care 
professionals, were examined to assess how they 
interact to increase or decrease the acceptability  
of screening. This review meets the relevant 
QUORUM reporting criteria (see Appendix 11.4 
for checklist and flowchart). A limitation is that we 
did not include studies, if they exist, of the views of 
men about health-care-based screening of women 
for domestic violence. 
  
Discussion 
 
Most of the surveys of women patients in health- 
care settings show that the majority agree with 
screening or routine questioning about partner 
violence, but there is variation, not explained by 
study quality, abuse status, setting or demographic 
factors. The quality of the surveys was generally 
good. A possible explanation for the variation 
of screening acceptability could be the variation 
in wording of the acceptability questions. 
Acceptability was measured by questionnaire 
statements to which women ‘agreed’ or ‘disagreed’. 
Most papers did not report the exact wording of 
the questions; however, these were not necessarily 
comparable. For example authors referred to 
statements like ‘women would have wanted to 
be asked’106 or ‘felt it was appropriate to screen 
them’.101 The term ‘screening’ was not necessarily 
used and authors often did not clarify whether 
the question addressed violence when the women 
were attending with an apparently unrelated health 
problem. We excluded studies where the reported 
questionnaire item was vague and could be 
interpreted as acceptability of any question about 
partner violence.  
In interviews and focus groups, women say they 
find screening beneficial, even if they are not yet 
ready to disclose abuse. Informants perceived 
screening as a method of raising awareness rather 
than eliciting disclosure of abuse. Women who 
were not yet ready to disclose abuse still found 
screening beneficial as it helped to remove the 
stigma attached to partner violence, raised 
awareness of partner violence, gave them a sense of 
validation and let them know there is somewhere 
they can go if they need help when they are ready 
to disclose. Although women may not disclose 
abuse immediately, screening may facilitate 
disclosure later when they feel more comfortable 
with the health-care professional, or when their 
circumstances change and they feel the need to get 
help. 
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Chapter 7 
Are  interventions  effective once partner 
violence is disclosed in a health‐care setting? 
(Question   IV) 
W and identified by screening were randomised to 
e found 33 studies measuring the 
effectiveness of interventions for women 
who have experienced partner violence and 
their children. Nineteen of these studies were 
examined in a previous systematic review,11 and 
have been summarised below with the new studies. 
Publication dates of the 14 studies not included in 
the previous review range from 2000 to 2006. The 
majority of these new studies were conducted in  
the USA, a few were conducted in Canada, two in 
Spain, one in Mexico and one in Hong Kong. The 
settings varied and included refuges, community 
settings, women’s homes, antenatal clinics, a 
methadone maintenance programme and primary 
care ‘public health’ clinics. Study designs included 
nine randomised controlled trials, two case–control 
studies and two before-and-after studies. For details 
of the included studies see Appendix 7.1. For 
results and quality scores of studies see Appendix 
7.2. The assessments of individual studies using the 
USPSTF criteria and the Jadad tool are detailed in 
Appendices 7.3 and 7.4, respectively. 
 
No qualitative studies were found that explored 
what outcomes abused women want for themselves 
and their children from programmes that include 
screening or other health-care based interventions. 
  
Advocacy interventions 
with abused women 
Eleven studies (four newly reviewed and seven from 
our previous review) evaluated the use of advocacy 
for women experiencing partner violence: one in 
Hong Kong, one in Canada and nine in the USA. 
 
Studies published since 
our previous review 
In an individually randomised controlled trial 
of an advocacy intervention in an urban public 
hospital antenatal ward, conducted by Tiwari et 
al.,121 advocacy benefited abused pregnant women 
who were still in a relationship with the abuser. 
Abused women at less than 30 weeks’ gestation 
 
the intervention group, which received advice on 
safety, choice-making and problem-solving, or 
to the control group, which received a referral 
card listing community resources and sources of 
partner violence services. The intervention sessions 
lasted about 30 minutes, and afterwards women 
were given a brochure reinforcing the information 
provided. Follow-up was 6 weeks post-delivery, 
and hence ranged from 16 to 34 weeks from the 
intervention, depending on gestational age at 
recruitment. At follow-up, the intervention group 
reported significantly less psychological abuse 
and less minor physical abuse; however, the rate 
of severe abuse and sexual abuse did not differ 
between the groups. The intervention group had 
significantly greater physical functioning and 
significantly improved scores on role limitation 
measures for both physical and emotional 
problems. Although the women did not report 
any adverse effects as a result of participation in 
the study, the intervention group reported more 
bodily pain than the control group. There were 
no differences between groups on outcomes of 
general health, vitality, social functioning and 
mental health. Significantly fewer women in the 
intervention group had postnatal depression at 
follow-up than in the control group.  
A pilot study by Constantino and colleagues  
of an advocacy intervention with a therapeutic 
component was conducted with first-time residents 
of an urban domestic violence refuge.122 This 
individually randomised controlled trial compared 
a structured nurse-led social support intervention 
with unstructured discussion sessions. Both groups 
continued to receive standard refuge services. The 
intervention comprised eight weekly sessions (each 
lasting 90 minutes) and sought to empower abused 
women through the provision of four dimensions 
of social support: belonging, evaluation, self- 
esteem and tangible support (BEST). It provided 
resources to the women as well as information 
on further resources; it allowed them time to 
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access resources when these were available; and 
provided an environment where they could talk 
with a counsellor and friends. Follow-up did not 
extend beyond the intervention period. At the 
end of the programme the experimental group 
had significant improvements on the ‘belonging’ 
function of social support, and had significant 
reductions in psychological distress and health-care 
utilisation. The authors reported non-significant 
improvements in ‘tangible’ social support and total 
social support, but no data were presented.  
An individually randomised controlled trial 
conducted by McFarlane and colleagues in two 
urban primary care public health clinics and two 
women, infants and children clinics compared a 
nurse case management intervention with a referral 
card that listed a safety plan and sources of partner 
violence services.123 Project nurses received a 40- 
hour training programme based on the March of 
Dimes protocol prior to study implementation. 
Advocacy sought to empower the women by 
increasing independence and control through 
encouraging the use of a 15-item safety-promoting 
behaviour checklist, supplemented with supportive 
care and anticipatory guidance by a nurse and 
guided referrals tailored to the women’s individual 
needs, such as job training. There were five 
20-minute case management sessions. The control 
group received standard refuge services provided 
to all residents. No effect for the intervention was 
found at the 24-month follow-up: all outcomes 
(use of safety behaviours and community 
resources, threats, assault, homicide risk and work 
harassment) improved over time, regardless of 
group allocation. Study participants did not report 
any adverse effects. For findings relating to the 
children of the participants, see Interventions with 
children of abused women below.  
Sullivan and colleagues tested the effect of an 
advocacy intervention aimed at abused women and 
their children (aged between 7 and 11 years) using 
an individually randomised controlled trial study 
design.124 The intervention took place in women’s 
homes in an urban setting. Advocacy was based on 
the individual needs of the mother and child, but 
all sessions actively assisted mothers in accessing 
community resources. The majority (79%) of the 
women were recruited when leaving a domestic 
violence refuge and the remainder were recruited 
from community family service organisations or 
social services. Unspecified control group care was 
compared with a multicomponent intervention 
consisting of: (1) a highly trained paraprofessional 
who worked for 16 weeks and helped mothers to 
mobilise and access community resources; (2) the 
same paraprofessional who advocated similarly for 
the children for 16 weeks; (3) a 10-week support 
and education group attended by the children 
within the 16 weeks. Families saw their advocates 
for a mean of 10 hours a week, averaging 5 hours 
with the children and an additional 2.7 hours 
with the women. The basis of advocacy and the 
content of the sessions was similar to that of 
earlier intervention studies by Sullivan and her 
colleagues125–129  (reported under Studies included 
in our previous review below). An important part 
of the intervention was ensuring that the advocate 
was no longer needed after 16 weeks. At a 4-month 
follow-up, women in the intervention group had 
significantly reduced depression and improved 
self-esteem. Mothers who received advocacy also 
reported better quality of life than mothers in the 
control group, although this was not statistically 
significant. However, the intervention did not have 
an effect on the incidence of actual abuse or social 
support. For findings relating to the children, 
see Interventions with children of abused women 
below. 
 
Studies included in our 
previous review 
Here we summarise the findings of studies 
examined in our previous review.11 In two separate 
randomised controlled studies (a pilot and a 
main study) by Sullivan and colleagues,125–129 
undergraduate psychology students were trained 
to provide 10 weeks of community-based advocacy 
to severely abused women exiting from refuges. 
Advocacy was tailored to the individual women’s 
needs to help them to access community resources 
(such as housing, employment, legal assistance, 
transport and childcare), as well as empowering 
the women themselves. A number of beneficial 
outcomes were observed over time. In the main 
study, at the end of the advocacy period, there 
was a significant improvement in the women’s 
perceived effectiveness in obtaining resources, 
quality of life and perceived social support as 
compared with baseline and control group scores. 
At 10 weeks postintervention, the women who 
received advocacy reported improvement in 
their quality of life, and this was maintained at 
6 months after the cessation of the programme. 
Initial improvements in perceived effectiveness in 
obtaining resources and perceived social support 
were no longer statistically significant at 6 months. 
However, when followed up 2 years after the 
cessation of advocacy, women in the advocacy 
group reported significantly less physical abuse 
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and still had a significantly higher quality of life 
than women in the control arm. Subsequent to the 
review by Ramsay and colleagues, a 3-year follow- 
up130 has been conducted. This shows that advocacy 
continued to have a positive impact on the women’s 
quality of life and level of social support, although 
there was no continuing benefit in terms of 
revictimisation.  
Advocacy and associated services also benefited 
pregnant abused women who were still in a 
relationship with the abuser, according to a parallel 
group intervention study conducted by McFarlane 
and colleagues.131–133  The women, attending an 
antenatal clinic, were offered an intervention of 
three brief sessions of individual advocacy (not 
described in any detail) – education, referral and 
safety planning – spread over their pregnancies. 
Additionally, half of the intervention group was 
offered three further support group sessions at 
a local refuge, but outcomes for these were not 
considered separately. The investigators found 
that women receiving the intervention significantly 
increased their use of safety behaviours, including 
hiding keys, hiding clothes, asking neighbours to 
call the police, establishing a danger code with 
others, and hiding money. At a 12-month follow- 
up, women in the intervention group reported 
significantly improved resource use but not use 
of the police, and there were also significant 
reductions in violence, threats of violence and non- 
physical abuse against the women compared with 
women in the control group  
Another advocacy study was also conducted in an 
antenatal setting by McFarlane and colleagues.134  In 
this randomised controlled trial, abused Hispanic 
women were allocated to one of three intervention 
groups: (1) ‘brief ’, where women were offered a 
wallet-sized card with information on community 
resources and a brochure; (2) ‘counselling’, where 
for the duration of the pregnancy women were 
offered unlimited access to a bilingual domestic 
violence advocate who was able to provide support, 
education, referral and assistance in accessing 
resources; and (3) ‘outreach’, which included all 
aspects of the ‘counselling’ intervention, plus the 
additional services of a bilingual trained non- 
professional mentor mother who offered support, 
education, referral and assistance in accessing 
resources. The investigators found that violence 
and threats of violence decreased significantly 
across time for all three intervention groups. At 
2 months postdelivery, violence scores for the 
‘outreach’ group were significantly lower compared 
with the ‘counselling’-only group; but there was 
no significant difference when compared with the 
‘brief ’ intervention group women who had received 
only a resource card and brochure. Subsequent 
follow-up evaluations at 6, 12 and 18 months 
found no significant differences between the three 
intervention groups. Use of resources was low for 
each of the groups and did not differ significantly 
by type of intervention at any of the follow-up 
evaluations.  
A third advocacy study by the same research group 
was a randomised controlled trial,135,136 based in 
a family violence unit of a large urban district 
attorney’s office. All women received the usual 
services of the unit, which included processing 
of civil protection orders and optional advocacy 
referral, and the phone number of a caseworker 
for further assistance. They also received a 15-item 
safety-promoting behaviour checklist. In addition 
the intervention group received six follow-on 
phone calls over 8 weeks to reinforce the advice on 
adopting safety behaviours. The number of safety- 
promoting behaviours increased significantly in 
the intervention group, both compared with the 
control group and up to 18 months later.  
An advocacy study by Feighny and Muelleman137 
took place in a hospital’s accident and emergency 
department. The advocate saw the woman within 
30 minutes of disclosure, discussed the incident 
with her, addressed safety issues, provided 
education about the cycle of violence, and  
informed her of community resources. A before- 
and-after design with historical controls was 
employed to evaluate outcomes, with data obtained 
from police/judicial, refuge and medical records. 
Women receiving advocacy significantly increased 
their use of refuges and refuge-based counselling 
services in comparison with preintervention 
controls. However, there was no effect on 
subsequent experience of abuse as measured by the 
number of repeat visits to the department over a 
mean follow-up period of 65 weeks, nor was there 
any significant difference in the number of police 
calls made by women after their initial visit, or in 
the number of women who went on to obtain full 
protection orders.  
Tutty138 considered the effects of advocacy for 
women leaving refuges using a before-and-after 
study design. The intervention programme of 
support and advocacy, of longer duration than 
the model used by Sullivan, was provided by a 
graduate social worker and provided counselling 
and other help for the women. The main goals 
of the advocacy were to respond to the individual 
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woman’s needs and to coordinate support services 
so that the woman could remain independent  
and safe. Tutty found that this programme of 
advocacy resulted in significant improvements 
over baseline scores for physical abuse and for 
‘appraisal support’ (the availability of someone to 
talk to about one’s problems). However, there was 
no significant improvement for ‘belonging support’ 
(obtaining support from friends and family) or 
perceived stress levels.  
In our previous review11  we found that evidence 
regarding the effectiveness of advocacy 
interventions is weakest for women who are still 
in an abusive relationship and there was little 
evidence that women identified through screening 
had improved outcomes from advocacy. In this 
update we found one well-executed study121 
showing that an advocacy intervention may be 
effective for women who disclose current abuse 
as a result of screening in an antenatal clinic, 
and a fairly well-executed study in primary care 
public health clinics and women, infants and 
children clinics123 showing no difference between 
intervention and control arms. The strongest 
evidence for advocacy-based interventions, 
emerging from the relatively well-executed trials of 
Sullivan and colleagues, is for an intensive advocacy 
programme for women leaving a refuge. The 
evidence for the effectiveness of advocacy with a 
less intensive intervention or for women identified 
in health-care settings is less robust, either because 
study designs were more prone to bias or because 
the execution of the studies was flawed. Yet most 
studies show some benefit from advocacy for some 
outcomes and therefore this is a legitimate referral 
option for health-care professionals. Evidence 
from advocacy studies suggests that this form of 
intervention, particularly for women who have 
actively sought help from professional services,  
can reduce abuse, increase social support and 
quality of life, and lead to increased usage of safety 
behaviours and accessing of community resources. 
Five of the studies121–124,130  were well-executed 
studies of good or fair design. Considering only 
these high-quality studies did not alter the overall 
findings, although two of the less well conducted 
studies134,137 showed less effect of advocacy. 
Continued severe abuse or revictimisation was the 
outcome most resistant to advocacy, although this 
may partly be a function of short follow-up, as one 
of Sullivan’s trials showed no decrease in abuse at 4 
months follow-up,124 but did find it at 2 years after 
the advocacy intervention.125–129 Moreover, abuse 
is a factor over which the survivor has least direct 
control. 
Support group interventions 
with abused women 
Two studies (one from our previous review and 
one newly reviewed) evaluated support groups 
for abused women; both of these were based in 
Canada. 
 
Study published since 
our previous review 
The study reported by Fry and Barker139  after 
our previous review was published had a case– 
control design and compared the effectiveness 
of a story-telling intervention with minimal  
care where women attended information-giving 
support groups. The geographical setting 
was not reported. The intervention group 
participated in 30–90-minute sessions in which 
each woman was given an opportunity to narrate 
a story about six salient events that she had 
experienced in the previous 4–6 months and that 
she believed had had the strongest impact on  
her self-confidence, self-esteem and self-worth. 
A group facilitator attempted to put relevant 
structure on the reminiscence process by offering 
encouragement, directing questions and steering 
the contents. At the 4-month follow-up, women 
who had received the intervention demonstrated 
significant reductions in depression, and significant 
improvements in self-esteem, global self-efficacy 
scores, the ability to share feelings, feelings of 
personal adequacy and a sense of reality. 
 
Study included in our 
previous review 
The study included in our previous review11 had 
a before-and-after design and was reported in 
two papers by Tutty and colleagues.140,141 They 
evaluated 12 feminist-informed support groups 
for survivors of partner violence, as part of a 
community family violence programme. The goals 
of the groups were to stop violence by educating 
participants about male/female socialisation, 
building self-esteem and helping group members 
to develop concrete plans. The groups were 
facilitated by professionals over a 10–12-week 
period. A number of statistically significant 
benefits were observed immediately after the end 
of the intervention, including improvements in 
all physical and non-physical abuse measures, 
perceived belonging support, locus of control, 
self-esteem, and perceived stress and coping. At 6 
months’ follow-up, there were continued reductions 
in physical abuse and one measure of non-physical 
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abuse, and increases in self-esteem and perceived 
stress and coping. Improvements in social support 
and locus of control were sustained. Using 
multivariable analysis, the investigators showed  
that groups with two facilitators, rather than one 
alone, may be more effective in reducing emotional 
abuse. 
 
Both these studies were poorly executed with weak 
designs and therefore there is insufficient evidence 
on which to judge the effectiveness of support 
groups for women experiencing partner violence. 
  
Psychological  interventions 
with abused women 
Seventeen studies (11 from our previous review 
and six newly reviewed) evaluated the use of 
psychological interventions. Most studies were 
conducted in the USA. Ten of the 17 studies 
reported on the effects of group interventions: 
one of these compared a group intervention with  
a slightly modified version, one included overall 
findings from 54 different partner violence 
programmes (which incorporated individual, 
group, or both individual and group counselling 
sessions), and one compared group and individual 
therapy. Seven studies considered the benefits 
of individual therapy, with two of these also each 
comparing two different interventions. 
 
In the studies that compared two types of 
psychological intervention, both groups tended 
to have improved outcomes, but there were no 
differences between the interventions. It is unclear 
whether this means that (1) neither intervention is 
effective, as there is spontaneous improvement in 
these outcomes once a woman has left an abusive 
situation; or (2) one intervention is more effective 
than the other, but with insufficient power to detect 
the difference; or (3) both interventions are equally 
effective (i.e. superior to no intervention). Positive 
outcomes from studies comparing a psychological 
intervention with no intervention suggest that (1) is 
unlikely. 
 
Individual psychological 
interventions 
Studies published since our previous review 
Koopman and colleagues142 conducted an 
individually randomised controlled trial in an 
urban setting comparing the effectiveness of an 
expressive writing intervention with a neutral 
writing control arm. Women were recruited 
through fliers, newspaper advertisements and 
electronic postings. Participants in the intervention 
group were asked to use expressive writing and to 
write about the most stressful events of their lives, 
exploring their deepest emotions and feelings. At 
the 4-month follow-up, women in the intervention 
group had significant reductions in depression 
compared with the control group. However, the 
reverse was true for bodily pain: women in greater 
pain at baseline benefited more if allocated to the 
control arm. The intervention had no effect on 
PTSD.  
A ‘matched, yoked and randomised’ experimental 
and control group design was used by Reed and 
Enright,143  in an urban setting, to compare the 
effectiveness of forgiveness therapy against an 
alternative treatment consisting of discussions 
about the validity of anger regarding the injustice 
of past abuse, present strategies for healthy 
assertive choices, and interpersonal relationship 
skills. Women, all self-selected volunteers, in the 
intervention group engaged in weekly 1-hour 
sessions based on the Enright forgiveness process 
model. Participants determined the time spent 
on each forgiveness topic, and the intervention 
finished when each participant reported that she 
had completed the work of forgiving her former 
partner. The mean treatment time (one session 
per week) for the pairs was 8 months, with a 
minimum of 5 months and a maximum of 12 
months. The intervention group demonstrated 
a significantly greater increase in forgiving their 
former abusive partner, self-esteem, environmental 
mastery (everyday decisions), finding meaning in 
suffering (moral decisions) and in ‘new stories’ 
(survivor identity). The intervention group also had 
significant reductions in trait anxiety, depression, 
post-traumatic stress symptoms and in old stories 
(victim identity). However, they did not have 
significant decreases in state anxiety scores.  
Labrador and colleagues conducted a case–control 
study in an urban setting in Spain to assess the 
efficacy of an intervention for the treatment of 
chronic PTSD in women experiencing domestic 
violence.144   The intervention consisted of four 
components: (1) self-evaluation and problem- 
solving; (2) breathing control; (3) exposure 
therapy (which involved recalling past events and 
confronting flashbacks); and (4) cognitive therapy. 
It was delivered in eight weekly sessions of 60 
minutes. Women in the intervention group were 
split into two groups, with one group receiving 
the components of the intervention in the  
above order, and the second group receiving the 
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cognitive therapy component before the exposure 
therapy to establish whether the efficacy of the 
intervention was affected by the order in which  
the cognitive and exposure therapy components 
were delivered. Women were referred from the 
‘municipal centre for women’ and victim support 
centres, by judges of domestic violence cases and 
by housing advisors. Women in the intervention 
group showed significant decreases in depression 
and ‘maladaptation’ and significant increases in 
self-esteem 2 months from baseline. Although 
women in the intervention group had reductions 
in PTSD symptoms post-treatment, these were not 
significant when compared with the control group, 
apart from negative cognitions. No differences 
were found between the two intervention groups. 
 
Studies included in our previous review 
In our previous review11 we examined two 
randomised controlled trials of a psychological 
intervention conducted by Kubany and 
colleagues.145,146 The intervention was based on 
cognitive behavioural therapy and was targeted 
at women survivors of partner violence who had 
PTSD. Specifically, the intervention included 
elements from existing treatments for PTSD, 
feminist modules that focused on self-advocacy and 
empowerment strategies, assertive communication 
skill building, the managing of unwanted contact 
with former partners, and identifying potential 
perpetrators to avoid revictimisation. The two 
evaluation studies, both randomised controlled 
trials, found a sustained improvement at 3 and 6 
months, respectively, in a range of mental health 
measures including PTSD, depression and self- 
esteem.  
In a randomised controlled study by Mancoske 
and colleagues, women who contacted a partner 
violence agency were provided with a rapid 
response crisis intervention.147 They were then 
randomly assigned either to feminist-oriented 
counselling or to grief resolution-oriented 
counselling, both of which were provided over 
eight weekly sessions by trained social workers 
and included basic problem-solving and 
psychoeducation. At the end of counselling, both 
groups showed improvements over baseline in 
self-esteem and self-efficacy, although these were 
only significant for women who received grief 
resolution-oriented counselling. 
 
In a parallel group study of women resident in  
a refuge or receiving refuge-associated services, 
conducted by McNamara and colleagues, two 
types of intervention were compared: individual 
counselling versus case management.148,149 When 
assessed after three sessions, women in both groups 
showed significantly improved life satisfaction 
and coping ability compared with baseline values. 
Additionally, women who had received individual 
counselling showed a significantly greater increase 
in global improvement scores than women in the 
case management group. 
 
Group psychological interventions 
Studies published since our previous review 
 
Gilbert and colleagues150 conducted a pilot study 
using a randomised controlled trial design to test 
the feasibility, safety and short-term preliminary 
effects of a relapse prevention and relationship 
safety (RPRS) intervention in reducing drug use 
and partner violence among women in methadone 
maintenance treatment programmes (MMTPs);  
the geographical region was not reported. The 
RPRS intervention consisted of eleven 2-hour 
group sessions and one individual session. The 
intervention was tailored to the realities of low- 
income, African American and Latina women and 
focused on the enhancement of self-worth, ethnic 
pride and risk avoidance in the future. Materials 
and exercises incorporated social cognitive skill 
building. At the end of each session, participants 
were asked to commit to specific skills practice 
exercises between sessions. The control group 
received an information session consisting of 
a 1-hour didactic presentation of a wide range 
of local community services that women in 
MMTPs can access, tips on help-seeking, and a 
comprehensive directory of local partner violence 
services. At the follow-up assessment women in 
the intervention group demonstrated reductions 
in minor physical, sexual and/or injurious partner 
violence in the past 90 days. They were also more 
likely than women in the information group 
to report a decrease in both minor and severe 
psychological partner violence. Other changes in 
abuse measures did not reach significance. Women 
in the intervention group also demonstrated 
decreases in depression at the 3-month follow- 
up. Compared with women in the control group, 
women in the intervention group were more likely 
to report a decrease in having sex while high on 
illicit drugs. Improvements regarding substance 
use and PTSD after receiving the intervention did 
not reach significance. No adverse events were 
detected.  
A cognitive behavioral therapy programme for 
women referred from social services, counsellors 
and the judiciary who displayed post-traumatic 
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stress symptoms but did not meet the diagnostic 
criteria for PTSD was evaluated in a case–control 
study by Arinero and Crespo conducted in an 
urban setting in Spain.151  The intervention, 
administered in a health-care setting, included 
psychoeducation, breathing controlling techniques, 
self-esteem improvement procedures, cognitive 
therapy, problem-solving and communication 
skills training as well as specific strategies for 
relapse prevention. Eight 90-minute sessions were 
conducted with groups of 3–5 women. Women 
in the intervention group, compared with the 
waiting list control group, showed a decrease in 
post-traumatic and depressive symptoms and an 
improvement in adaptation levels up to 6 months’ 
follow-up. There were no significant changes in the 
levels of self-esteem, although there may have been 
a ceiling effect as self-esteem levels were already 
high at the outset compared with other studies. 
The authors point out that the effect sizes were not 
as large as those in previous studies, such as that 
of Kubany et al.,145 and suggested that this might 
be because participants in their study had lower 
(i.e. better) symptom scores at baseline, producing 
a ceiling effect. There were significant decreases  
in depression for the intervention group post- 
treatment; the authors state this was still significant 
at 6 months but no data were presented. The effect 
size post-treatment was 0.95, and at the 1-month 
follow-up it was 0.66, but effect sizes for the 3- and 
6-month follow-ups were not presented.  
A before-and-after study, conducted in Mexico by 
Cruz and Sanchez,152 assessed the effectiveness 
of a group cognitive behavioural intervention 
on promoting self-esteem, coping strategies 
and assertiveness in abused spouses of problem 
drinkers. The intervention comprised three 
components: (1) identifying and correcting 
cognitive biases and defective information; (2) 
establishing emotional regulation strategies; 
and (3) acquiring assertiveness skills. Women 
received eighteen 150-minute weekly group 
sessions. Women’s self-esteem was found to have 
improved significantly from pre-test at the 3-, 
6- and 18-month follow-ups, but not immediately 
after the intervention. There were also significant 
improvements in coping strategies at the 3-, 6- 
and 18-month follow-ups. Women’s assertiveness 
increased significantly from pre-test to the 3- and 
6-month follow-up, but this was not sustained at the 
18-month follow up.  
Studies included in our previous review 
Included in our previous review11 was a parallel 
group study by Cox and Stoltenberg153 in which 
new refuge residents were recruited to a personal 
and vocational group psychological programme 
that included cognitive therapy, skills building 
and problem-solving. The 16 Personality Factors 
instrument (16PF) was administered to half of 
the intervention group, which was then given full 
feedback, creating two intervention subgroups. 
The control group received normal refuge care, 
which included weekly non-structured counselling 
sessions. When assessed immediately after the 
cessation of the intervention, both intervention 
groups showed significant improvements over 
baseline levels of self-esteem. However, all other 
benefits over time, including anxiety, depression, 
hostility and assertiveness, were limited to those 
women who received the intervention without 
any feedback from the 16PF. Neither of the two 
intervention groups improved in terms of locus of 
control. None of the outcome measures improved 
over time for women in the control group.  
Cognitive behavioural therapy was also the method 
used by Laverde in a randomised controlled trial  
in Columbia.154 Abused women in the intervention 
arm were given cognitive behavioural therapy, with 
lectures and structured exercises. The women were 
shown models of appropriate and inappropriate 
behaviour in different situations, and this was then 
followed by role play. Twenty 3-hour group sessions 
were held over a period of 11 weeks. Abused 
women allocated to the control condition attended 
a support group; these sessions were unstructured 
and aimed to discuss issues around partner 
violence and to provide information about the 
women’s legal rights and the availability of services. 
It was found that the frequency and intensity of 
abuse decreased markedly in both groups at 15, 
30 and 45 days postintervention, but the numbers 
were too small for any conclusions to be drawn. 
Other benefits over time for intervention group 
participants were also observed. In comparison  
with their baseline scores, women in this group 
significantly improved on several measures: 
communication skills, handling of aggression, 
assertiveness, and their feelings towards their 
partners and the relationship, such as feeling less 
sentimental. These improvements did not extend  
to the control group, and significant between-group 
differences were observed.  
A psychoeducational group programme was 
evaluated in a parallel group study by Limandri 
and May.155  The content of this programme 
included information about partner violence, 
safety planning, stress management, building self- 
esteem, coming to terms with loss and grief, and 
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developing a number of life skills. Women were 
recruited primarily through the victim witness 
programmes of two district attorney offices. 
Follow-up did not extend beyond the 12-week 
intervention. At the end of the intervention, self- 
efficacy scores improved for the women receiving 
group counselling, but declined slightly for women 
in the control arm of the study. There was an 
improvement in women’s perception of abuse 
across time in both groups. There were no between- 
group comparisons, no scores for the outcome 
measures and no reporting of any statistical 
analysis.  
Variable results were obtained by Melendez and 
colleagues156 in a randomised controlled trial of 
group counselling, in which abused and non- 
abused women recruited from a family planning 
clinic were offered four or eight group sessions of 
cognitive behavioural therapy to prevent human 
immunodeficiency virus (HIV)/sexually transmitted 
disease (STD) infection. (The data for the abused 
and non-abused women were reported separately 
and only those relating to the abused women 
are given here.) Two measures were used to test 
safe-sex practices: condom use in general and 
episodes of unprotected sex. At 1 month and 12 
months of follow-up, abused women who received 
eight sessions of counselling were significantly 
more likely to say that they used condoms at 
least sometimes, compared with controls or with 
women receiving only four sessions of counselling. 
However, there was no difference between groups 
in the number of unprotected sex occasions. 
Short-term benefits were reported in the use of 
alternative safer-sex strategies in both intervention 
groups, and negotiation over safer sex after eight 
sessions of therapy, but these were not maintained 
at 12-months’ follow-up. There was no difference 
in abuse outcomes between the intervention and 
control groups at any postintervention assessment.  
A parallel group study by Rinfret-Raynor and 
Cantin in Canada evaluated feminist-informed 
therapy for survivors referred to social services, 
either in individual or group sessions.157  The 
intervention was compared with the normal non- 
structured therapy provided to clients by the 
agencies. The therapies were administered in a 
number of settings, including community health 
centres. When followed up after 12 months, women 
in all three arms of the study showed similar 
improvement over time in terms of abuse, self- 
esteem and assertiveness. 
Another group intervention was reported by 
Kim and Kim158 in a parallel-group evaluation in 
Korea, conducted with women survivors of partner 
violence residing long-term in a refuge. The 
intervention group women were given eight weekly 
sessions of counselling based on an empowerment 
crisis-intervention model that was problem focused 
and goal directed. Follow-up was restricted to an 
immediate postintervention assessment. Women 
who received counselling had significantly reduced 
levels of trait anxiety compared with women in the 
control group. There were no differences between 
groups for state anxiety and depression scores, 
which decreased in both. Self-esteem did not 
change between or within groups.  
A before-and-after evaluation conducted by 
Howard and colleagues159 considered counselling 
delivered by 54 partner violence providers in 
Illinois, USA. These providers varied in terms 
of theoretical framework and delivery. Generic 
counselling significantly improved the well-being 
and coping of physically abused women who 
approached support services for help, and was of 
particular benefit to women who had been both 
physically and sexually assaulted as compared with 
women who had suffered physical assault on its 
own.  
In summary, there was a wide range of individual 
psychological interventions, which demonstrated 
improvements in psychological outcomes including 
depression, PTSD and self-esteem. Two fairly well- 
executed trials125–129,145,146  of individual cognitive 
therapy-based interventions for women with PTSD 
who were no longer experiencing violence provide 
reasonable evidence for this intervention, but this 
cannot be extrapolated to the women who were still 
in an abusive relationship. Consideration of only 
the high-quality studies142,143,145,146  for individual 
interventions did not alter the findings.  
Although there are 10 studies of group 
psychological interventions, all showing 
improvement in one or more psychological or 
mental health outcome, all but one are poorly 
executed. Consequently, the effectiveness of this 
type of intervention remains uncertain, particularly 
for women who are still experiencing partner 
violence. 
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Interventions with children 
of abused women 
Five studies (seven papers) evaluated the use of 
interventions with children where there was also a 
degree of involvement of the mothers. These are all 
newly reviewed studies; such interventions were not 
included in our previous review. Four of the studies 
were conducted in the USA and one was conducted 
in Canada.  
An individually randomised controlled trial, 
conducted by Lieberman and colleagues,160,161 
examined the effectiveness of child–parent 
psychotherapy compared with case management 
plus referrals for individual treatment in the 
community for abused mothers and their children. 
The geographical region was not reported. Child– 
mother dyads were recruited if the child was aged 
between 3 and 5 years, mothers had experienced 
marital violence and the perpetrator was not living 
at home. These dyads were referred from family 
courts, partner violence service providers, medical 
providers, preschools, self-referrals, other agencies, 
child protective services and former clients. Dyads 
were referred because of clinical concerns about  
the child’s behaviour or the mother’s parenting 
after the child had witnessed or overheard marital 
violence. The intervention (setting not specified) 
consisted of weekly joint child–parent sessions 
interspersed with individual sessions for the 
mothers, offered for 50 weeks (average attendance: 
32 sessions). Children in the intervention group 
had significant reductions in symptoms of PTSD 
after the intervention. There was also a significant 
reduction in the children’s behaviour problems, 
which remained significant at the 6-month follow- 
up. Mothers in the intervention group reduced 
their number of avoidant PTSD symptoms and 
their number of current distress symptoms 
postintervention. The reductions in mothers’ 
number of current distress symptoms remained 
significant at the 6-month follow-up. 
 
Jouriles and colleagues162 conducted an 
individually randomised controlled trial to 
assess the effectiveness of an intervention in 
reducing conduct problems among the children of 
survivors of partner violence and improving the 
mothers’ child management skills. The women 
were recruited from urban refuges. Recruited 
children were aged between 4 and 9 years, met  
the DSM-IV (Diagnostic and Statistical Manual 
of Mental Disorders IV) criteria for oppositional 
defiant disorder or conduct disorder, and lived 
with their mother but not the perpetrator. The 
intervention had two components: (1) providing 
mothers and children with problem-solving skills; 
and (2) teaching mothers to use certain child 
management skills designed to help reduce their 
children’s conduct problems. The intervention 
consisted of weekly sessions of 1–1.5 hours,  
began after the subjects had left the refuge, and 
continued for up to 8 months, with the families 
attending 23 sessions on average. Mothers in the 
control group were contacted monthly, either in 
person or by telephone, and were encouraged to 
use existing community or refuge services. Both 
mothers and children benefited from participating 
in the intervention. At the 16-month follow-up, 
the intervention group’s mean level of child 
externalising problems did not differ from the 
mean of the normative population, whereas the 
mean level of externalising problems in the control 
group did. Children’s internalizing problems 
diminished over time, with similar rates of change 
in both groups. Mothers in the intervention 
group displayed a significantly higher mean  
level of child management skills at the 8-month 
follow-up. Psychological distress of the women 
diminished over time but there was no difference 
between the two groups. At 2 years after cessation 
of treatment163 there was no significant difference 
between the intervention and control groups 
with regard to recurrence of violence against 
the mothers. At baseline all the children met 
DSM-IV criteria for either oppositional defiant 
disorder or conduct disorder. By follow-up, 15% 
of the children in the intervention group and 
53% in the control group were reported to have 
externalising problems at clinical levels. There 
was a similar differential reduction in conduct 
problems. Children in the intervention group 
significantly improved in terms of happiness/social 
relationships. Externalising and internalising 
behaviour scores for children in the intervention 
and control groups did not differ significantly from 
one another at the 24-month follow-up.  
McFarlane and colleagues evaluated the effects on 
children’s behaviour of a nurse case management 
intervention for mothers.164,165  For details of the 
intervention, see Advocacy interventions with 
abused women above. The level of children’s 
behavioural problems was assessed over a 
24-month period, but there was no statistically 
significant beneficial effect of the intervention. The 
extent of behavioural problems for both young and 
older children improved over time regardless of the 
trial arm allocation of their mothers. The scores 
of children aged 5 years or below improved most, 
whereas scores of the teenagers improved the least. 
Review Question  IV 
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Sullivan and colleagues considered the effect 
of a 16-week advocacy intervention for abused 
women and their children.124  For details of the 
intervention, see Advocacy interventions with 
abused women above. Children’s scores for self- 
worth, physical appearance and athletic ability all 
increased, and the effect of the intervention on 
these variables was found to be significant over and 
above the effects of time. Children’s witnessing of 
abuse decreased in both groups, and again this 
effect was found to be significant over and above 
the effects of time. Assailant’s abuse of the child 
decreased in both the intervention and control 
group, but the within- and between-groups change 
decreases were not significant.  
A before-and-after study by Ducharme and 
colleagues evaluated an intervention seeking to 
improve parent–child cooperation in women who 
were not living with the abuser.166 The geographical 
region was not reported. Two groups received 
immediate intervention and two received delayed 
treatment. The intervention used ‘errorless 
compliance training’, a success-based, non-  
coercive intervention involving the hierarchical 
introduction of more demanding parental requests 
at a gradual pace, and lasted between 14 and 29 
weeks. Mother–child dyads were self-referred 
or referred from child welfare agencies, school 
boards, women’s refuges and other social service 
agencies. Children were aged between 3 and 10 
years and had severe behaviour problems. All 
of the children came from families where the 
mothers had experienced partner violence. Data 
for all four groups were pooled and showed that  
all children demonstrated increased compliance 
following the intervention. There was significant 
improvement in perception by mothers of their 
children’s externalising, internalising and total 
behaviour problems. Mothers rated their children 
as being significantly more cooperative after the 
intervention, and reductions in maternal stress and 
improvements on the parenting stress index were 
seen both on child and parent characteristics.  
Four of the five studies examining the effectiveness 
of interventions with children of abused women 
were randomised controlled trials and well 
executed. These studies suggest that this type of 
intervention is promising and helps to reduce 
children’s behaviour problems and mother’s stress 
and PTSD symptoms. Such interventions may also 
increase a mother’s child management skills. The 
majority of these interventions were conducted with 
women who had left the abusive relationship, so 
these findings may not be generalisable to women 
who remain with an abusive partner. 
  
Sensitivity analysis 
 
As we did not meta-analyse the studies, we could 
not formally test the effect of study quality on 
pooled effect sizes with a subgroup analysis 
or metaregression. We examined variation for 
comparable outcomes (see Appendix 7.5) and 
made a qualitative judgment on whether study 
quality was related to effect size. Before-and 
after studies were not included in this sensitivity 
analysis due to the inherent risk of bias in this 
study design. Where studies did not report effect 
sizes, values for Cohen’s d between group effect 
sizes were calculated using means and standard 
deviations when such data were present. There 
were a sufficient number of studies measuring 
PTSD, depression, self-esteem and physical 
abuse to explore study quality on these outcomes. 
Five studies (four RCTs) measured PTSD as an 
outcome.142–146,160,161   The better-quality studies 
had smaller effect sizes.162–166 Five studies (four 
RCTs) measured the effects of the intervention  
on depression,126,142–146,150,157   with the better- 
quality studies showing smaller effect sizes. Four 
studies  (two  RCTs)138,140,143–146,152,153,157   measured 
the effects of the intervention on self-esteem. 
There was no clear relationship between effect size 
and study design and execution. Three studies 
(all RCTs)121,123,126,140  measured the effects of 
interventions on physical abuse. There was little 
variation in the effect sizes, which were all low. 
This sensitivity analysis highlights the importance 
of a high standard of design and execution of 
intervention studies. 
  
Strengths of this review 
 
We did not exclude studies on the basis of 
language, translating those that were not reported 
in English. We appraised the quality of all primary 
studies: the Jadad score was applied to randomised 
controlled trials, and all studies were appraised 
using the USPSTF quality criteria, which give a 
measure of internal and external validity, and also 
the strength of evidence of the studies as a whole, 
which can be used to assess the level of evidence for 
the particular type of intervention being assessed. 
Effect sizes were calculated where means and 
standard deviations were reported or obtainable 
from the authors. Our review meets all the relevant 
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QUORUM reporting criteria (see Appendix 11.5 
for QUORUM checklist and flowchart). 
  
Limitations of this review 
 
We did not pool outcomes for any of the 
interventions for several reasons: heterogeneity 
of outcome measures, variable follow-up between 
studies and, in the case of psychological treatments, 
the content of the interventions. Incomplete 
reporting of effect sizes would also have made 
meta-analysis difficult. It was not possible to test 
for publication bias with a funnel plot because 
the small number of studies reporting effect sizes 
would make the results misleading.167 The largely 
positive findings of most of the studies suggest that 
publication bias may be operating in this field. 
 
Limitations of our review originating in the 
primary studies include the absence of effect sizes 
or the data needed to calculate them, a lack of 
detailed reporting of the content of interventions, 
and poor study design or execution. These 
limitations weaken the strength of evidence for the 
various  interventions. 
  
Discussion 
 
The level of evidence for effectiveness of advocacy 
interventions was assessed using the USPSTF 
criteria. We have already mentioned the incomplete 
reporting of effect sizes as a major limitation in the 
application of these criteria. Furthermore, whether 
or not overall effect sizes are ‘sufficient’ or not is a 
matter of judgment, as effect sizes may be sufficient 
for one outcome, but not for others. When analysed 
with the USPSTF criteria, the level of evidence 
for the effectiveness of advocacy interventions was 
borderline between insufficient and sufficient. We 
decided not to average the effect sizes for all the 
outcomes, but consider them individually, as it is 
arguable that one positive important outcome may 
be sufficient evidence to endorse an intervention. 
This is, however, a very conservative measure of 
the level of evidence as it is only based on four 
studies121–123,126  – the other studies included in our 
review either did not meet the quality criteria for 
inclusion in this analysis or did not provide the 
data required to calculate effect sizes.  
The level of evidence for individual psychological 
interventions is sufficient, based on five studies,142–
146  two of which were conducted by the 
same authors. Another reason for caution when 
interpreting this finding is that the interventions 
are quite different from each other, ranging  
from forgiveness therapy to expressive writing to 
cognitive trauma therapy designed for women 
with PTSD. The level of evidence for effectiveness 
of group psychological interventions is currently 
insufficient owing to a lack of studies meeting the 
quality criteria and having the necessary data from 
which to calculate effect sizes.  
The level of evidence for effectiveness of support 
groups is currently insufficient owing to a lack of 
studies meeting the quality criteria and having 
the necessary data from which to calculate effect 
sizes. Although the evidence for psychological 
interventions and work with women and their 
children has grown more robust with recent trials, 
most did not recruit women identified in health- 
care settings. In those that did, it is not clear that 
the women were identified through screening. We 
have kept these studies in our review because our 
inclusion criteria covered interventions to which 
survivors of partner violence could have access 
through health services.  
The strength of evidence for effectiveness of 
interventions with children of abused women 
is currently insufficient. Only three studies met 
the quality criteria and had the data required to 
calculate effect sizes;160–165 however, the effect sizes 
were not sufficient or consistent between these 
studies. 
 
If one takes into account additional good-quality 
studies that could not be analysed with the USPSTF 
criteria124,125  there is enough evidence to justify 
access to advocacy services for survivors of partner 
violence in general, but the evidence is weakest for 
women who are identified through screening. Most 
of the studies measuring the effect of advocacy 
recruited women who have already disclosed 
abuse and have actively sought help. Many of the 
participants in these studies were recruited in 
refuges. We cannot confidently extrapolate the 
findings of these studies to women identified in 
health-care settings, whether by screening or case 
finding. Those advocacy studies that did identify 
and recruit women in health-care settings were 
based in antenatal clinics, therefore the evidence 
for the effectiveness of advocacy for women 
identified in health-care settings is strongest for 
antenatal services.  
A big caveat in this judgment on advocacy services 
is the range of outcomes that were measured and 
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the potential gap between women’s perception of 
benefit and these measures. Although part of this 
review question included a question about what 
outcomes women would want from advocacy and 
other interventions, we did not find any qualitative 
studies that addressed this.  
Most studies did not specifically assess potential 
harm from the interventions, although worse 
outcomes in intervention groups compared with 
controls would have been an important indication 
of harm. The only examples of this from our review 
are two studies, one evaluating the effectiveness 
of advocacy,121 the other looking at individual 
psychological therapy,142 which found that women 
in the intervention arms experienced more bodily 
pain. The types of harm that would not have been 
detected unless the investigators specifically tried 
to measure them are more akin to adverse events 
in pharmacological trials. In the qualitative studies 
reviewed in Chapter 5, women cited breaches of 
confidentiality, stigmatisation and judgments by 
health-care providers as actual or potential harms 
of screening. 
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Chapter 8 
Can mortality or morbidity be reduced 
following screening? (Question V) 
  
e identified eight studies of interventions 
to implement screening with a total patient 
sample of 16,272 (one study did not report the 
number of participants). Publication dates ranged 
from 1998 to 2006, and the majority of studies 
were based in the USA. One study was conducted 
in Australia. Settings varied and included family 
practice sites and community clinics, health 
maintenance organisations (HMOs), women’s 
health clinics, and accident and emergency 
departments. One study trained nurses who visited 
vulnerable women in their homes. Experimental 
designs included seven before-and-after studies 
with varying follow-up periods (6 months to 2 
years), and one randomised controlled trial. For 
further details of the design of included studies  
see Appendix 8.1. Results of included studies and 
quality scores are detailed in Appendix 8.2.  
Morbidity and mortality are central to this NSC 
criterion, but we found no studies that measured 
these outcomes. Therefore we have included 
studies with proxy outcomes: identification of 
women experiencing partner violence after a 
system-based intervention to implement screening 
plus one other activity (such as referral to partner 
violence advocacy, or full documentation of the 
abuse). Studies that only reported one proxy 
outcome were excluded, unless this was referral to 
expert partner violence services. The justification 
for including identification plus another activity  
as relevant outcomes is that there is evidence that 
these additional activities may be associated with 
improved morbidity or mortality. As we discussed 
in Chapter 7, advocacy improves outcomes for 
survivors of partner violence and this may also be 
the case for psychological interventions.  
The other specific outcome in our review protocol 
was harm associated with screening, but no studies 
reporting evidence of harms were found during 
this review.  
The sections below are organised by health-care 
setting. 
Health-care setting 
Primary care, community 
clinics and health maintenance 
organisations 
Harwell and colleagues168 used a before-and-after 
design with a 3-month follow-up at community 
health centres in the USA. The effects of the 
RADAR (Routine screening; Ask direct questions; 
Document your findings; Assess patient safety; 
Review patient options and referrals) training 
project was assessed via medical chart reviews, 
extracting data that allowed calculation of relative 
risk for screening being performed, suspicion  
and identification of partner violence, safety 
assessment, documentation of abuse, and referral 
to internal and external partner violence services. 
Training of all community health centre staff in the 
intervention group was 3–6 hours. Using trauma 
theory as a framework, it included a video on the 
emotional impact of partner violence, introduction 
to the use of and modelling of RADAR, and a 
survivor’s story. Follow-up support tailored to the 
needs of the centre staff continued for 2 years 
after training. Baseline measurements taken at 
pretraining for both phases were used as control 
data. During the intervention period women were 
more likely to have partner violence suspected 
(2% versus 6%, relative risk 1.49, 95% confidence 
interval 1.13–1.99), to have a safety assessment 
performed (5% versus 17%, relative risk 1.65, 95% 
confidence interval 1.39–1.97) and to be referred 
to an outside agency (0% versus 4%, relative risk 
1.81, 95% confidence interval 1.45–2.28) compared 
with women in the baseline period. The authors 
state no differences were found for confirmation 
of partner violence; however, reported confidence 
intervals suggest a significant effect (2% versus 5%, 
relative risk 1.49, 95% confidence interval 1.08– 
1.97). This study showed improved proxy outcomes 
after implementation of RADAR.  
Thompson and colleagues169 studied the impact 
of a system-based intervention to implement 
screening and effective responses to disclosure 
of partner violence in an HMO, recruiting five 
Review Question V 
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primary care clinics in a cluster randomised trial 
design. Utilising the Precede/Proceed model, the 
intervention focused on changing practitioner 
predisposing factors (such as knowledge and 
attitudes), enabling factors (environmental 
and infrastructure processes supporting the 
intervention) and reinforcing factors (i.e. the use 
of feedback). Staff attended two separate half- 
day training sessions, targeting skills building 
and empowering practice teams to ask about 
partner violence. Additionally, four educational 
sessions on skills improvement, community 
resources and early results were attended, with 
opinion leaders attending three extra training 
sessions. In intervention sites, posters about 
partner violence were displayed, cue cards given 
to clinicians, and screening questionnaires and 
newsletters periodically sent to participating 
health-care professionals. Identification of women 
experiencing partner violence at the intervention 
sites had increased at 9 months’ follow-up, 
although this was not significant (2% at baseline  
to 4% at follow-up, odds ratio 1.5, 95% confidence 
interval 0.73–3.17). At the intervention sites, the 
morbidity outcomes depression and physical injury 
did not improve and pelvic pain actually showed a 
significant increase (from 4% to 8%, odds ratio 3.8, 
95% confidence interval 1.1–12.5). 
 
McCaw and colleagues101 conducted a before-and- 
after study with historical controls within various 
departments of an HMO. Although the paper 
reporting the study was entitled ‘Beyond screening 
for domestic violence’, increased screening by 
clinicians was an aim of the intervention. The 
intervention was designed to take advantage 
of existing infrastructures and to avoid taking 
clinicians away from their clinical practice. 
Several brief training and information sessions 
were delivered to clinical staff and receptionists. 
Additionally, using a systems model approach, 
the HMO actively sought to improve its links 
with community services, inform patients about 
partner violence and appropriate services, provide 
clinicians with information and prompts, and 
employ an on-site domestic violence specialist. 
Nine months after training started, referrals had 
increased from 51 to 134. Unfortunately there was 
insufficient information to determine referral rates 
and no statistical analysis.  
Coyer and colleagues170 conducted a before-and- 
after study in a rural, nurse-managed US health- 
care centre, testing whether the addition of a 
screening protocol into the clinic would increase 
the identification of violence against women. The 
system-centred intervention was relatively informal 
and involved discussions with nursing staff, which 
identified a need for improving their knowledge  
of local community resources. Due to staff interest, 
two local agencies that support women in violent 
situations visited the members of the clinic in order 
to provide background information, local statistics, 
information about the resources available and the 
processes of referrals, and a strategy on how to 
manage patients who gave a ‘yes’ response to the 
question ‘Is anyone hurting you?’. An audit of the 
medical notes 12 months prior to the intervention 
revealed no notation of abuse or use of partner 
violence services in any of the records. During 
the 12 months after the intervention, chart audit 
showed six women had notation of abuse in their 
medical records, and of these, four were referred 
to domestic violence refuges or the local drug 
treatment facility, and one was provided with the 
abuse hotline telephone number. 
 
Women’s health services 
In a parallel group study in an antenatal setting, 
Wiist and McFarlane171 provided clinic staff with  
a single session of 90 minutes of didactic training 
about screening for partner abuse and associated 
procedures, including making referrals to an on- 
site bilingual counsellor. This was supplemented 
with a protocol and with weekly visits by the trainer 
to provide support and for training any new staff. 
Referrals at follow-up showed an increase from 0% 
to 67% of women disclosing abuse at 3 months, and 
53% at 12 months. 
 
Ulbrich and Stockdale172  used a before-and-after 
design with historical controls to evaluate the 
implementation, in rural family-planning clinics, 
of ‘routine screening’ for partner violence. All staff 
were given didactic core training, pocket cue cards 
and a protocol to follow; key staff also received 
intensive follow-on training over 2 years. As part 
of the intervention, community-based domestic 
violence agencies provided advocates. At three of 
the clinics, the advocates worked mostly off-site 
but attended the clinics in emergency situations;  
at the fourth clinic, an on-site service was available 
for 1 day per week. Due to the low numbers in the 
study, only descriptive statistics were reported. For 
nurse-practitioners and registered nurses, a trend 
for discussing partner violence with patients on a 
weekly basis increased from 19% at pretraining to 
57% at the 6-month follow-up (difference 38.3%, 
95% confidence interval 37.0–39.6). Self-reported 
referrals over the past 3 months increased from 0% 
for four or more referrals to 21% at the 6-month 
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follow-up (difference 21.4%, 95% confidence 
interval 20.0–22.8). 
 
Accident and emergency 
department 
In a before-and-after study with historical 
controls, Ramsden and Bonner173  evaluated the 
implementation of screening by nursing staff of 
all women aged over 15 years. The staff training 
focused on partner violence, screening protocols 
and a referral pathway. Information about 
resources, including local services and contact 
numbers, was also provided. Regardless of the 
patient’s response, all screened women were 
supposed to receive an information resource card. 
The duration and frequency of training was not 
stated. No data were presented on adherence to 
the protocol or on identification rates. It was found 
that the number of referrals to a social worker or to 
the police nearly doubled (8 compared with 14) as 
compared with preintervention numbers. However, 
the authors did not report enough information 
for referral rates to be calculated; neither did they 
report the findings of any statistical analyses. 
 
Home visit 
The before-and-after study with historical controls 
conducted by Shepard and colleagues174 differed 
from the others in that the health professionals who 
were instrumental in the intervention were nurses 
who routinely visited women in their own homes 
as part of a maternal and child health programme. 
For this project, the nurses received training in 
partner violence, and a partner violence response 
protocol was developed to increase referrals and 
information-giving. The protocol included a 
general question about the women’s history of 
abuse. Two years after the protocol was introduced, 
the authors reported that referral rates increased 
from 3% at preintervention to 17%. This positive 
trend was not statistically significant; however, the 
data on referral before and after the intervention 
were not fully comparable. Increases were found 
in both information-giving by nurses following the 
intervention (0.03% to 78%) and identification of 
partner violence (6% to 9%), although only the 
former was significant. 
  
Sensitivity analyses 
 
When considering outcomes by settings, system- 
level screening interventions in primary care and 
women’s health clinics are more effective than 
those within accident and emergency departments 
and home visits. Some of the studies did not 
adequately report data on referral outcomes, or 
combined several different outcomes under one 
category; thus it is hard to judge changes in these 
outcomes. 
 
In terms of study quality, only one study169 had the 
‘greatest’ strength of design and a ‘fair’ execution 
rating. The other seven studies rated ‘poor’ for 
execution and ‘moderate’ for strength of study 
design, most using a before-and-after method. 
Details of the assessment of execution of individual 
studies are in Appendix 8.3. Due to all but one 
of the studies having a poor execution rating,  
there is insufficient evidence for system-centred 
interventions increasing identification, referral and 
other activities aimed at reducing morbidity and 
mortality. The lack of variation in study quality 
precludes a detailed sensitivity analysis by quality. 
Yet it is striking that the highest quality study,169 
and the only randomised controlled trial, did not 
find a significant increase in identification. 
  
Strengths and limitations 
 
By extending to proxy outcomes it was possible 
to explore the potential benefit of system-based 
screening interventions. For those studies where 
no statistical analysis was given, we calculated 
95% confidence intervals for differences in the 
proportions if absolute numbers were reported, 
thus allowing some assessment of the precision 
of the comparisons reported by the authors. The 
USPSTF quality appraisal criteria were used to 
rate the primary studies. This not only gives us 
a measure of internal and external validity, but 
also the strength of evidence of the studies as a 
whole. This review fulfils the relevant QUORUM 
reporting criteria (see Appendix 11.6 for 
QUORUM checklist and flowchart).  
Limitations are twofold, those arising from 
our review and those related to the primary 
studies. Excluded studies included those that 
only measured identification; it may well be that 
an intervention could have excellent efficacy 
in increasing detection rates, or improving 
the rapport and communication skills of staff, 
which improves patient disclosure. However, 
identification is a necessary but not sufficient 
condition of improved outcomes for women, and 
the additional activity inclusion criterion brings 
it further along a causal pathway towards patient 
benefit. Limitations of some of the primary studies 
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include incomplete reporting of outcome data (as 
a result we could not construct a funnel plot to  
test for publication bias), no statistical analysis and 
poor reporting of the intervention. No reporting 
of adherence to screening protocols limits the 
interpretation of identification rates. These study 
limitations weaken overall findings and ultimately 
reduce the strength of evidence of these primary 
studies. The main limitations arising from the 
primary studies are failure to measure or lack of 
power to detect actual morbidity (in the case of  
the study by Thompson and colleagues169) and the 
generally weak study designs. 
Discussion 
Despite the finding that interventions in primary 
care settings produced overall a trend for 
increased identification and other activities aimed 
at reducing morbidity and mortality, there is 
insufficient evidence of effectiveness. The most 
methodologically robust study showed least effect 
on identification rates. 
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Chapter 9 
Is  screening  for partner violence acceptable  to 
health‐care professionals?  (Question VI) 
  
Qualitative  studies 
We identified 10 journal articles and one UK  
Home Office report reporting the attitudes of 
health-care professionals towards screening for 
partner violence. For details of study design and 
quality scores see Appendix 9.1. Four studies were 
conducted in the USA, three in the UK, two in 
Sweden, one in Australia and one in New Zealand. 
There are six studies exploring midwives’ attitudes, 
one about nurses, two about physicians, one about 
nurses and mental health service providers, and 
one about a range of professionals. The total 
number of recruited health-care professionals was 
446, ranging between 8 and 124 per study. The 
methodological quality score assessed by CASP was 
between 19 and 37, with most of the studies scoring 
more than 31. 
 
First-order constructs 
We identified 12 first-order constructs concerning 
health-care professionals’ views about partner 
violence screening. There were variations between 
studies regarding the first-order constructs but 
there were no systematic differences in relation to 
country or health-care setting. 
 
1. Screening  for  partner  violence  is  acceptable  to 
some health-care professionals 
Edin and Högberg found that the idea of asking 
all pregnant women questions about abuse, as 
is done with respect to smoking and alcohol, 
was acceptable to almost all the midwives they 
interviewed.175 Stenson and colleagues also 
found that health-care professionals generally 
consider routine questioning about partner 
violence acceptable. A typical statement from their 
informants: ‘Regarding certain questions, routine is 
very important; to raise them at this point in time 
because then you know it will get done’.176 
 
2. Health-care  professionals  felt  that  they  have  a 
responsibility to screen for partner violence 
It was felt that all health professionals need to be 
aware of the issues involved and share responsibility 
for detecting partner violence and supporting the 
women concerned.177,178 Screening was seen as an 
expression of wanting to make a difference to the 
social issue of partner violence.179 
 
3. Asking about abuse helps remove stigma attached 
to partner violence and indicates openness to the issue 
Edin and Högberg reported that one justification 
for screening expressed by their midwife 
informants was that asking every pregnant woman 
in their antenatal clinics questions about abuse 
‘would play down the issue; no one would need to 
feel singled out when confronted with a sensitive 
question’.175 
 
4. Screening for partner violence is an indicator of 
good care 
Some accident and emergency staff thought that 
asking all women about abuse was an indication of 
good care.180 
 
5. Screening for  partner violence  is  conditioned by 
the way professionals ask and timing is important for 
screening 
Timing of screening was considered important  
by informants. Screening during routine medical 
intake, such as during the triage process, was 
considered inappropriate.120 Concerns were 
raised about patients with a range of conditions: 
drug and alcohol intoxication, acute psychosis, 
active labour, stroke, heart attack or other acute 
conditions. These groups might be unable to 
respond appropriately to screening or their 
priority is immediate medical management.181 
The informants of Edin and Högberg suggested 
the issue could be brought up during the first 
antenatal visit of the women or at a later visit.175 
In the study by Stenson and colleagues, midwives 
did not perceive questions about violence as being 
more delicate than many other questions that are 
ordinarily asked in antenatal care.176  Others said 
that ‘they did not feel it to be a problem to ask, 
although they reported different situations when 
they found questioning about abuse inappropriate’. 
Although different opinions were expressed 
regarding screening, some midwives suggested 
the use of routine questions; other informants 
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preferred including asking as part of an ordinary 
conversation, because of the threat questions might 
pose to the integrity of the woman.175 
 
6. Somebody else should screen 
In general, informants felt there should 
be a dedicated health-care professional or 
paraprofessional assigned to do the screening120 
or they believed the screening could be handled 
more appropriately by somebody else in a different 
department (‘Nurses asked why physicians do 
not screen, nurses suggested that the question be 
asked once a patient is transferred to the Women & 
Infants unit, and the emergency department staff 
questioned the practice of screening patients who 
are in a medical crisis.’).175 
 
7. Training    for    partner    violence    screening    is 
important 
Some informants did not feel competent to  
screen patients because they were not comfortable 
with their current knowledge about partner 
violence.120,177,181 
 
8. Screening for partner violence needs good resources 
Time constraints and poor infrastructure of the 
working environment were identified as major 
obstacles by most informants. A female physician 
stated: ‘It’s irresponsible for us to initiate screening 
if we don’t have the staff and resources. Can we 
appropriately direct them and meet their needs?’120 
Staff requested greater feedback on whether 
screening provided any real benefit to patients 
(i.e. ‘Is there positive feedback on anyone we have 
helped or from referral sources?’).181  When health- 
care professionals were not trained in responding  
to disclosure they were concerned about 
encouraging women to talk about abuse. Clinical 
staff in an accident and emergency department 
mentioned that the department did not provide 
patient follow-up and they did not want to initiate a 
process that they were neither able to complete nor 
felt certain would be completed elsewhere in the 
hospital.180  
9. Insufficient evidence for screening effectiveness 
Some informants noted that ‘there is no data on 
how effective asking is’,181 and this appeared to be a 
major reason for those informants who did not find 
screening by health-care professionals acceptable. 
 
10. Potential risk to relationship with women as a 
result of screening for partner violence and methods 
for protecting the relationship 
Fear of offending caregivers (when women 
attended with their children) and patients was 
64 also a recurrent theme from nurse and physician 
informants.120,176 In a study by Hindin the 
importance of the relationship with women was 
reported by all midwives as one of the foundations 
of their professional practice.182 The informants 
said that they did feel able to discuss a range of 
sensitive subjects with women because they gave 
time to listen to the women. 
 
11. Health-care professionals were concerned about 
women’s safety and their own safety when they screen 
for partner violence 
Midwives emphasised the importance of seeing  
the woman without her partner when screening for 
partner violence or if there was a known history of 
partner  violence.176,177,183 
 
12. Screening for partner violence might be considered 
judgmental 
Some midwives expressed frustration about the 
perceived passivity of many women in the face of 
partner violence and their apparent inability to 
seek help or leave the abusive relationship.177 Some 
informants also were sceptical about getting an 
‘honest’ response to screening questions.175 
 
Second-order constructs 
The second-order constructs representing authors’ 
interpretations are presented below.  
1. Uncertainty about the appropriateness  
and value of screening for some patient 
presentations and in some clinical settings. 
2. Range of opinion on which health-care 
professionals should screen for partner 
violence. 
3. Inadequate health-care professional expertise 
resulting in feelings of frustration. 
4. Concerns about time and increased workload 
associated with screening. 
5. Concerns about screening increasing 
vulnerability to abuse and violence to the 
woman and potentially to the health-care 
professional. 
6. Concerns about the effectiveness of screening 
in terms of improved outcomes for women. 
7. Potential to stigmatise women as a result of 
screening for partner violence. 
8. The importance of a good relationship between 
health-care professionals and women as a 
context for screening.  
The second-order constructs were generally 
supported by the first-order constructs in all 
studies. 
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Contradictions between studies 
Although most of the informants thought it was 
the responsibility of health-care professionals  
to screen for partner violence, some midwives 
remained anxious and sceptical about screening 
women for abuse.177 In the study by Minsky-Kelly 
et al.,181 informants expressed frustration over 
being required to screen all patients, feeling that 
‘no one across the country ... is doing this’. They 
further questioned, ‘How much responsibility do I 
own to save the world?’. Many participants found 
screening for partner violence to be a disconcerting 
experience, arousing feelings of discomfort and 
embarrassment.179 When they felt that screening 
was not having an impact, there was a sense of 
hopelessness in the face of what seemed like an 
insurmountable problem. 
 
Informants in some studies expressed the view 
that screening for partner violence indicates 
openness of the health-care professional towards 
the problem, but Loughlin and colleagues found 
that clinical staff in an accident and emergency 
department were concerned that a screening 
protocol might have a negative impact on the 
public’s perception of the department.180 
  
Quantitative studies 
 
Twenty papers reporting 20 studies fulfilled 
our inclusion criteria (see Appendix 9.2 for 
characteristics of included studies). Eleven studies 
were conducted in the USA, five in the UK, one 
in Pakistan, one in Kuwait, one in Northern 
Ireland and one in Belgium. Two studies were 
self-report postal questionnaires, one was an 
online self-report questionnaire, and the others 
were based on face-to-face interviews or self- 
completed questionnaires. There were seven 
studies of physician attitudes, four of midwives, 
one of nurses, one of medical students, one of 
midwife students, and six including different 
types of health-care professionals. Response rates 
were between 17% and 100%, and the number of 
recruited health-care professionals ranged between 
27 and 976, with a total of 4553 respondents. The 
quality score assessed by STROBE was between 
11 and 19, with most of the studies scoring more 
than 15. There was a wide range of acceptability 
of partner violence screening among health-care 
professionals, from 15% to 95%. Results and quality 
scores are detailed in Appendix 9.3.  
Bair-Merritt and colleagues184 assessed residents’ 
views of partner violence screening in a postal 
questionnaire survey sent to all civilian paediatric 
residency programmes in the USA, with a 68% 
response rate. Ninety-three percent of chief 
residents felt that paediatricians should screen 
for partner violence. Seventy-one percent of 
respondents felt that their training was not 
sufficient to make them comfortable performing 
this screening. 
 
Bair-Merritt and colleagues185 surveyed 151 
clinicians in a US urban paediatric emergency 
department. Sixty-five percent agreed that they 
should screen for partner violence. Age, gender 
and role in the emergency department did not 
affect opinions about screening.  
Baig and colleagues186   surveyed 167 residents  
across six primary care (internal medicine, 
obstetrics and gynaecology, paediatrics, family 
medicine,  emergency  medicine  and  combined 
medicine/paediatrics) residency programmes in a 
US hospital. Ninety-five percent of respondents 
thought partner violence screening was ‘important’. 
Resident characteristics, such as gender, year in 
residency and personal history of abuse, were not 
independently associated with importance placed 
on screening or on stated intention to screen 
for partner violence. Residents who managed a 
survivor of partner violence were more likely to 
report that screening was very important than  
those who had never taken care of a partner 
violence victim. In multivariate logistic regressions, 
emergency medicine residents were less likely than 
other residents to consider that partner violence 
screening was important. Some paediatric residents 
did not screen because of privacy concerns and 
thus may miss partner violence among their 
adolescent patients. Residents reported lack of 
time, personal discomfort and forgetting to ask as 
personal barriers to partner violence screening. 
Although residents cited lack of or poor training in 
partner violence as a barrier, training in residency 
was not independently associated with priority 
placed on screening or on stated intention to 
screen. 
 
Baird187 surveyed 29 preregistration midwifery 
students about their views on routine enquiry about 
partner violence. Fifty-two percent of respondents 
felt it was the midwife’s role routinely to inquire 
about partner violence, 38% were unsure, whereas 
10% felt there was no role for the midwife. Sixty- 
eight percent thought that women may be offended 
if asked about partner violence by a midwife. 
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Barnett188 surveyed midwives in Scotland about 
their attitudes towards routine enquiry. One 
hundred and thirty-two midwives responded. 
Sixty-six percent of midwives thought that they 
should ask women about partner violence, 27% 
were unconvinced and 7% believed that it was 
inappropriate. The majority said that it should be  
a multidisciplinary task with general practitioners 
and health visitors (who would know the whole 
family) asking routinely about partner violence. 
Ninety-two percent felt strongly that robust referral 
systems should be in place before they asked 
women about partner violence and feared that if 
this was not the case then questioning could in fact 
make a woman’s situation worse.  
Ellis,189 in a survey of nurses in an emergency 
department in the USA, elicited 40 responses. 
Although 88% of the respondents had attended in- 
service training on partner violence, only 53% felt 
that nurses should screen all women for partner 
violence.  
Fikree and colleagues190 surveyed a stratified 
random sample of 100 obstetricians in Pakistan. 
Almost half of the respondents were favourably 
inclined towards routinely screening patients. 
Among the three categories of obstetricians 
interviewed, junior obstetricians (59%) were more 
likely to be favourably inclined towards routine 
screening compared with either senior (42%) or 
trainee (43%) obstetricians. Reasons articulated by 
those obstetricians who did not consider routine 
screening important included no solution to the 
problem (30%), enquiry was an invasion of privacy 
(19%), and insufficient time to inquire (9%).  
In a survey of 27 primary care attending physicians 
in two US hospitals, Friedman and colleagues110 
found that one-third believed that physical abuse 
and sexual abuse questions should be asked 
routinely. 
 
Goff and colleagues191 surveyed 541 physicians, 
general dentists and nurse practitioners in one 
town in Texas, with a 34% response rate. Twenty- 
nine percent of the health-care professionals 
believed that they did not see enough survivors  
of partner violence to do screening, 29% believed 
they should screen in the presence of non-specific 
complaints, 22% believed they should screen 
if patients present with a physical injury, 20% 
believed all women should be screened, and 2% 
believed a women should be asked once about 
abuse, during her first consultation. 
Lazenbatt and colleagues192 surveyed all midwives 
in Northern Ireland, eliciting a response rate of 
57%. Fifty-three percent of respondents thought 
that every pregnant woman should be screened for 
partner violence. When midwives were asked if they 
had ever raised the issue of partner violence with a 
client, only 28% had done so.  
Nayak193 surveyed medical students at a Kuwait 
university. Of the 106 respondents, 93% felt that 
training in issues related to interpersonal violence 
is necessary, but only 25% agreed that patients 
should be routinely assessed for a history of 
victimisation.  
Nicolaidis and colleagues194 surveyed 278 health- 
care professionals from 31 US family practices. 
Sixty-two percent had prior partner violence 
training. The majority agreed that it is the 
primary care provider’s responsibility to ask about 
partner violence when seeing patients for health 
maintenance visits (66%), chronic pain (56%) 
or injuries (62%). Fifteen percent agreed with 
screening for partner violence at every visit.  
Price and Baird195  sent a questionnaire to all 
midwives in an acute trust in the UK. Fourteen 
percent of the respondents did not believe it was 
the role of health-care professionals to screen at 
all, with 39% stating that routine screening should 
not occur within professional practice. When asked 
who should screen, a wide range of responses 
was given, from ‘any one who is in contact with 
women to specialists’. A large majority of hospital- 
based midwives felt that it was the responsibility  
of the primary health-care team, specifically 
naming relevant individuals or by responses such 
as ‘any health professional that has an ongoing 
relationship with the woman, i.e. a community 
midwife’.  
Richardson and colleagues196 surveyed general 
practitioners, practice nurses and health visitors 
in one London health authority. Among the 401 
respondents, 32% thought that health visitors 
should routinely ask about partner violence, 
15% thought this for practice nurses, and 14% 
for general practitioners. Practice nurses were 
significantly less likely than health visitors or 
general practitioners to think that routine enquiry 
about partner violence should take place (odds 
ratio 0.46, 95% confidence interval 0.27–0.77, 
p = 0.003). Other predictor variables were not 
significant in a multivariable regression model. 
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Roelens and colleagues197 surveyed 289 board- 
certified obstetrician-gynaecologists in Flanders, 
Belgium, with a 52% response rate. Seventy percent 
disagreed with universal screening of women 
patients and 81% disagreed with screening women 
once each trimester of pregnancy.  
Salmon and colleagues,198 in an evaluation of an 
educational programme on midwives’ knowledge, 
skills, attitudes and implementation of routine 
antenatal enquiry for partner violence, surveyed 70 
community midwives in one acute trust. At baseline 
89% agreed with a statement that screening for 
partner violence was important, rising to 98% after 
the programme.  
Shye and colleagues199 surveyed 203 primary care 
clinicians in a health maintenance organisation in 
north-western USA, finding that 75% would prefer 
routinely to ask patients at health maintenance 
visits, 8% would prefer to ask only women who are 
at high risk, 15% would let the clinician decide who 
to ask, and 2% percent would let the woman bring 
the subject up herself. 
  
Synthesis 
 
There was heterogeneity in the results of qualitative 
and survey studies about the acceptability to health- 
care professionals of partner violence screening. In 
the surveys, acceptability ranged between 15% and 
95% of respondents.  
Across the surveys, a higher proportion of 
physicians were in favour of screening compared 
with midwives, who raised different concerns and 
reported frustration regarding partner violence 
screening. Nevertheless, there was considerable 
heterogeneity within professions, including 
midwives. Acceptability of screening was generally 
lower outside the USA, although there was 
considerable variation among US health-care 
professionals in different surveys. There was no 
consistent association between type of health-  
care setting and acceptability, with the exception 
of paediatric emergency and ambulatory care, in 
which a large majority of clinicians were in favor of 
screening caregivers.  
Findings from the qualitative studies showed that 
some informants thought screening was important 
but should be carried out by another health-care 
professional, and these findings were reinforced  
by the surveys. For example, midwives identified 
general practitioners and health visitors as being 
well placed to screen for partner violence.188 
Other health-care professionals felt there should 
be a dedicated professional or paraprofessional 
assigned to do the screening,120 or they believed the 
screening could be handled more appropriately by 
somebody else in a different department.175  
Those studies that measured respondents’ personal 
characteristics, such as gender, age and personal 
history of abuse, and tested their association with 
acceptability of screening generally found that 
they were not independently associated.117,185,186 
However, Baig and colleagues186 found that 
physicians who had managed survivors of partner 
violence were more likely to state that partner 
violence screening was very important.  
In sensitivity analyses excluding the poorer quality 
studies, as assessed by STROBE for quantitative 
studies and the CASP criteria for qualitative 
studies, we did not find a relationship between 
study quality and the findings on the acceptability 
of screening. We also scrutinised the reported 
survey data to determine whether there was a 
relationship between survey response rates and 
the acceptability of screening, but found none 
even when studies were stratified by type of health 
professional (see Appendix 9.4). 
  
Strengths and limitations 
 
Strengths of this review include the synthesising of 
qualitative and quantitative studies to answer this 
question, the quality appraisal of studies (using 
the STROBE checklist for quantitative studies and 
the CASP tool for the qualitative studies) and the 
performance of a sensitivity analysis. This review 
fulfils the relevant QUORUM reporting criteria 
(see Appendix 11.7 for QUORUM checklist and 
flowchart). Health professional-related variables, 
demographic features and features relating to the 
screening process were examined to assess how they 
interact to increase or decrease the acceptability of 
screening by health-care professionals. A limitation 
is that the attitudes of male members of the public 
towards screening were not examined. Many of 
the response rates in the quantitative studies were 
generally less than 70% and often less than 50%. 
This is a limitation because it implies that the 
acceptability rates may well be inflated, as non- 
respondents are less likely to consider partner 
violence an important clinical issue and would be 
less likely to consider screening acceptable. 
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Discussion 
There is a wider variation in the acceptability of 
partner violence screening among health-care 
professionals than among women (see Chapter  
6), with many surveys showing that a majority of 
clinicians do not find it acceptable. Although we 
do not report the data here, those studies that 
also measured screening behaviour found an even 
smaller proportion of health-care professionals 
performing screening, even in the USA where this 
is policy in many health-care settings. There is 
scepticism about the benefit of screening and, again 
in contrast to the views of women, little mention of 
potential benefits beyond eliciting disclosure. From 
the qualitative studies we learn that, even when 
health-care professionals find screening acceptable, 
they are wary of implementation without training 
and possibly additional resources to deal with 
referrals after disclosure. The findings of surveys 
of clinicians internationally and in the UK and 
of the qualitative studies mean that the criterion 
of acceptability of partner violence screening in 
health-care settings is not fulfilled. 
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Chapter 10 
Is screening for partner violence cost‐effective? 
(Question VII) 
I women with a mental health or substance abuse 
n this chapter we investigate whether screening 
for partner violence in any health-care settings 
is cost-effective. First, we conducted a systematic 
review of the primary studies that reported the 
cost-effectiveness of partner violence screening. 
Second, a cost-effectiveness model was constructed 
based on a pilot trial of a system-based intervention 
to implement routine enquiry about partner 
violence in a primary care setting. 
  
Systematic review of cost-
consequence  and cost-
effectiveness studies 
The search for economic analyses of screening 
interventions in health-care settings for partner 
violence retrieved nine potentially eligible papers 
detailing eight studies published between 1986 and 
2005. All studies were sited in the USA. None of 
these studies fulfilled our inclusion criteria.  
Six studies did not evaluate two alternative 
interventions; they simply measured costs of assault 
and homicide within families,200 hospital charges 
associated with partner violence,201 and costs of 
correct and false detection of partner violence.202 
The other three papers described the costs 
associated with resource utilisation by survivors of 
partner violence compared with women who have 
never experienced it.203–205  
Clark and colleagues206 performed a cost– 
benefit analysis on the implementation of the 
Violence against Women Act (VAWA) of 1994, 
suggesting that the benefit of the VAWA outweighs 
implementation costs from a societal viewpoint 
in the USA. However, the results of this analysis 
cannot inform the question whether screening 
programmes in health-care settings are cost- 
effective.  
Two articles from Domino and colleagues reported 
the results from the Women, Co-occurring 
Disorders, and Violence Study (WCDVS), a 
multicentre, non-randomised trial comparing an 
integrated counselling and advocacy service with 
usual services as control.207,208 The study recruited 
 
diagnosis and a co-occurring history of physical or 
sexual abuse. Follow-up of the women took place 
at 6 and 12 months. Screening for and detection 
of partner violence was not part of the study 
protocol, however, and the analyses therefore do 
not address the research question for this review. 
In spite of this, the study can serve as an indication 
of the effectiveness and costs of a partner violence 
intervention. For the population of 2026 women 
in the study, the intervention of integrated 
counselling and advocacy was likely to be cost- 
effective when compared with usual care.  
The analysis was based on changes in four clinical 
outcome measures: the Addiction Severity Index 
drug and alcohol composite scores (ASI-D and 
ASI-A), the Global Severity Index (GSI) and the 
Post-traumatic Stress Disorder Symptom Scale 
(PSS). The analysis at the 6-month follow-up207 
evaluated the cost from a Medicaid perspective, 
which included service delivery costs, as well 
as a societal perspective, which also comprised 
additional costs to service such as housing schemes 
and crime-related costs.  
At the 12-month follow-up,208  costs were evaluated 
from a societal perspective, which included service 
delivery plus participants’ costs for time and 
transportation. Clinical outcomes were reported to 
be in favour of the intervention, and incremental 
cost-effectiveness ratios (ICERs) were presented 
per unit improvement on each of the four clinical 
outcome measures. Quality-adjusted life-years 
(QALYs) were not calculated. ICERs ranged from 
$123 to $12,227, and bootstrapped confidence 
intervals included 0, which was interpreted as 
uncertainty that incremental costs or savings 
are achieved. These results have to be viewed in 
the light of usual care containing a structured 
counselling intervention already, which partly 
explains similarities in treatment costs in both 
arms. Generalisations to other populations and 
countries would therefore strongly depend on 
existing usual care provisions, although it is likely 
that a similar intervention in an NHS context 
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would also be cost-effective if the clinical outcomes 
were comparable. What Domino and colleagues 
have not demonstrated, however, is that screening in 
a health-care setting can be cost-effective. 
  
Cost-effectiveness model of 
PreDoVe: a pilot trial of a 
primary care-based system- 
level intervention to improve 
identification and referral 
of women experiencing 
partner violence 
 
The pilot study investigated a general practice- 
based intervention in the UK and tested the 
feasibility of this intervention in four general 
practices (three acting as an intervention and  
one as a control). The multifaceted, system-based 
intervention aimed to change the behaviour of 
clinicians towards women experiencing partner 
violence, and was designed to increase routine 
enquiry about partner violence and thereby 
disclosure of current partner violence. Following 
disclosure, clinicians were prompted to refer 
women to an advocate based in a domestic violence 
specialist agency or to a psychologist with specific 
training related to partner violence. The system- 
based intervention included initial educational 
sessions for all clinicians within the practice, which 
emphasised a pragmatic approach to enquiry and 
referral and also gave an overview of the wider 
community response. The referral component 
of the intervention was supported by a direct 
referral pathway to a domestic violence advocate 
and a psychologist, both of whom were involved 
in the initial training. In addition, prompts in 
the electronic medical record were used to probe 
for partner violence during routine consultations 
based on a four-item screening tool termed HARK 
(an acronym based on the dimensions of abuse, 
i.e. Humiliation, Afraid, Rape and Kick) linked  
to a range of coded diagnoses such as depression, 
insomnia, sexually transmitted infections and 
fatigue.209 The HARK questions and a prompt 
to refer women to the advocate or psychologist 
were installed as a template onto the electronic 
medical record in the practices. Although the 
aim of the intervention was not a comprehensive 
screening programme for all women, it aimed to 
implement screening or routine enquiry for women 
presenting with other problems. We maintain that 
an economic analysis of this intervention is relevant 
to the question of whether screening for domestic 
violence could be cost-effective. 
 
Model 
A Markov model was developed to combine  
the intervention costs and benefits. It was fitted 
comparing the PreDoVe programme with usual 
care and used the differences between the two 
simulations to calculate the incremental net benefit. 
The model evaluated the impact of increased 
assessment and referral rates upon further violence 
and quality of life over a 10-year period. Partner 
violence affects several public services as women 
experiencing such violence come into contact with, 
for example, local authority housing departments 
and social services. Women experiencing violence 
who come into contact with the criminal justice 
system are now routinely recorded. Taking a  
societal perspective permitted a wide range of data 
from sources to be incorporated into the model. 
See Appendix 10.1 for summary of data sources for 
the model. 
  
The model defines six health states in which 
women can find themselves (Figure 3). Following 
assessment, women experiencing partner violence 
can (1) remain unidentified, or are (2) identified 
and subsequently referred and treated, or (3) 
identified but decline referral to advocacy or 
psychology services. Women who receive treatment 
following disclosure during assessment can (4) drop 
out without improvement, or (5) enter a state of 
medium-term improvement where they can stay or 
move to the no-abuse or identified/untreated state. 
Women can also (6) die of non-related causes or 
specifically from partner violence. The transition 
probabilities for movement between these states 
were taken from the literature or in discussion with 
partner  violence  researchers.  See  Appendix  10.2 
for details of transition probabilities. The average 
length of time a woman remains in contact with 
advocacy services is 6 months, and therefore the 
model cycle length was set to 6 months with a 
time horizon of 10 years. Following the approach 
suggested by the National Institute for Health and 
Clinical Excellence (NICE), we discounted both 
costs and outcomes at 3.5% per annum. The reason 
for this is that it is the approach most commonly 
taken in UK cost-effectiveness analyses, facilitating 
comparison of our results with other studies.  
Costs associated with advocacy and/or psychological 
interventions were collated for each woman in the 
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PreDoVe pilot trial, and averaged across all women 
in the arm. These directly recorded pilot data  
were used to populate the model with the number 
of women attending the practices, the number  
who were asked about partner violence by GPs or 
practice nurses, the number of women disclosing 
partner violence, the number of subsequent 
referrals to the advocate or psychologist, and the 
number of women who declined to take up the 
referral to these services.  
Simplifying assumptions about current abuse 
incidence included: 16 years as a woman’s 
minimum age for first experiencing partner 
violence; a lifetime prevalence of 40%; and that 
moving to a state of abuse occurs at a constant 
rate over a woman’s lifetime. Assessment rates at 
intervention and control practices were assumed 
to be 10.7% of abused women and 7.1% of non- 
abused women, based on actual rates of asking 
and extrapolation from the prevalence of partner 
violence found in east London general practices.  
Costs comprised health-care use in terms of 
assessment, mental health and treatment costs 
as well as other social costs. Social costs included 
criminal justice costs, civil justice costs and cost of 
divorce involving children, societal employment 
loss, temporary housing costs and costs of social 
services.  
Quality of life was based on survey data using the 
Short Form 12 (SF-12) measurement tool. SF-12 
data were converted into quality of life utilities 
between 0 (equivalent to death) and 1 (equivalent 
to optimal health) for those with less severe and 
more severe violence, based on the US study by 
Wittenberg and colleagues.272  See Appendix 10.3 
for a summary of treatment cost sources, and 
Appendix 10.4 for other costs and QALYs per 
woman per year for each state.  
The majority of women in the model are likely 
to be in ‘No abuse’ (State 1) although a flow of 
women will become ‘Abuse unidentified’ (State 
2). Following assessment, women experiencing 
partner violence can remain unidentified (State 2), 
or be referred to a psychologist and/or advocate 
(States 3 and 4), or disclose abuse to a health-care 
professional but not be seeking intervention (State 
5). If the psychologist and/or advocate intervention 
is successful, the women can be termed as 
‘Medium-term improvement’ (State 6) and, if this 
does not worsen, can return to the ‘No abuse’ 
category. 
 
Results 
Univariate sensitivity analysis was carried out, 
and model parameters were both increased and 
decreased by 25%, unless these figures were 
internally invalid (such as if probabilities were 
less than zero or greater than one). For transition 
probabilities for which the intervention was 
assumed to be preferable to the control, the 
sensitivity analysis was constrained to assume the 
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transition probabilities were at worst equal. In 
addition, the sensitivity analysis used an upper and 
lower confidence interval for the impact of abuse 
on health.  
Combining net benefits and net costs in the model 
resulted in an incremental cost-effectiveness 
ratio (ICER) of £2450 per QALY. This result 
would be considered cost-effective had a service 
use perspective been applied under the implicit 
willingness-to-pay threshold applied by NICE. 
Including costs from a societal perspective will 
result in lower costs per QALY. The estimated 
cost-effectiveness was most sensitive to women 
taking up an intervention and the success of these 
interventions ‘downstream’ from disclosure to a 
health-care professional (in PreDoVe this entailed 
partner violence advocacy and a psychological 
intervention), and to the likelihood that medium- 
term improvement will continue into living outside 
of an abusive relationship. Most ICERs did not 
increase above £5000 per QALY and only one 
was greater than the £30,000 notional threshold 
for cost-effectiveness in the UK. For details of the 
sensitivity analysis results, see Appendix 10.5.  
We have made a number of simplifying 
assumptions in our model that could be 
addressed with more research. We considered 
the possibility that women may relapse into an 
abusive relationship, but we did not capture the 
fact that women with past histories of partner 
violence have a greater likelihood of entering 
into another abusive relationship. We also did not 
differentiate between women in a relatively new 
abusive relationship and those in longer-standing 
relationships or long-term harassment after they 
have left an abusive relationship. The latter group 
may take longer to change their situation. Our 
model draws upon the available evidence for the 
effect of partner violence programmes but these 
studies are based upon different populations and 
   
 
  
this may affect the accuracy of our findings. For 
instance, the main intervention effects were based 
on data from the PreDoVe pilot trial, based in inner 
city general practices with multiethnic, relatively 
deprived populations in the UK. The population 
targeted in PreDoVe were patients in primary care, 
and the majority of referrals were women who 
had not previously disclosed abuse. By contrast, 
our estimate of effect of advocacy came from a 
US study126 focused on a refuge population who 
had already self-identified and sought help, not 
necessarily in the context of health care. There 
is considerable uncertainty regarding both the 
modelling of partner violence, and the costs and 
quality of life for the women involved.  
A limitation of the model for estimating the cost- 
effectiveness of screening is that the intervention 
was aimed at implementing routine enquiry 
of women presenting with a range of specific 
conditions, rather than a comprehensive screening 
programme within a health-care setting. 
  
Discussion 
 
In our review we were unable to identify any studies 
that tested the cost-effectiveness of screening 
women in health-care settings for partner violence. 
We did find a study that calculated the costs and 
service use for women with co-occurring mental 
health and substance abuse disorders who were 
survivors of partner violence and taking part in 
an intervention programme. Overall costs were 
the same for women within and without the 
programme and clinical outcomes were improved, 
which suggests that the intervention was cost- 
effective. Our cost-effectiveness model of a pilot 
trial of a primary care intervention that resulted 
in increased enquiry about partner violence by 
clinicians supports the hypothesis that this type of 
intervention could be cost-effective. 
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n the basis of our review findings, we believe 
that the NSC criteria are not fulfilled for a 
policy of screening women in health-care settings 
for partner violence. The main unmet criterion 
is evidence of improved morbidity and mortality 
from screening programmes (Question V). 
Notwithstanding the poor methodological quality 
of most studies of screening interventions, there 
is a trend for increased identification and referral 
to partner violence advocacy services. However, 
the strength of this evidence is insufficient as 
there is only one randomised controlled trial 
of a screening intervention showing a limited 
impact on the identification of partner violence. 
More importantly, there is no robust evidence 
that screening for partner violence has any direct 
benefits in terms of reducing levels of abuse or in 
improving the physical and psychological health 
of abused women. A further gap in the evidence 
base is that none of the screening studies has 
measured whether screening is associated with  
an increase in potential harm for abused women. 
Those that measured health outcomes for women, 
such as the cluster randomised controlled trial of 
Thompson and colleagues,169 would have been able 
to detect harm if the participants in the control 
group had better outcomes than those in the 
intervention group, but would not have been able 
to detect adverse events that were not outcome 
measures. We do know that two of the intervention 
studies (Question IV) found increases in bodily 
pain in treatment arms, although this may have 
been a temporary state, and arguably part of the 
therapeutic process.210  The question of potential 
harm from a screening programme was also 
raised by survivors of partner violence in interview 
and focus group studies reported in Chapter 6, 
although the breaches in confidentiality they were 
particularly concerned about are not specific to 
screening. The risk of breaches of confidence 
should be negligible if health-care professionals 
have adequate training in appropriate and safe 
responses to disclosure of partner violence.211 
Health-care professionals also were concerned 
about adverse effects of screening, although the 
worry about offending patients raised in some 
of the studies reviewed in Chapter 9 was not 
confirmed by the survivors participating in the 
interviews and focus group studies or the surveys. 
To what extent are the 
NSC criteria fulfilled? 
Question I: What is the prevalence of partner violence 
and its health consequences? 
NSC criterion 1, that the condition should be an 
important health problem, is met. Abuse of women 
by their partners or ex-partners is widespread 
internationally212 and there is no longer any debate 
about the large public health impact of partner 
violence, although prevalence rates and the 
magnitude of health sequelae vary depending on 
population and study design. However, even based 
on the lower estimates for prevalence, morbidity 
and mortality, it is clear that partner violence is a 
potentially appropriate condition for screening and 
intervention.  
Question II: Are screening tools valid and reliable? 
A variety of partner violence screening tools are 
available, ranging from single-question tools 
to 30-item research inventories. We limited our 
review to screening tools comprising 12 items or 
less, for ease of administration in busy health- 
care environments. NSC criterion 5 states that 
the screening test should be simple, safe, precise 
and validated, the distribution of test values in 
the target population should be known, and a 
suitable cut-off level defined and agreed. We 
reviewed the diagnostic accuracy of 12 screening 
tools, none of which had been evaluated in terms 
of the subsequent safety of women following their 
administration. Overall, the 4-item HITS (Hurts, 
Insults, Threatens and Screams) screening tool 
demonstrates the best predictive power, concurrent 
and construct validity and reliability, with a suitable 
cut-off score. It fulfils the NSC criterion and could 
be used to screen for partner violence in a variety 
of health-care settings. However, it does not ask 
about sexual abuse or ongoing violence, and so it 
may need to be administered alongside another 
screening tool to detect these forms of abuse. 
Alternative short screening tools, such as the WAST 
and the AAS, perform almost as well as the HITS in 
the health-care settings in which they were tested. 
The North American context of diagnostic accuracy 
studies of screening tools requires extrapolation of 
these findings to the NHS, but there is no a priori 
73 
© 2009 Queen’s Printer and Controller of HMSO. All rights reserved.
Health TechnologyAssessment 2009; Vol. 13:No. 16DOI: 10.3310/hta13160  
 
   
 
  
reason why the tools should perform substantially 
worse in a UK setting. 
 
Question   III:   Is   screening   for   partner   violence 
acceptable to women? 
NSC criterion 7 is that the screening test should 
be acceptable to the population. We therefore 
evaluated both the quantitative and qualitative 
evidence eliciting the views of women. In general, 
the evidence from the survey studies of women 
patients in health-care settings shows that most 
agree with screening or being asked routinely about 
partner violence. However, from the qualitative 
studies, it is also clear that women perceive the 
purpose of screening as lying outside the public 
health screening framework and differently from 
health-care professionals. On the whole, health- 
care professionals see screening as a method for 
obtaining disclosure of abuse, which then leads 
to appropriate care being offered. By contrast, 
women tend to view screening as a method of 
raising awareness rather than eliciting disclosure of 
abuse. Thus, even though abused women may not 
disclose immediately, screening may facilitate later 
disclosure when the women feel more comfortable 
with the health-care professional, or when their 
circumstances change and they feel the need to get 
help. This has implications for health service policy 
in relation to screening and the training of health- 
care professionals in relation to partner violence,  
as we discuss further below. Although only 2 out of 
the 18 surveys were based in UK populations, their 
results are consistent with the range of opinion in 
the totality of studies. 
 
Question IV: Are interventions effective once partner 
violence is disclosed in a health-care setting? 
NSC criterion 10 is that there should be an  
effective intervention for patients identified 
through early detection, with evidence of early 
treatment leading to better outcomes than late 
treatment. Further, the benefit from the screening 
programme should outweigh the physical and 
psychological harm caused by the test, diagnostic 
procedures and treatment. We reviewed studies that 
have evaluated the effectiveness of interventions  
for women who have disclosed abuse, including 
evidence from an increasing number of randomised 
controlled trials. Most were targeted at women who 
had already disclosed abuse, many from refuge 
populations, so extrapolation to women identified 
through screening is problematic. None of the 
studies tested whether early detection of partner 
violence leads to better outcomes. The evidence of 
effectiveness of advocacy interventions is growing, 
although using the USPSTF criteria for sufficiency 
of evidence for policy, it is on the borderline 
between insufficient and sufficient. As we discuss  
in Chapter 7, this is probably too conservative a 
judgment. On the whole, well-designed studies 
show improvements in outcomes for women 
receiving advocacy, but the evidence is strongest 
for women who have actively sought help or are 
already in a refuge. This evidence has informed 
UK central government funding of specialist 
independent domestic violence advocates (IDVAs) 
attached to both statutory and voluntary agencies. 
The only studies of advocacy interventions in 
women identified through screening in health-care 
services were based in antenatal clinics.121,131–133 The 
evidence for individual psychological interventions 
is sufficient according to the USPSTF criteria, 
but this is based on only three studies and, more 
so than the advocacy studies, the interventions 
are very heterogeneous. The evidence for 
group psychological interventions and that for 
mother and child programmes is insufficient as 
a basis for policy. Overall, considering all types 
of interventions that women might be offered 
following disclosure, there is still uncertainty about 
their effectiveness. However, there is little evidence 
that they are ineffective. As none of the controlled 
studies of interventions was based in the UK, the 
uncertainty about their effectiveness within the 
NHS is even greater. 
 
Question V: Can mortality or morbidity be reduced 
following screening? 
This question addresses NSC criterion 13, 
that there must be evidence from high-quality 
randomised controlled trials that the screening 
programme is effective in reducing mortality or 
morbidity. We extended the review to include proxy 
outcomes for improved morbidity and mortality, 
particularly referral to partner violence advocacy 
and other community support agencies following 
screening. We found no studies that directly 
measured morbidity and mortality. Although 
most of the studies measuring proxies showed 
improvements in these outcomes, study design and 
execution were generally poor. The most robust 
study methodologically showed the least effect on 
identification rates. There was no measurement of 
potential harms of screening, although these were 
raised by women and health-care professionals 
in the qualitative studies. Criterion 13 remains 
unfulfilled. As none of the studies was based in the 
UK, this is even more the case for NHS policy than 
it is for US health-care policy. 
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Question VI: Is a partner violence screening 
programme acceptable to health professionals  and 
the public? 
To fulfil the NSC criterion 14, there has to be 
evidence that the complete screening programme 
(test, diagnostic procedures, treatment/ 
intervention) is clinically, socially and ethically 
acceptable to health professionals. We reviewed 
quantitative and qualitative studies of acceptability 
to clinicians. There was heterogeneity in the 
findings of qualitative and survey studies about the 
acceptability to health-care professionals of partner 
violence screening, but overall the evidence shows 
that this NSC criterion is not met. This contrasts 
with the surveys of women, which reported 
largely positive views of screening in health-care 
settings. The surveys of health-care professionals 
reported that a majority of clinicians do not find a 
screening programme to be acceptable, although 
the proportion of respondents who thought it 
acceptable ranged between 15% and 95%. The 
qualitative studies tended to report more positive 
views of screening from health-care professionals. 
However, even when clinicians think that there 
should be screening for partner violence, some 
held the view that it is other groups of health- 
care professionals who should be carrying out the 
screening. The qualitative studies also demonstrate 
that positive attitudes towards screening are 
tempered by a wariness of implementation without 
training and the possible need for additional 
resources to deal with referrals after disclosure. 
Although only 5 out of 20 surveys of health- 
care professionals were conducted among UK 
populations, the results of these were consistent 
with the range of opinion in the totality of surveys. 
 
Question VII: Is screening for partner violence cost- 
effective? 
This question addressed NSC criterion 16, that the 
cost of the screening programme (including testing, 
diagnosis, treatment, administration, training and 
quality assurance) should be economically balanced 
in relation to expenditure on medical care as a 
whole (i.e. screening for partner violence should 
give value for money). We sought to review studies 
evaluating the cost-effectiveness of screening 
and we complemented this by modelling of costs 
and outcomes using data from a pilot study in 
primary care. We found no studies examining 
the cost-effectiveness of screening women for 
partner violence. Our cost-effectiveness model, 
based on pilot data, suggested that a system- 
level intervention in primary care that improves 
identification (well below the disclosure rate one 
might expect with a screening programme) and 
referral of women survivors of partner violence is 
likely to be cost-effective. Nevertheless, at present 
this NSC criterion is not fulfilled. 
  
Strengths and limitations 
of this report 
We have broken down a complex health-care 
policy issue with multiple criteria – should women 
be screened for partner violence in health-care 
settings? – into seven questions amenable to 
systematic review. We carried out these reviews to 
a high methodological standard and concluded 
that there was insufficient evidence to recommend 
screening as a policy. We have synthesised 
quantitative and qualitative studies for the two 
reviews on the views of health-care professionals 
and women patients respectively. Changes in 
our protocol included not reviewing three NSC 
criteria: (1) there should be an agreed policy on the 
further diagnostic investigation of individuals with 
a positive test result and on the choices available 
to those individuals; (2) there should be agreed 
evidence-based policies covering which individuals 
should be offered treatment; and (3) management 
of the condition and patient outcomes should 
be optimised. The criteria we reviewed are more 
central to a policy decision about screening, and 
reviews of these additional three criteria would 
not have changed our conclusions. We have 
highlighted limitations of the individual reviews 
in the relevant chapters. Generic limitations of all 
our reviews include: no hand searching for primary 
studies, no forward citation tracking, quality 
appraisal performed by one reviewer, and no 
funnel plots for publication bias. These additional 
components would not have changed the overall 
conclusion of our report. The main limitations 
of this report are the relatively small number 
and poor quality (or poor reporting) of primary 
studies and the absence of controlled studies of 
interventions in the UK. 
  
Are the NSC criteria 
appropriate tests for 
a partner violence 
screening  programme? 
 
From our review of current research evidence, it 
is clear that key criteria for the effectiveness and 
appropriateness of a partner violence screening 
programme are not fulfilled, not even in antenatal 
clinics for which the Department of Health has a 
Conclusions and  implications for health  care  
  
  
 
 
policy of ‘routine enquiry’.213 This term is broader 
than ‘screening’, ranging from asking every woman 
patient about abuse to enquiry only in particular 
groups of patients.16 Although reference to routine 
enquiry rather than screening seems to circumvent 
the NSC criteria, its implementation as policy still 
needs to be based on research evidence showing 
that it is safe and effective, which brings us back 
to the evidence we have reviewed here, with three 
notable differences.  
First, the purposes of routine enquiry can include 
information about partner violence and signal 
to the patient that the clinician is a potential 
source of support if she discloses. Disclosure or 
identification is no longer the only outcome, as it  
is within a screening paradigm. One of the striking 
findings of our review is that survivors of partner 
violence value purposes other than identification 
for routine enquiry, although this view is not  
widely shared by the health-care professionals 
interviewed in the qualitative studies. Proponents 
of routine enquiry maintain that there are other 
benefits, such as reducing stigma214 about partner 
violence and changing prevailing social attitudes,211 
although there is no compelling evidence that this 
is an outcome of routine enquiry. Second, routine 
enquiry does not require standardised screening 
tools, allowing a greater flexibility in how women 
are asked about abuse and, potentially, greater 
sensitivity to differences between women in how 
they might want to be asked. Third, there is less 
potential for the woman to feel pressurised to 
disclose abuse, as this is not the only purpose 
of routine enquiry. The Department of Health’s 
current policy of routine enquiry during pregnancy 
is not based on trial evidence of improved 
outcomes for women who are asked about abuse 
antenatally, although the trial by Tiwari and 
colleagues121  of advocacy suggests that women who 
do disclose abuse in pregnancy may benefit from 
an advocacy-based intervention, notwithstanding 
these  differences.  
Chamberlain, in her response215  to the lack 
of support for screening by the United States 
Preventive Service Task Force on intimate partner 
violence, concluded that the evidence criteria for 
a positive recommendation were too narrow and 
reflected a lack of understanding of the nature of 
partner violence by the task force. Specialists within 
domestic violence services highlight the dynamic 
nature of partner abuse and the legitimate reasons 
women may have for not wanting to disclose 
it to a particular health-care professional, with 
implications for any evaluation of its effectiveness. 
76 
Nevertheless, if controlled evaluations of screening 
programmes are intrinsically problematic and the 
NSC criteria are flawed in relation to a problem 
like partner violence, we are left with the dilemma 
of how to judge whether a policy of screening or 
even routine enquiry is justified.  
The debate about screening for partner violence 
and the shift in emphasis, at least in the UK, to 
routine enquiry has distracted attention from the 
uncontested importance of training for health- 
care professionals in being open to disclosure of 
partner violence and responding appropriately, 
whether they ask about abuse routinely or not. The 
remit of this review was the evidence for a policy 
of domestic violence screening, and we have not 
reviewed the evidence for other policy questions 
and recommendations. 
  
Research  questions 
 
1. Do system-level interventions in health-care 
settings improve the response of health services 
to survivors of partner violence? Trials to 
answer this question may incorporate routine 
or selective enquiry and, potentially, could 
compare differences in outcomes between the 
two policies, although those outcomes would 
need to be broader than identification. 
2. Do system-level interventions in health-care 
settings improve outcomes for women? Trials 
to answer this question are logistically more 
challenging in terms of recruitment and long- 
term follow-up of participants than those 
needed to answer research question 1. 
3. Do psychological and advocacy interventions 
after disclosure of partner violence to health- 
care professionals in health-care settings – 
whether this is the result of screening, routine 
enquiry or selective enquiry – reduce violence 
and improve quality of life and mental health? 
These trials should have follow-up for years, 
not months, and include mental health and 
quality of life outcomes. 
4. Study designs for research questions 2–4 need 
to incorporate the theoretical basis for different 
components of domestic violence interventions 
in order to enhance our understanding of how 
such interventions work (or do not work), for 
whom and in what contexts. 
5. What do women want from health-care 
or health-care-related interventions after 
disclosure of partner violence? Qualitative 
studies would inform the design of these 
interventions and choice of outcome measures 
to evaluate them. 
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6. What is the ‘natural’ history of partner 
violence? This question includes exploring 
individual risk factors for survivors, factors 
supporting resilience of survivors and 
perpetrators, the trajectory of abuse across 
the life course, and predictors of severity and 
outcomes. 
7. What is the long-term prognosis for survivors 
of partner violence after identification in 
health-care settings? 
 
Research questions 6 and 7 are best addressed in 
cohort studies with long-term follow-up, studies 
that are almost absent in the field of domestic 
violence research.  
Programmes addressing these seven research 
questions need to have the resources and expertise 
to include participants from majority and ethnic 
minority communities in the UK.  
Listing important research questions is de rigeur 
for a systematic review. We believe it is almost as 
important to discuss research that does not need to 
be pursued. From this review, we conclude that the 
following types of study are not a priority in the UK. 
 
1. Cross-sectional prevalence studies from 
antenatal clinics, accident and emergency 
clinics and, probably, general practice. 
Although there are only a few of these studies 
at present, more precise or generalisable 
estimates of prevalence will not materially 
inform health service policy. 
2. Surveys of attitudes of health-care professionals 
towards partner violence, unless in the context 
of interventions to improve care, in which case 
measurement of attitudes may help to explain 
the results. 
3. Surveys of women’s attitudes towards routine 
enquiry. Measuring the size of the minority of 
women who do not want routine enquiry about 
partner violence is not going to help develop 
policy.  
We are not saying that this research should never be 
undertaken in the UK or funded in the future; but 
that in a competitive funding environment, where 
historically there has been little support of health- 
related domestic violence research, the priority 
should be given to the seven research questions 
listed above. We have found that the epidemiology 
of domestic violence in clinical populations in the 
UK is not particularly robust, but more precise 
measures of prevalence in different health-care 
settings and of health-care professional and patient 
attitudes towards screening is not the best use of 
resources while these questions remain unanswered. 
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